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SECTION I
GENERAL INTRODUCTION - TRANSLATIONAL 
PHARMACOLOGY OF DRUG EFFECTS IN CHRONIC PAIN

CHAPTER  1
Challenges in translational drug research in 
neuropathic and inflammatory pain: 
Towards a new paradigm
Amit Taneja1,  Meindert Danhof1 and Oscar E. Della Pasqua1,2
Submitted
1 Division of Pharmacology, LACDR, Leiden University, The Netherlands




Ongoing research through the past decades has led to an improved understanding of 
molecular mechanisms involved in pain. yet there have been negligible tangible gains, and 
existing analgesic drugs remain limited in terms of efficacy in chronic conditions, with opioid 
analgesics and NSAIDS still being the mainstay of analgesic therapy. Pharmaceutical R&D 
activities have in most cases identified new drugs that suppress symptoms, despite the 
efforts and rationale for treatments that alter the underlying disease processes. 
Multiple molecular and cellular mechanisms act concurrently to produce pain symptoms, 
which in turn are non-specific manifestations of the underlying nociceptive mechanisms. At 
the biological level, these manifestations can be divided into neuropathic and inflammatory 
pain. There is however, some overlap amongst the two categories, with inflammatory 
mechanisms as a common trigger for symptoms in both types of pain. 
Despite the evidence for inflammatory components, the assessment of drug effects 
on neuropathic pain has relied primarily on overt behavioural measures. This situation 
contrasts with the use of mechanistic biomarkers in inflammatory pain, which has provided 
the pharmacological basis for dose selection and evaluation of NSAIDs in the treatment of 
acute and chronic pain.
A new paradigm is required for the identification of relevant targets and candidate 
molecules in which pain is coupled to the cause of sensorial signal processing dysfunction 
rather than to the symptom. furthermore, it must become evident that any behavioural 
measure of response involves cortical components, which may be unrelated to the 
neuropathological dysfunction that leads to pain symptoms. Biomarkers are required that 
enable characterisation of drug binding and target activity. Here we show how a biomarker-
guided approach can provide the basis for future pain therapy research. In addition, 
we show how such biomarkers can be integrated in a systematic manner by the use of 
pharmacokinetic-pharmacodynamic modelling, enabling the characterisation of exposure-
response relationships and consequently of the level of target engagement required in 
patients. 







Chronic pain remains a debilitating condition with high morbidity and heavy impact on the 
quality of life of patients who experience it. yet, currently marketed analgesic drugs are at 
best moderately effective, in that not all patients respond to treatment accordingly [1, 2]. In 
addition, some drugs are known to cause debilitating side-effects or have been linked to long 
term safety issues [1, 2]. The search for effective and safe compounds remains therefore a 
challenge for pharmaceutical R&D.
The current landscape for the development of analgesic drugs
Ongoing research throughout the past decades has led to an improved understanding 
of molecular mechanisms involved in pain. This is evidenced by the rising number of 
publications in the aforementioned period which numbered 171,400 in the period between 
2000 and 2009. Nevertheless the mainstay of pain treatment continues to focus on 
opioids and non-steroidal anti-inflammatory mechanisms, with very few novel selective 
mechanisms effective in clinical practice (e.g., opioids,  triptans and coxibs) [3].  In addition, 
rapid progress has been made in pain genetics, which has led to a better understanding of 
potential sources of variability in pain perception and nociceptive response [4, 5].Despite 
these developments, drug research continues to rely on traditional experimental models of 
pain which adequately reproduce symptoms, but clearly lack construct validity [6]. In fact, it 
can be stated that the available models are sensitive enough to detect analgesia, but pain is 
mostly evoked by external stimuli, leading to response that involves non-specific substrates 
and consequently to the selection of false positive compounds. One example of such non-
specificity is illustrated by the development of aprepitant, an NK1 antagonist which was 
effective in preclinical species but failed in clinical studies [7].
In the following paragraphs we provide an overview of the issues underpinning the challenges 
for the development of novel analgesic drugs. Of particular interest is the insight into the 
molecular mechanisms of pain signalling. We will highlight how further understanding of 
the pathways and of the reversibility of the mechanisms leading to sensorial dysfunction are 
critical for the identification of effective treatments. These points are then complemented 
by a detailed description of the experimental protocols and approaches currently used in 
the assessment of pain behaviour, which focus primarily on pain perception rather than 
pain signalling. We conclude the discussion by shedding light on the so-called translational 
challenge, which has prevented the development of suitable compounds for neuropathic 
pain. In this context, we emphasise the role of biomarkers and in particular of the need 
to understand target engagement, reversibility of the underlying dysfunction as well as of 
the timing of the intervention.  An integrated approach is proposed in which not only are 
treatments are aimed at the underlying mechanisms, but diagnosis also takes place before 
nociception evolves into pain symptoms.
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PATHWAYS INVOLVED IN THE ONSET AND MAINTENANCE OF PAIN
The process from tissue injury and inflammation to signal transduction reflects multiple 
molecular and cellular pathways involved in the processing and perception of pain. This is 
illustrated figure 1.1  where the role of known pathways is schematically depicted.
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Nature Reviews | Drug Discovery
Can we detect medical utility for analgesic 
drugs with novel mechanisms in humans? 
The promise of pharmacogenetics to identify 
new targets for analgesic drug development 
and subsequent improvements in the preven-
tion and management of pain may falter on 
the reality of current methods and strategies. 
Animal models for screening drugs for 
analgesic activity have largely been validated 
on their ability to detect drugs with known 
analgesic effects in humans, that is, opiates 
and aspirin-like drugs. It is not surpris-
ing then that new molecules selected on 
the basis of activity in these models have 
similar pharmacological profiles to existing 
analgesic drug classes. The magnitude of the 
distortion from normal physiology when 
inflaming a rat’s paw with carrageenan, for 
example, may not be suitable for detecting 
subtle analgesic effects, particularly of 
drugs that do not target anti-inflammatory 
Figure 1 | schematic illustration of the ‘moving pain target’. Well-
characterized receptors in the periphery are activated by noxious stimuli, 
tissue injury and acute inflammation, and send afferent information to the 
dorsal horn of the spinal cord where synaptic transmission to ascending 
pathways is subject to modulation by descending pathways, local neuronal 
circuits and a variety of neurochemicals. a | Neurochemical modulation of 
synaptic transmission in the dorsal horn showing examples of postsynaptic 
receptors and ion channels that are activated by excitatory amino acids 
released presynaptically and sensitized by cytokines from activated glial 
cells following nerve injury. b | Peripheral mediators of pain transduction 
after tissue injury: inflammation leads to the release of numerous chemicals 
from mast cells, macrophages and injured cells that act directly or indirectly 
to alter the sensitivity of receptors and ion channels on peripheral nerve 
terminals. these receptors release secondary messengers such as protein 
kinase A (PKA) and PKc that can activate other membrane bound receptors 
and gene transcription. A2, adenosine A2 receptor; AsIc, acid-sensing 
channels; B1/2, bradykinin receptors 1 and 2; cNs, central nervous system; 
eAAs, excitatory amino acids; eP, prostaglandin e receptor; GABA, γ-amino-
butyric acid; GIrK, G-protein-coupled inwardly rectifying K+; H1, histamine 
H1 receptor; 5-Ht, 5-hydroxytryptamine; IL, interleukin; IL-1r, interleukin 1 
receptor; M2, muscarinic M2 receptor; NO, nitric oxide; P2X3, purinergic 
receptor X3; PAF, platelet-activating factor; PGs, prostaglandins; rOs, 
reactive oxygen species; tNF, tumour necrosis factor; ttXr, tetrodotoxin 
receptor; trkA, tyrosine receptor kinase A.
PersPect ives
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© 2007 Nature Publishing Group 
 
Figure 1.1 : a) Upper panel: following nerve injury, neurochemical modulation of synaptic transmission  occurs in 
the dorsal hor , post-synaptic rece to s and ion chan els ar  activated by excitatory amino a ids released pre-
synaptically and further sensitised by cytokines from activated glial cells. b) Lower panel: Peripheral mediators of 
pain transduction after tissue injury. following tissue injury, mast cells, macrophages and other injured cells directly 
or indirectly rel ase numerous chemicals that lter sensitivity of receptors and ion channels on peripheral nerve 
endings. These receptors release secondary messengers such as protein kinase A and C that can activate other 
membrane bound receptors a d gene tr nscriptio . A2 =ad n sine 2 receptor, ASIC=acid sensing channels, B1/2 
=bradykinin receptors, CNS= central nervous system; EAA= excitatory amino acids; EP= prostaglandin E receptor, 
GABA= γ amino butyric acid; GIRK= G protein coupled inwardly rectifying K+; H1= histamine receptor;5HT=5 hydroxy-
tryptamine; IL 1/2=interleukins 1/2; M2= muscarinic 2 receptor; NO= nitric oxide; P2X3= purinergic receptor X3;PAf= 
platelet activating factor; PGs=  prostaglandins; ROS= reactive oxygen species; TNf= tumour necrosis factor; TTXr= 
tetrodoxin receptor; TrkA= tyrosine receptor kinase A. Adapted with permission from[4].
following cellular or tissue injury, there is an inflammatory reaction which leads to the release 
of inflammatory mediators that sensitise sensory receptors on peripheral nerve endings. 
These receptors are known to release secondary messengers such as protein kinase A and C, 






which activate other membrane-bound receptors and trigger gene transcription. As shown 
in the diagram, both the peripheral sensitisation and transduction processes described 
above can progress into  central sensitisation, which reflects a functional and histological 
change in the afferent fibres that are present  in the dorsal horn of the spinal cord.
Emerging drugs in neuropathic pain
116 Expert Opin. Emerging Drugs (2007) 12(1)
Figure 2. Mechanisms of neuropathic pain. Noxious stimuli are transduced into electrical activity at peripheral terminals of primary
afferent neurons (e.g., unmyelinated C fibres). This activity is then transmitted to the dorsal horn of the spinal cord and relayed to
second-order neurons that send projections via the anterolateral (spinothalamic tract) pathway to supraspinal structures in the brain. At
the level of the spinal cord, pain transmission is modulated by descending bulbospinal pathways and intrinsic spinal interneurons.
Neuropathic pain arises following injury or dysfunction of the nervous system. A. After nerve damage, there is an increase in transcription
and axonal trafficking of sodium channels to the site of injury, concomitant with an attenuation of potassium channels. Consequently,
the altered ion-channel expression modifies neuronal excitability such that neurons become hyperexcitable and can generate ectopic
activity, which is thought to lead to the genesis of spontaneous and paroxysmal pain. B. At the cell body of primary afferent neurons
located within the dorsal root ganglia, sympathetic neuronal sprouting has been demonstrated and may account for
sympathetically-maintained pain. C. Peripheral nerve injury causes a multitude of changes in gene transcription and activation of various
kinases and proteins including enhanced NMDA receptor activity. However, nerve injury also elicits hypertrophy and activation of glial
cells including microglia within the gray matter of the spinal cord. Microglia express P2X4 purinergic receptors allowing them to be
activated by ATP. Following activation, microglia release various pro-nociceptive cytokines including IL-1, TNF-α and neurotrophins
including brain-derived neurotrophic factor that in turn exacerbates nociceptive transmission and contributes to sensitisation and
maintenance of neuropathic pain.
Reprinted from GILRON I, WATSON CP, CAHILL CM, MOULIN D: Neutopathic pain: a practical guide for the clinician. CMAJ (2006) 175(3):265-275 with permission of
the publisher © Canadian Medical Association.
5-HT: Serotonin; Aβ: Aβ neuron; Aδ: Aδ neuron; C: C nociceptor; DRG: Dorsal root ganglion; KCC2: Chloride transporter; Kv: Potassium channel; NA: Noradrenaline;
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Figure 1.2: NP arises following nerve injury or dysfunction. a): following nerve damage, transcription and axonal 
trafficking of Na+ channels to the site of injury is increased, with oncomitant attenuation of K+ channels. The 
altered expression of ion channels results in hyperexcitable neurons and the generation of ectopic activity, which is 
thought to lead to the genesis of spontaneous and paroxys al pa n. b) At the cell body of primary aff r t neurons 
within the dorsal root ganglia (DRG), sympathetic neuronal sprouting occurs and may account for sympathetically 
maintained pain. c) Peripheral nerve injur  causes a multitude of c ng s in gene transcription nd activation of 
various kinases and proteins including enhanced N-methyl-D-aspartate (NMDA) receptor activity. However, nerve 
injury also eli its hypertrophy and activ tion of glial cells, in luding neuroglia within the grey matter of the spinal 
cord. Microglia expresses P2X4 receptors allowing them to be activated by adenosine triphosphate (ATP). following 
activation, microglia rele ses various pronociceptive cytokines, such as interleukin-1(IL-1), tumour necrosis factor 
(TNf-α), and neurotrophins, including brain-derived neurotrophic factor, which in turn exacerbates nociceptive 
transmission and contributes to the sensitisation and maintenance of NP. Aß=A beta neuron, Aδ=A delta neuron, 
C=C nociceptor, 5 HT=serotonin, KCl2=chloride transporter, NA=noradrenaline, Nav=sodium channel, NO=nitric 
oxide, Kv=potassium channel, PGs=prostaglandin, PKs=protein kinases, P2X4=purinergic receptors. Adapted with 
permission from[9].
Whilst many of the mechanisms discussed above are applicable to acute and chronic pain 
conditions, certain important differences need to be considered when evaluating neuropathic 
pain. The complex pathways involved in the initiation, transmission and maintenance of 
neuropathic pain (NP) are shown in figure 1.2. Among many of the changes associated with 
central hypersensitisation, trafficking of Na channels is increased whilst K channel activity 
is reduced. Together these changes lead to neuronal hyper-excitability and irregular firing. 
At the cell bodies of afferent neurons in the dorsal root ganglion, sympathetic neuronal 
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sprouting occurs and may account for sympathetically mediated pain. Peripheral nerve 
injury also causes enhanced NMDA activity, glial cell activation and hypertrophy within 
the spinal cord. Activated microglia expresses P2X4 receptors and releases pro-nociceptive 
cytokines such as IL1, TNf-α, neurotrophins, which exacerbate nociceptive transmission and 
ultimately sustain the symptoms of hypersensitisation. See figure 1.3. REVIEW























AFigure 2 Mechanisms of peripheral and central 
sensitization in neuropathic pain. (A) Primary afferent 
pathways and their connections in the spinal cord 
dorsal horn. Nociceptive C-fibers (red) terminate 
at spinothalamic projection neurons in upper 
laminae (orange neuron), whereas non-nociceptive 
myelinated A-fibers (blue) project to deeper laminae. 
The second-order projection neuron is of the wide 
dynamic range (WDR) type, that is, it receives 
direct synaptic input from nociceptive terminals 
and also multisynaptic input from myelinated 
A-fibers (non-noxious information, blue neuron 
system). γ-aminobutyric acid (GABA)-releasing 
interneurons (green neuron) normally exert inhibitory 
synaptic input on the WDR neuron. Furthermore, 
descending modulatory systems synapse at the 
WDR neuron (the green descending terminal 
represents an inhibitory projection). Spinal cord glial 
cells (brown cell) also communicate with the WDR 
neuron. (B) Peripheral changes at primary afferent 
neurons (nociceptive C-fibers, red; non-nociceptive 
myelinated A-fibers, blue) after partial nerve lesion, 
leading to peripheral sensitization. Some axons 
are damaged and degenerate (upper two axons), 
whereas others (lower two axons) are still intact and 
connected with the peripheral end organ (skin). The 
lesion triggers the expression of sodium channels 
on damaged C-fibers. Furthermore, products such 
as nerve growth factor that are associated with 
Wallerian degeneration are released in the vicinity 
of spared fibers (arrows), triggering channel and 
receptor expression (sodium channels, TRPV1 
receptors, adrenoceptors) on uninjured fibers. 
(C) Spontaneous activity in C-nociceptors induces 
secondary changes in central sensory processing, 
leading to spinal cord hyperexcitability (central 
sensitization of second-order WDR neurons, 
indicated by star in orange neuron). This causes 
input from mechanoreceptive A-fibers (light 
touch and punctate stimuli; blue neuron system) 
to be perceived as pain (dynamic and punctate 
mechanical allodynia; ‘+’ indicates gating at synapse 
via AMPA/KA [α-amino-3-hydroxy-5-methyl-4-
isoxasole propionic acid and kainate] receptors). 
Several presynaptic (opioid receptors, calcium 
channels) and postsynaptic molecular structures 
(glutamate receptors, NE [norepinephrine] receptors, 
5-HT [serotonin] receptors, GABA receptors, sodium 
channels) are involved in central sensitization. 
Inhibitory interneurons and descending modulatory 
control systems (green neurons) are dysfunctional 
after nerve lesions, leading to disinhibition or 
facilitation of spinal cord dorsal horn neurons and 
to further central sensitization. (D) Peripheral nerve 
injury activates spinal cord non-neural glial cells 
(brown cell), which further enhances excitability in 
WDR neurons by releasing cytokines and increasing 
glutamate levels. 5-HT, 5-hydroxytryptamine 
(serotonin); GABA, γ-aminobutyric acid; 
NE, norepinephrine.
ncpneuro_2005_008.indd   99 10/1/06   3:47:13 pm
Nature Publishing Group ©2006
Figure 1.3: Mechanisms of peripheral and 
central sensitisation in NP a) Primary afferent 
pathways and their connections in the dorsal 
horn of the spinal cord. Nociceptive fibres 
terminate at the spinothalamic projection 
neurons in the superficial laminae whereas 
non- nociceptive myelinated A fibres project 
to deeper laminae. Second-order order 
projection neurons (WDR) receive direct 
synaptic input from nociceptive terminals and 
also from myelinated A fibres. GABA releasing 
interneurons exert inhibitory synaptic input 
on the WDR neurons. b) Peripheral changes 
at primary afferent neurons. Some neurons 
are damaged and degenerate after partial 
nerve lesion while others are intact. The 
lesion triggers the expression of Na+ channels 
on damaged C fibres. Nerve growth factor 
triggers the expression of Na+ channels, 
TRV1 receptors, and adrenoceptors on 
uninjured fibres. c) Spontaneous activity in 
C nociceptors induces secondary changes in 
central sensory processing leading to spinal 
cord hyperexcitability. This causes input from 
A fibres (light touch and punctuate stimuli) 
to be perceived as allodynia. Inhibitory 
interneurons and descending modulation 
are dysfunctional following nerve lesions. 
d) Cytokine and glutamate release after 
peripheral injury further enhances 
excitability in WDR neurons. Adapted with 
permission from[10].






Clearly, the multiplicity of signalling pathways involved in the onset and maintenance of 
pain cannot be ignored when devising novel pharmacological interventions. Given the 
nature and irreversibility of some of the pathophysiological processes, it can be anticipated 
that effective treatments may not be achievable unless both the timing of intervention and 
level of engagement of the target(s) are considered.
 
The molecular pathophysiology of pain 
from a pathophysiologial standpoint, chronic pain may be subdivided as neuropathic (NP) 
and inflammatory pain (IP). In the following paragraphs we discuss the various mechanisms 
associated with pain signalling and perception in chronic pain. 
Peripheral and central sensitisation in neuropathic pain 
Peripheral sensitisation can result from the sensitisation of nociceptors by inflammatory 
mediators (e.g., ATP, PGE2, 5-HT, bradykinin, epinephrine, adenosine), by neurotrophic 
factors released during tissue damage (e.g., nerve growth factor (NGf)) or by pro-
inflammatory cytokines (e.g., interleukin-1α, 1ß, tumour necrosis factor-α (TNf- α) and COX-
2). Peripheral sensitisation is also associated with intense, repeated, or prolonged action 
potential generation in primary sensory afferents that is mediated by altered expression and 
activity of voltage-gated sodium and calcium channels [10, 11]. One of the consequences 
of peripheral sensitisation is a lowering of the activation threshold of nociceptors and an 
increase in their firing rate, which results in symptoms such as allodynia and hyperalgesia. 
In addition, these peripheral processes also play an important role in the development and 
maintenance of central sensitisation[12], which  ultimately causes irreversible increased 
neuronal excitability [13]. 
While both peripheral and central sensitisation play a role in chronic pain, central 
sensitisation clearly plays a key role in neuropathic pain. In fact, it explains why established 
pain is more difficult to suppress than acute pain [11, 12]. Interestingly, not only neurons, 
but also glial cells (e.g. astrocytes and microglia), as well as infiltrating mast cells are 
involved in the generation and maintenance of central sensitisation [10].  Among the various 
mechanisms, four processes should be mentioned that seem to determine the continuous, 
chronic nature of the symptoms, namely: 1) Release of pro inflammatory neurotransmitters 
by pathologically sensitised C fibres; 2) Over expression of voltage gated Na-Ca-channels, 3) 
Loss of supraspinal inhibitory control maintained by γ-aminobutyric acid (GABA) releasing 
interneurons and 4) Loss in function of descending serotonergic pathways ( see figure 1.2 
and figure 1.3). Central sensitisation is also associated with expansion of dorsal horn neuron 
receptive fields, reduction in central inhibition and long-lasting spontaneous dorsal horn 
neuron activity [10, 14]. Such activity leads to sensory response to low intensity stimuli 
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(altered neural connections following sprouting of Aß fibres to superficial laminae). In 
addition, these changes cause pain signalling to spread to uninjured tissue, i.e., secondary 
hyperalgesia. This process is known as “wind-up” in that the response of sensitised dorsal 
horn neurons is exaggerated relative to the normal situation [10, 12]. 
As mentioned previously, the sensitisation of the nervous system in response to chronic pain 
involves the alteration and/or activation of many neurotransmitter systems [11, 15]. Clearly, 
these changes are responsible for a shift in the balance between excitatory and inhibitory 
systems, which leads to the disruption of normal intracellular signalling cascades. Taken 
together chronic pain results from a large variety of deranged patterns of neurotransmission 
with considerable target redundancy. Consequently, even in the absence of sustained injury, 
chronic pain can progress as a pathophysiological condition or disease in itself. An overview 
of the inflammatory mediators and neurotransmitters involved in central hypersensitisation 
is presented in Table 1.1. 
Plasticity and other changes in pain processing 
Plasticity is a term used to refer to changes that occur in neuronal structure; connections 
between neurons; and alterations in the quantity and properties of neurotransmitters, 
receptors, and ion channels that can ultimately result in increased functional activity 
and ultimately in increased pain. Tissue injury, inflammation, and disease can all induce 
neuronal plasticity and increased pain by means of increased excitatory or decreased 
inhibitory mechanisms. An important feature of plasticity is that long-term changes may 
be permanent. Compelling evidence suggests that plasticity in nociceptors contributes 
substantially to the increased pain one feels in the presence of injury [14]. Moreover, imaging 
studies demonstrate fundamental changes in the somatosensory cortical representation and 
excitability in patients with phantom limb pain, complex regional pain syndromes (CRPS) 
and central pain syndrome, as well as in experimental pain models [16-19]. Interestingly, 
these alterations appear to correlate with the intensity of the perceived pain and wane after 
successful treatment of the pain [20, 21].
Mechanisms of chronic inflammatory pain
Although NP and IP have been clinically and biologically defined as distinct entities, Omoiqui 
hypothesises that, all pain originates from inflammation, with the different substrates 
underlying hyperexcitability such as wind-up, neuroplasticity and central sensitisation being 
considered a continuum from injury to persistent inflammatory response [22]. Obviously, 
in contrast to neuropathic pain, chronic inflammatory pain (IP) does not involve primary 
damage to neuronal tissue. It is defined as pain that lasts longer than the expected time 
that is needed for healing, or pain caused by progressive, non-malignant disease. Typically, 
inflammatory mediators, originating from arachidonic acid degradation are released from 






the site of injury resulting in the transduction of painful stimuli. Although other pathways 
have been shown to contribute to the onset and maintenance of pain symptoms, it is cyclo-
oxygenase that triggers the production of prostacyclins and thromboxanes. These pathways 
have determined most of the research activity involving non-steroidal anti-inflammatory 
drugs. 
An overview of the inflammatory cascade is shown in figure 1.4. Similarly to the 
phenomenon of central hypersensitisation in which neuronal activity in up-regulated, cyclo-
oxygenase 2 activity is greatly augmented in response to tissue injury. The initial step in 
the inflammatory cascade is the conversion of arachidonic acid to prostaglandin H2 (PGH2), 
which is the precursor of other prostaglandins and thromboxanes [22]. Increased levels of 
these lipids leads to various physiological and pathophysiological responses associated with 
inflammation and pain signalling, including fever. In addition, they are also responsible for 
the regulation of renal function and maintenance of the mucosal integrity in the stomach. 
In fact, these homeostatic functions seem to be a differentiating factor between the role of 
mediators in neuropathic and inflammatory pain. A more comprehensive description of the 
pathophysiology and mechanisms of inflammatory pain is beyond the scope of this review, 
but details can be found elsewhere [23].
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physiologic roles of this isoenzyme, including gastric
mucosal defense, renal homeostasis and endothelial
PGI2 production (for review see 11-15). Furthermore,
serious cardiovascular effects of some selective COX-
2 inhibitors emerged from clinical studies and phar-
macosurveillance, forcing the drug companies to with-
draw from the market rofecoxib and, soon afterwards,
valdecoxib (16-18). Although clinical trials gave con-
flicting results, partly due to the influence of pharma-
ceutical manufacturers (19), pharmacological evidence
se ms to support the con ept that cardiova cular toxi-
city of selective COX-2 inhibitors may be a class ef-
fect (20). This has raised serious concerns about the ri-
sk of thrombotic events during treatment with coxibs,
marking off the therapeutic benefits that could be ex-
pected from COX-2 selectiv  inhibition and questio-
ning the need of more selective compounds (21-22).
Following the withdrawal of rofecoxib, which has
been considered the most serious disaster  after talido-
mide, the search for safe  NSAIDs has found a re-
newed interest and novel strategies have emerged to
improve the therapeutic efficacy and tolerability of
these drugs. The rationale underlying the develop-
ment of dual inhibitors of COX and 5-lypooxygenase
(5-LOX) was based on both the proinflammatory ac-
tivity of leukotrienes (LTs) (Fig. 1) and their delete-
rious effects in the gastric mucosa; furthermore, these
compounds appear to be the major arachidonate pro-
ducts of the gastric mucosa under COX inhibition
(23, 24). As such, dual COX/5-LOX inhibitors should
theoretically display enhanced antiinflammatory ef-
fects and improved gastric tolerability (25-27). Recen-
tly, great interest has emerged for lipoxins, which can
be considered as counter-regulatory arachidonic acid
Figure 1. General scheme representing the main metabolic pathways leading to arachidonic acid products involved in the inflam-
matory process. Targets of antiinflammatory drugs are also shown. COX = cyclooxygenase; 5-LOX = 5-lipooxygenase; LTs = leuko-
trienes; PGs = prostaglandins; PLA2 = phospholipase A2; TxA2 = thromboxane A2.
Figure 1.4: Main metabolic pathways associated with arachidonic acid degradation during the inflammatory 
response. K own targets for anti-inflammatory drugs are also shown.COX=cyclo-oxygenase,5-LOX=5-
lipooxygenase,LTs=leukotrienes, PGs= prostaglandins, PLA2=phospholipase A2, TXA2= thromboxane A2 . Adapted 
with permission from [22].
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In view of the common biochemical substrates for inflammatory and neuropathic pain, it 
is reasonable to assume that the pathways involved in pain signalling and processing may 
show significant overlap. In this context, it should be noted that chronic pain must be 
considered the result of a preceding dysfunction in sensory signalling. The identification of 
effective treatments requires therefore further insight into the reversibility of the underlying 
dysfunction as well as the timing of intervention relative to the onset of the disease. These 
aspects will form the basis for the requirements for translation of drug effects from pre-
clinical species to humans.
Pain: from aetiology to syndrome
Despite current focus on the assessment of pain relief and pain intensity, it is the dysfunction 
in signalling pathways that needs to be characterised and targeted by novel therapeutic 
interventions. The concept of an underlying dysfunction prior to diagnosis and overt 
symptoms is not strange to medical practice and is best illustrated by the progression of 
diabetes into diabetic peripheral neuropathy (DPN), in which the symptoms of neuropathy 
are clearly a consequence of the underlying disease. In this case, it has been established 
that both hyperglycaemia and the duration of disease are predisposing factors in the 
development of DPN[24].
Likewise, dysfunction in pain signalling and subsequent changes due to neuroplasticity is 
known to precede the appearance of the symptoms of neuropathic pain. furthermore, 
it is important to emphasise that the delay between the onset of the disease and overt 
symptoms is associated with irreversible changes in neuronal activity, which makes the 
timing of any therapeutic intervention a key factor for the success or failure of treatment.  
As can be seen in figure 1.5, current guidelines for diagnosis and treatment rely on 
evidence of persistent allodynia and/or hyperalgesia, a phenomenon which develops after 
the occurrence of sprouting and other relevant changes induced by hypersensitisation and 
neuroplasticity. Diagnosis and therapeutic interventions at that stage of the disease will be 
sub-optimal given that the pathophysiological and functional changes that have taken place 
are likely to be irreversible or cannot be reset by further neuronal remodelling.
     
Such irreversible changes are common in the course of progressive disease and have 
triggered the need for different intervention strategies in other therapeutic areas. for 
instance, the use of imaging has become a powerful diagnostic tool in rheumatoid arthritis 
and oncology, whilst inflammatory or genetic markers have been used to guide treatment 
in Crohn’s disease and cystic fibrosis. Such an approach does not apply to the diagnosis 
of neuropathy. In the absence of a well-defined diagnosis, prophylaxis is therefore barely 
considered; current pharmacological targets cannot offer more than symptomatic relief.

















(Glutamate, GABA, adenosine, etc(?))  
Nerve damage 
sprouting, excessive neuronal firing, 
hypersensitisation  
Trauma, viral infection,  
metabolic disturbances, surgical lesions 
Figure 1.5: A flow diagram showing the progression of an underlying aetiology to the ultimate clinical/outward 
manifestations of NP. Adapted with permission from[25]. 
The role of early diagnosis, timing of the intervention and reversibility of the underlying 
processes cannot be disentangled from each other. The identification of effective targets 
and therapies must account for these factors. This line of reasoning also contributes to 
further understanding of the efficacy of treatment in acute inflammatory pain following 
injury. In the majority of cases, diagnosis (inflammatory reaction) is reasonably immediate 
relative to onset of the underlying dysfunction, which allows interventions to be initiated 
before pathophysiological activity induces irreversible changes, such as fibrosis. 
Clearly there is a gap between diagnosis, target selection and therapeutic intervention that 
needs to be addressed to ensure further advancement of the field. The role of functional 
imaging and other relevant biomarkers describing the underlying pathophysiolgical changes 
needs to be considered in the evaluation of efficacy.
These considerations also have major implications for drug discovery, which relies on a 
paradigm that mimics current standard of care in neuropathic pain. Pre-clinical models 
of neuropathic pain rely primarily on the suppression of symptoms and on behavioural 
measures of pain to define efficacious doses. Undeniably, such an approach contrasts 
with the evolving understanding of disease and creates a paradox or gap in the discovery 
process in which despite extensive research efforts novel therapies cannot be delivered 
[26]. In this context, lessons can be learned from other therapeutic areas, in particular 
from oncology research, where processes associated with tumorigenesis and metastasis 
has been defined at genetic, cellular, organ and system level [27, 28]. Based on the use of 
hallmarks as an organizing principle for rationalizing the complexities of neoplastic disease, 
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six biological capabiliti es have been identi fi ed that describe the multi step development 
of human tumours. The changes in normal cell functi on are captured in modules which 
comprise proliferati ve signalling, evasion of growth suppression, resistance to cellular 
death, replicati ve immortality, angiogenesis, and invasion and metastasis. In additi on to the 
multi level elements underlying each of the hallmarks, the concepts introduced by Hanahan 
facilitate the link between biological processes to outcome.  from a pharmacological 
modelling point of view, these elements integrate the ti me course of disease with drug 
acti on [29]. This approach resonates with the point made previously about the importance 
of the ti ming of interventi ons in relati on to symptoms and disease progression.  
Based on the aforementi oned, one would need to approach the treatment of pain in a 
more mechanisti c manner, taking into account the  possibility for pre-empti ve treatments 
and prophylacti c interventi ons. Any dysfuncti on in nocicepti ve signalling will likely involve 
sequenti al recruitment of diff erent inherently dynamic pathways and neurobiological 
components, including multi ple sensory pathways originati ng in the spinal cord which project 
to diff erent areas of the brain and requiring corti cal acti vati on to determine descending 
modulati on of nocicepti ve acti vity [30].
Hence, we defend the view that the earliest hallmark for eff ecti ve interventi on in neuropathic 
pain is the acknowledgement that dysfuncti onal signalling  is a disease enti ty in itself [1]. In 
this sense, it is worth menti oning that a commonly held view was that the nocicepti ve system 
was acti vated in the periphery only by nociceptors in response to an adequate noxious 
sti mulus. Although this is true of nocicepti ve pain (pain evoked by a noxious sti mulus) in 
normal circumstances, it is certainly incorrect for pain hypersensiti vity or spontaneous pain, 
where diff erent aff erent channels can lead to the pain symptoms [6, 25]. 
The use of dysfuncti onal signalling as hallmark for the treatment and preventi on of pain 
symptoms entails a diff erent strategy for target identi fi cati on, screening and selecti on 
of compounds in drug discovery. In the next paragraphs we will highlight how current 
processes and methods contribute to R&D’s inability to bridge the gap between our basic 
understanding of disease and the clinical implicati ons of an interventi on.
SCREENING AND SELECTION OF COMPOUNDS IN DRUG DEVELOPMENT 
A drug discovery programme begins with target selecti on, oft en followed by high-throughput 
screening and generati on of lead compounds. Subsequently, lead opti misati on starts taking 
into account pre-defi ned developability criteria that are aimed at assessing the drugability 
of the molecule as well as its safety profi le (figure 1.6) [1]. This approach is primarily aimed 
at identi fying drugs with greater specifi city for the target without taking into account the 
heterogeneity of pain mechanisms or their relati ve contributi on to the progression of 
underlying signalling dysfuncti on.






from a conceptual perspecti ve, the aforementi oned imposes an approach that accounts 
for the ti ming, reversibility and diversity of pathways involved in the onset, progression and 
maintenance of neuropathic pain symptoms. In practi cal terms, in additi on to early diagnosis 
and availability of functi onal markers, this means that drug combinati ons or molecules with 
acti on on diff erent targets and pathways may be required to ensure effi  cacy in pati ents [2, 
4]. Based on current practi ce, this requirement also implies that screening procedures will 
oft en face high rates of false positi ve and/or false negati ves, even when animal models show 
some degree of construct validity. 
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 statistical design can help find large signals in fewer patients, 
which is preferable to our current efforts of sifting small signals 
from large, noisy cohorts. This strategy would involve choosing 
patients who are most likely to respond to a particular therapy 
with an outcome measure and, ideally, a biomarker, that reflects 
the desired clinical response. Unfortunately, regulatory agencies do 
not like enrichment designs, which identify and then test patient 
subpopulations selected from the general population that are more 
likely to show drug benefit, because they do not reflect common 
practice, and they instead prefer an empirical approach that can 
be generalized to the whole population. Yet, as targeted therapy is 
introduced, this will require a shift in attitude by the regulatory 
agencies to enable development and marketing of treatments that 
only act on defined subpopulations.
Noninferiority or equivalence studies to show that a new treatment 
is either better than or at least indistinguishable from a gold stand-
ard, are also problematic when there is no gold standard for targeted 
therapy. Yet another problem with current regulatory practice relates 
to how to evaluate combination therapy. It may not always make sense 
to demand that sponsors demonstrate that the efficacy of a combi-
nation therapy is greater than the additive efficacy of its individual 
components, if there is a mechanistic explanation of why two different 
drugs should be given together in a fixed-dose combination. One drug 
may have no action on its own but alter the metabolism of the other 
or target it to specific cells41. This adds substantially to the expense 
of trials, usually with little benefit, and it should be dealt with on a 
case-by-case basis. The reality of analgesic treatment is polypharmacy, 
co-prescription of several different drugs, and the question, then, is 
how to use this in an evidence-based way to increase efficacy and 
reduce adverse effects.
The major problem with analgesic efficacy trials is ‘contamination 
by placebo’. fMRI studies show that the placebo effect is a specific and 
distinct neural function associated with activation or inhibition of 
particular brain regions42,43 and the spinal cord44. The presence of a 
placebo response, however, obscures analgesic efficacy because the 
effects are not additive. To detect analgesic signals, we need to reduce 
the placebo. This could be done by eliminating placebo responders 
in a pretrial study of those individuals who respond to placebo and 
active drug or only to active drug. Cross-over studies are more dif-
ficult but are helpful for comparing the placebo and drug response in 
individuals. Conducting large, expensive trials with a methodology 
that fails is wasteful and uninformative. Smaller, more focused studies 
designed to reduce variability and increase mechanistic information 
may be a better path, but this will require both sponsors and regula-
tory agencies to change.
Analgesic target selection and validation
The standard drug development model begins with target selection 
and moves onto high-throughput screens, generation of druggable 
lead compounds by medicinal chemistry, validation of these com-
pounds in preclinical disease models, and toxicology and safety 
assessments (Fig. 1). If a compound survives all this phases, it moves 
into phase 1 studies in human volunteers to measure safety and phar-
macokinetics, and only then can it be tested for efficacy in phase 2 
POC trials (Fig. 1). If the wrong target is chosen, it does not matter 
how good the drug is. Similarly, a drug with poor bioavailability, low 
potency, a short half-life or limited penetration into the brain may 
fail even if the target is important for pain. A clear clinical outcome is 
crucial to ensure that highly druggable leads acting on an important 
target succeed.
Because many drugs with efficacy in animal models of pain have 
failed in clinical trials, such as NK1 receptor antagonists and CB2 ago-
nists, and NMDA receptor antagonists where demonstrable efficacy is 
accompanied by unacceptable CNS side effects, we must ask whether 
these results are due to systemic failure of target selection and of the 
preclinical models used to validate targets. As failure is so expensive, it 
reduces tolerance to risk, and, not surprisingly, almost every company, 
like lemmings, goes after the same targets in the mistaken belief that 
there will be safety in numbers. To reduce risk, companies obviously 
prefer targets with a precedent, where there is some supportive human 
data, but this usually generates ‘me-too’ drugs. The concerns that ani-
mal models may not always predict efficacy in patients are legitimate. 
Some of the animal models may not mimic human pain syndromes, 
because different mechanisms are engaged (pain-like behavior can 
be provoked in animals as a result of neurobiological changes that 
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Figure 1 The standard analgesic drug development pathway. New small-
molecule analgesics are currently developed by a series of linear steps, 
starting with selecting a target, and ending with marketing the drug with 
a label for pain relief in particular patients. In this model, preclinical 
research is distinct from clinical development. Failure late in  
the path, in phase 2b or phase 3, is expensive and time consuming.  
If the preclinical pathway, driven by biased hypotheses typically obtained 
from rodent surrogate pain models, selects a target irrelevant to human 
pain conditions or does not suggest the most relevant patient cohort 
and outcome, clinical development will probably fail. The notable lack 
of success in producing new analgesics over the past two decades has 
been driven by this model, as well as by the difficulty in validating lead 
candidates on human targets in human cells, and by the differences 
between rodent and human pharmacokinetic profiles. ADME, absorption, 
distribution, metabolism and excretion; PK, pharmacokinetics; POP, proof 




























Fig ure 1.6:Sequenti al steps used in the discovery and development of analgesic drugs. Typically, R&D eff orts start 
with target selecti on and end with regulatory approval for the indicati on in the target pati ent group. Clearly, failures 
in phases 2 or 3 are a major cause of att riti , d represen  the bulk of losses/expenses in this therapeuti c area. 
Clinical programmes will always fail without informati ve, predicti ve models during the screening phase. The lack of 
construct validity  of preclinical models currently used in drug screening, the irreversibility of changes induced by 
signalling dysfuncti on and the absence of early diagnosti c tools lead to  diff erent pharmacological eff ects in animals 
and humans . Adapted with permission from[1].
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In addition to the aforementioned shortcomings,  it should be noted that dose selection 
in early human studies are based primarily on an empirical criteria, such as the maximum 
tolerated dose without taking into consideration how differences in exposure correlate 
with pharmacodynamics and most importantly how systemic drug exposure relates to 
target engagement. The deficiencies arising from these early clinical studies are further 
amplified in Phase 2, given that the mechanisms associated with pain in patients may differ 
considerably from those by which the pain symptoms are induced in animal models of 
disease [1, 6].These differences are likely to explain why most failures in Phase 2 are due to 
lack of efficacy and possibly to limited target engagement[31]. Inadequate exposure at the 
target site (biophase) is mostly overlooked, as systemic pharmacokinetics may not reflect 
drug levels in the CNS and the use of functional imaging or positron emission tomography 
with radiolabelled ligands is not routine practice[1].
Lastly, it should be emphasised that patient inclusion criteria as well as the selection of 
clinical endpoints to detect pain relief after treatment also play an important role in the 
attrition observed in the late phases of clinical development. Many of the clinical scales 
are be insensitive to the underlying pharmacological effects or lack precision to enable 
accurate dose selection[1]. In addition, factors such as gender, ethnicity, age, temperament 
and genetic differences are known to contribute to wide inter- and intraindividual variation 
in pain response [32, 33]. These covariates affect not only pain perception but also alter the 
tolerance to painful stimuli.
From behavioural measures to functional markers of pain signalling
As can be inferred from the previous paragraphs, the successful identification of efficacious 
candidate molecules will depend on a number of factors and processes, which should 
ultimately contribute to clear insight into the nature of the signalling dysfunction, its 
reversibility and the extent of target engagement observed upon administration of the 
drug. Such a scrutiny has however never been considered as the basis for the development 
of analgesic drugs, which has traditionally relied on suppression of behavioural measures 
of pain. Huntjens et al have argued that such measures lack the sensitivity to be able to 
discriminate between compounds with different pharmacological properties. Also these 
measures may not necessarily correlate with the time course of inflammatory response 
[34]. They further argue that behavioural endpoints of pain such as those measured in 
preclinical models represent a qualitative rather than a quantitative measure of drug effect 
in vivo with little correlation to the underlying mechanisms of action [35]. These views are 
further corroborated by Woolf, who has eloquently stated that while many pain assessment 
tools have been developed, they are mainly designed to measure pain intensity and not its 
identity [1].






furthermore, laboratory animal models of pain have been essentially designed to mimic 
pain in humans. Experimental studies are often considered ‘behavioural studies’ in which 
responses to graded-strength mechanical, thermal, or chemical stimuli (nociceptive) are 
measured. However, pain measurements are based on the detection of a change in the 
threshold or response to an applied stimulus, making them unsuitable for the quantification 
of spontaneous pain, a major feature of disease in humans [25, 36]. In this regard, observed 
behavioural measures such as reduction of spontaneous activity characteristic of pain as in 
the formalin induced pain (fIP) [37] or the reduction in spontaneous activity by adjuvant 
(RSAA) models [38] represent an advantage but yet do  not map the changes in spontaneous 
behaviour to the underlying biological substrates.
Although there are a number of potential mediators associated with neuronal firing 
and hypersensitisation, identification of the pathway(s) determining the progression of 
disease remains elusive. Consequently, in the absence of easily measurable markers of 
signalling dysfunction, behavioural measures have remained the endpoint of choice in the 
development of analgesic drugs. These difficulties may explain why NK1 antagonists have 
shown clear efficacy in preclinical models but failed in clinical trials [7].
The predictive value of animal models of pain
The predictive value of any animal model resides in our ability to understand which 
mechanisms are involved and which endpoints are measured, so that one can accurately 
assess and interpret correlations between pharmacokinetics and pharmacodynamics. yet, 
there is no unanimity on how well a compound should be expected to perform in animal 
models before it should be selected for study in patients [39, 40]. Translational studies in 
animal models and human subjects have identified an association between pathological 
mechanisms and symptoms such as tactile allodynia in the non-inflamed area and 
central sensitisation. However, it is not clear if this association represents a mechanistic 
underpinning for this particular symptom. Thus a critical path analysis is missing to explore if 
the tactile allodynia is always a consequence of central sensitisation or may also result from 
other related pathological processes such as sprouting of low threshold afferent terminals in 
the dorsal horn. A recent critique by van Der Worp et al. conclude that whilst animal models 
have contributed to our understanding of disease mechanisms, in most cases they may not 
be deemed suitable to inform clinical trials. They attribute the translational failure across 
species to the methodological flaws in preclinical protocols which cause a systematic bias in 
the evaluation of drug effects [41].
Apart from considerations of how translatable the preclinical models of disease are, findings 
from these studies are often confounded by poor experimental design. Meta-analyses of 
over 100 published studies have revealed that random allocation of treatment was done 
in less than 28% of the studies, while observer blinding was done in less than 2% of these 
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publications. Often no formal sample size calculations are done a priori to determine the 
appropriate number of animals given the expected effect size. In other cases, unplanned 
interim analyses are performed and experimental protocols continued when interim results 
are in favour of the working hypothesis. When results show a promising trend, additional 
data are collected, a practice commonly referred to ‘sampling to a foregone conclusion’[41].
Shortcomings of clinical measures of pain response
As discussed previously for pre-clinical models, the lack of appropriate tools to detect 
and quantify signalling dysfunction imposes the use of symptoms for diagnosis and pain 
management in the clinic. Global pain scores which quantify symptom severity provide 
evidence of the problem, but not its nature[1]. Patients are assessed according to symptom 
clusters under the assumption that common mechanisms underlie many if not all of the 
diverse etiological factors eliciting pain. Despite these limitations, subjective pain scales are 
still considered the gold standard to evaluate pain responses in clinical trials. The assessment 
of pain symptoms imposes some additional constraints to the evaluation of efficacy above 
and beyond the fact that the underlying pathophysiological processes may be irreversible. It 
creates a distortion of the magnitude of the symptoms. A typical visual analogue scale (VAS) 
is based on a continuous metric ranging from no pain to worst imaginable pain. Peak pain 
sensation for each individual is based on his/her previous experience which differs widely. 
As seen in figure 1.7 a standard VAS would distort this difference by equating the maximum 
pain for all individuals irrespective of their different subjective experiences[42].  
In analgesic trial reports it is also customary to report mean outcomes of global pain rating 
scales, as these studies are based on a hypothesis testing approach[25]. The differences 
in mean responses of apparently homogenous populations of patients are construed as 
evidence of clinical benefit.  This is counter-intuitive to the wide inter-individual variability 
alluded to in the preceding paragraphs. Subsequently, such a ‘group’ response is used as 
the basis for dose selection and formal assessment of efficacy. The lack of attention to 
inter individual differences and the concept of a ‘one-dose-fits-all’ means that analgesia 
is achieved in some patients, in others the same dose could either be ineffective or even 
toxic. In fact, in many cases such interindividual variability may be caused by differences in 
the underlying biological substrate.  Lee et al. showed that variability in gene expression for 
COX 2 (PTGS2) correlated with pain responses to different analgesics. Subjects homozygous 
for the gene had a better response to rofecoxib, while the heterozygote responded better 
to ibuprofen on VAS [43].
Lastly it should become clear to the reader that interindividual variability in pain response 
may be also explained by differences in target or even systemic exposure to the drug. The 
lack of pharmacokinetic sampling and sensitive measures of exposure thwart most attempts 






to establish exposure-response relationships. In contrast to situations such as anaesthesia, 
in which clinical response (nociception) is closely linked to systemic levels of an anaesthetic 
drug, nonlinearity and other time-variant processes make instantaneous circulating 
concentrations in plasma inappropriate metrics of drug exposure.
In summary, the absence of tools for early diagnosis and the lack of a dose rationale based 
on target engagement give rise to a chain reaction which prevents the identification of 
appropriate targets and compounds capable of restoring or blocking the progression of the 
underlying signalling dysfunction. These limitations are compounded by the fragmented 
process used throughout the various phases of development. There is little or no opportunity 
for the enforcement of a learning and confirming paradigm [44]
continuum, of adjectives to describe pain is roughly
constant (e.g. ‘small’ ! ‘medium’ ! ‘large’), adjectival
scales are elastic and can be stretched or compressed to fit
the domain of interest [26]. Thus, we can speak of small or
large mice and small or large elephants without difficulty.
The same occurs whenever we rate sensory experiences. If
individuals have experienced different levels of pain in the
past, they will stretch or compress the pain adjectival
scale to fit these past experiences.
The key to making valid comparisons across groups
composed of subjectswith differing sensory experiences is to
find a standard that is unrelated to pain. For example, we
can create a generalized VAS by including standards that
are unrelated to pain. A general VAS for pain could have
anchors such as ‘no sensation’ and ‘strongest sensation of
any kind’. This permits the inclusion of additional sen-
sations that can serve as standards for cross-modality
matching: for example, the brightest light ever seen (such
as the sun) or the loudest sound ever heard. Subjects could
also be asked to rate their sensations using a standard such
as an audible tone, and to express pain intensity rel tive to
the standard. In a recent study, subjects were asked to rate
the ‘strongest pain they had experienced’ and a variety of
remembered sensations, including the ‘brightest light ever
seen’ [26]. The strongest pain was rated approximately
equal to thebrightest light, onaverage, for themale subjects
(nZ72). For female subjects who had selected childbirth as
their most intense pain (nZ38), the pain was rated w20%
higher (P!0.01) than the brightest light [26].
The use of the term ‘imaginable’ does not solve
problems in making across-subject comparisons. In a
recent study (K. Fast, MD thesis, Yale University School
of Medicine), subjects rated both the ‘strongest imaginable
sensation of any kind’ and the strongest sensation of any
kind that they had ever experienced. ‘Imaginable’ was
rated w40% above the most intense sensation actually
experienced, and so it varies across subjects just as the
most intense sensation experienced also varies. Conse-
quently, a conventional VAS can conceal a real difference
in pain intensity across subjects (Figure 1).
Is it possible to make valid comparisons across
individuals given these considerations? It might be
possible by using multiple standards for comparisons. If
we share common experiences, we might be able to
capture specific differences by asking subjects to show us
how a given experience relates to these common experi-
ences. A scale could be constructed based o standards
such as the sound of a whisper, the intensity of a low-beam
headlight, the heat of an oven door, or the brightest light,
anchored by no sensation and the strongest sensation ever
experienced. The measurement of the unpleasantness of
pain just as important as the measureme t of the pain
sensation itself; however, the use of labeled scales can
invalidate affective comparisons just as it invalidates
sensory comparisons. In the case of taste, this problem
was addressed by asking subjects to rate the pleasantness/
unpleasantness of foods i the context of all pleasant and
unpleasant experiences [26]. Unfortunately, we know
much less about cross-modality matching of affect than
we do about sensation. It is possible that affective scales
can be used with sensory standards. Current pain scaling
might not be valid across subject and/or group
No pain No pain No pain No painNo painNo painNo painNo pain
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Figure 1. Illustration of the errors that can result from pain comparisons using the visual analog scale (VAS). If one subject’s worst pain is childbirth and another subject’s
worst pain is a stubbed toe, a rating at the same point on a scale anchored by worst pain imaginable could result in a discrepancy between the actual magnitude of pain
experienced and the amount reported on a conventional VAS. For example, in a representation of the ‘real’ world (a), Subject A has experienced much worse pain than has
Subject B, shown by differing length lines for their pain response continuum. The arrows illustrate each subject’s response to a painful experience that produced greater pain
to Subject A than to Subject B. By contrast, a conventional VAS could distort this view (b). Thus, when ‘worst pain’ is treated as if it were the same for both Subjects A and B, as
shown by equal length lines, the pains depicted by the arrows erroneously appear to have the same perceived intensity to both subjects. An even greater problem is depicted
in (c) and (d). (c) A pain that is only slightly greater to Subject A than to Subject B is shown. (d)When ‘worst pain’ is treated as if it were the same for both Subjects A and B, the
pains depicted by the arrows erroneously suggest that the pain is greater for Subject B than for Subject A. This is referred to as a reversal artifact; we have observed this in
taste [26]. Thus, a conventional VAS anchored by ‘no pain’ and ‘worst pain imaginable’ can conceal real differences in pain intensity across subjects.
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Fi re 1.7: fallaci s f p in compariso s using the VAS. If o e subj ct’s w rst pain is childbirth and an her’s is a 
stubbed toe, rating the same point on a scale would result in a discrepancy between the actual agnitude of pain 
experienced and that reported on a conventional VAS. Thus, as depicted in (a), subject A has experienced greater 
mag itude of pain t an B, it appears that th  pain intensity i  the same for b th s jects. In (c) he discrepancy 
is com ounded. Subject A experiences pain that is only slightly greater than that of subject B. When maximum 
pain is treated as it were the same for both subjects, the pain depicted by the arrows in (d) erroneously suggests 
greater pain for B than for A. This is referred to as reversal artefact. Thus a conventional VAS anchored by ‘no pain’ 
and ‘worst pain imaginable’ can conceal real differences in pain intensity across subjects. Adapted with permission 
from[32].
TOWARDS A NEW PARADIGM
The focus of this review was a critical appraisal of the reasons why analgesic drug development 
is plagued by high failure rates. Despite the few landmark publications in which a roadmap 
is proposed for the development of analgesic drugs [1, 4, 45], most of the new strategies 
overlook some of the conceptual elements highlighted in the various sections of this review. 
Our purpose is not to dispute the proposals put forth in the aforementioned publications, 
but focus on a few workable and practical aspects which are urgently required even in the 
current drug development paradigm.
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The role of biomarkers 
Morgan et al have summarised three elements that need to be demonstrated for a 
development candidate to survive all phases of development. These are 1) exposure at 
the target site of action over a desired period of time; 2) binding to the pharmacological 
target as expected for its mode of action and 3) expression of pharmacological activity 
commensurate with the demonstrated targeted exposure and target binding [31]. In 
conjunction with integrative techniques, such as mathematical modelling, we envisage that 
a biomarker guided strategy can play a central role in dose selection and in the screening of 
new candidate molecules.
A biomarker as defined by the Biomarkers Definitions Working Group is a characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes or pharmacologic responses to a therapeutic intervention. They can 
be classified as predictive markers or markers of pharmacology, when used early on in 
development and as prognostic markers or markers of disease/clinical response, when used 
in the later phases [46] In early development the availability of markers of pharmacology 
can provide evidence of target engagement and activation. Such biomarkers can be used as 
the basis for establishing exposure–response relationships, especially for progression from 
Phase 1 to Phase 2 studies.
In a concept allied to the three pillars of survival, Hargreaves et al. have categorised 
biomarkers into target, mechanism and clinical response. They stress that biomarkers 
should be deployed as early as possible first to confirm target engagement and then to 
test  whether target engagement alters the pathophysiological processes downstream and 
subsequently whether this mechanism affects the clinical response[47]. In addition to this 
functional classification, Danhof et al. have proposed a seven point mechanistic classification 
based on the location in the chain of events from underlying subject genotype or phenotype 
through to clinical scales [48].  An example of the concept is the KRAS mutation in advanced 
colorectal cancer which has been demonstrated in multiple trials to predict a lack of effect 
of monoclonal antibodies [46]. An application of such biomarkers is to optimize patient 
selection, wherein only those patients predicted to benefit most are enrolled in the clinical 
trial, i.e., in this case patients with HER2/neu positive gastric cancer are most likely to 
respond to trastuzumab therapy[46].
It should also be noted that in conjunction with mathematical modelling techniques, these 
classifications provide a framework for defining and discriminating drug from system-
specific properties. Such information can be used for inferences, extrapolations and 
hypothesis generation when evaluating novel molecules or exploring the efficacious dose 
range. An inherent challenge here is the level of evidence available to demonstrate the 
correlations between biomarker and response are causative and biologically consistent 
across different stages of disease [49]. This challenge is very pertinent to the assessment 
of the underlying signalling dysfunction which precedes the symptoms of neuropathic pain. 






Ideally, analogously to the use of thromboxane B2 and prostaglandins E2 as biomarkers for 
the evaluation of anti-inflammatory drugs acting on the arachidonic acid cascade, mediators 
or other functional measures are required that describe target engagement in nociceptive 
pathways. Such markers can subsequently serve as a tool for differentiating the sensitivity 
of other physiological and behavioural measures arising from signalling dysfunction. In fact, 
Huntjens et al. have given examples of how drug effects on biomarkers unravel differences 
in the sensitivity of behavioural measures to the selectivity of COX inhibitors [35].
In contrast to the developments observed in the evaluation of anti-inflammatory drugs, 
potential biomarkers such as glutamate, endocannabinoids, GABA or cyclo-oxygenase 
were identified but ultimately failed to provide qualitative and quantitative information on 
underlying processes[2]. None of these markers appear to satisfy the essential requirements 
for establishing a biomarker i.e. expression of the pharmacology or pathophysiology, 
feasibility, clinical relevance and ease of use [47]. Notwithstanding these failures, promising 
results have been observed with functional imaging techniques, such as functional magnetic 
resonance (fMRI), which allows characterisation of nociceptive phenotypes and positron 
emission tomography (PET), which yields reliable measures of receptor occupancy. Challenge 
models have also been considered as an alternative to the evaluation of disease processes 
under controlled conditions, such as the induction of secondary allodynia and hyperalgesia 
following subcutaneous or topical administration of capsaicin [45]. However, none of these 
markers have yet been adopted as mainstream technologies for the development of analgesic 
drugs. Their application in drug development requires similar efforts in medical practice, as 
clinical criteria will have to consider early diagnosis and prophylaxis. Similar awareness has 
evolved in the evaluation of drugs for Alzheimer’s disease, where interventions aimed at 
improving cognitive function are probably unlikely to prevent or mitigate the impact of brain 
tissue loss [50].
Modelling and simulation 
A discussion on biomarkers cannot be complete without highlighting their role in model-
based drug development. In contrast to empirical evidence, the central focus of model-based 
drug development is to use mathematical and statistical models that describe biological 
system and drug properties in a quantitative manner. Hierarchical or population models are 
among the various approaches currently used. An important property of hierarchical models 
is the ability to describe variability at individual level by identifying stochastic distributions 
that describe within and between-subject differences. Subsequently, these models can be 
used for inferences about the role of distinct components of a biological system as well as 
for making predictions about treatment effects and disease progression. 
Prior to any modelling activities, efforts are required  to clearly identify the modelling goals, 
understand the statistical requirements and  evaluate the most suitable parameterisation to 
solve the questions relevant to the modelling exercise[44]. This is an iterative process which 
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consists of the following steps: knowledge gathering, parameterisati on and model building, 
parameter esti mati on, model validati on and predicti on or extrapolati on by simulati on 
or simulati on scenarios [51]. At the simplest level of implementati on, pharmacokineti c-
pharmacodynamic (PKPD) models provide the ability to relate the drug exposure to the 
ti me-course of the pharmacological eff ects (or side-eff ects) [52]. Given the role of absorpti on 
and distributi on processes as well as the presence of functi onal barriers, pharmacokineti c 
equilibrati on models can be incorporated into the analysis to ensure accurate descripti on 
of drug dispositi on properti es, enabling inferences about drug exposure at the biophase 
(target site). furthermore, models also allow correlati ons to be established when nonlinear 
processes are required to describe signal transducti on or disease progression, both of which 
are associated with delays between the pharmacological eff ect and the ti me course of drug 
concentrati ons. Overall, one of the major advantages of a model-based approach is the 
opportunity to leverage prior informati on and integrate historical data in a more robust 
manner. Existi ng scienti fi c knowledge may be incorporated in the analysis of experimental 
data through deterministi c or stochasti c parameters (e.g., informati ve prior probability 
distributi ons) ,(see figure 1.8)[51]. 
Knowledge gathering  
• Listing assumptions 
• Leveraging prior 
knowledge 
• Obtaining experimental 
NME data 
Model Construction  
• Describing disease progression 
• Building structural exposure 
response model 
• Identifying covariates; explaining 
variability 
Outcome Simulation 
• Optimizing study design 
• Selecting perspective 
candidates 
• Testing sensitivity to 
assumptions 
Model based drug 
development 
Figur e 1.8: Main steps for the implementati on of model-based approaches in drug development. NME=New 
molecular enti ty. Adapted with permission from [51].
Perti nent to the uti lisati on of biomarkers in drug discovery and development is the role 
of mechanism-based PKPD models, which contain specifi c expressions to characterise, in 
a strictly quanti tati ve manner, processes on the causal path between drug administrati on 
and eff ect. This includes distributi on to the target site, interacti on with and acti vati on 
of the target, transducti on and infl uence of in vivo homeostati c feedback mechanisms 
[48]. Of parti cular relevance is that mechanism-based models facilitate the integrati on of 
informati on, including pooling of data from diff erent experimental conditi ons. Using the 
appropriate choice of parameterisati on it is possible not only to disti nguish drug from 






disease specific properties, but also to evaluate the impact of influential covariates on 
pharmacokinetics, pharmacodynamics and disease.
Another important dimension of model-based approaches is the use of models as a design 
and optimisation tool. In conjunction with other relevant statistical models, it is possible to 
explore trial or protocol-related issues such as, sampling requirement, drop-out, compliance 
as well as the statistical power to detect a predetermined treatment effect size [53].
One must also realise that not all experimental protocols are equally informative, irrespective 
of how accurate they are. In addition to the use of prior information, the use of a hierarchical 
model enables one to cope with experimental limitations, such as design imbalance and 
sparse sampling. In pain research, pharmacokinetic information is barely considered 
due to the potential interference pharmacokinetic sampling represents to behavioural 
experiments. Information from a satellite cohort can be complemented with very sparse 
samples from the actual treatment group providing evidence of differences in individual 
exposure, instead of relying on the dose or satellite data to describe pain response and the 
underlying exposure-response relationships [48].
The same principles apply to experimental design issues in clinical development. Efficacy 
trials with analgesic drugs barely take systemic or target tissue exposure into account. 
Attempts have been made to establish a dose-response relationship, without full 
understanding of the implication of intra and interindividual variability in pharmacokinetics 
and pharmacodynamics. The use of hierarchical models allows pharmacokinetic data 
from phase 1 studies to be integrated with sparse blood sampling from efficacy trials. This 
approach contributes to greater understanding of the role of pharmacokinetic variability on 
the observed individual differences in biomarkers and clinical response.
The availability of a validated PKPD model also provides the basis for further optimisation of 
experimental protocols by exploring what-if scenarios. In contrast to meta-analysis, clinical 
trial simulation (CTS) allows for the investigation of a range of design characteristics on the 
power to detect a treatment effect prior to exposing patients to an experimental drug. In a 
field where most clinical trials have a conservative design, this methodology offers a unique 
opportunity to evaluate innovative designs.  
In general, CTS utilises two types of models. first, a drug-action (PKPD) model is considered, 
which comprises pharmacokinetic and pharmacodynamic factors. In chronic diseases the 
model also accounts for disease progression. Unfortunately, the lack of knowledge about 
the mechanisms underlying treatment response in many therapeutic indications has 
prevented the development of mechanistic PKPD models, as is the case for chronic pain 
populations. Secondly, CTS requires a trial execution model. These models simulate other 
important aspects of the trial, such as dropout and protocol deviations. Thereby, one can 
determine all possible outcomes under candidate trial designs. It is also important to stress 
that CTS allows investigation of factors that cannot be scrutinised by meta-analysis or 
empirical design. first, designs which have not been implemented cannot be included in 
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a meta-analysis. Second, it is difficult to separate the influence of multiple design factors, 
whereas CTS allows evaluation of a single factor at a time. 
One of the main advantages of such a virtual or statistical experiment is the possibility to 
predict ‘trial performance’ and so to identify potential limitations in study and protocol 
design prior to its implementation. Regrettably, PKPD modelling and clinical trial simulations 
have been applied only sporadically in pain research. Data in the published literature 
suggests that such efforts were made to answer specific research questions, rather than 
used as the basis for a new paradigm or strategy [54].
CONCLUSIONS
There are several methodological issues that hinder the development of novel medications 
for the treatment of chronic pain. Essentially those issues can be clustered around a 
common denominator in that they are related to the construct validity of the experimental 
protocols used to assess drug effects. Multiple molecular and cellular mechanisms act 
concurrently to produce pain symptoms, which in turn are non-specific manifestations 
of the underlying nociceptive mechanisms. Most pain research has focused on transient 
behavioural models of pain that do not necessarily reflect what is occurring in a chronic pain 
patient. It is important to understand the changes in the nervous system that result in the 
pain experience and consider the need for interventions before symptoms evolve.  It follows 
that the appropriate measures of patient response are crucial in establishing a pattern of 
response, or lack thereof. On the other hand, studies focusing solely on chronic pain have 
overlooked the fact that such conditions may require prophylaxis rather than symptomatic 
intervention only. There are certainly missed opportunities whereby central sensitisation 
can be interrupted, effectively halting the metamorphosis of acute injury to chronic pain.
A new paradigm is required for the identification of relevant targets and candidate 
molecules in which pain is coupled to the cause of sensorial signalling dysfunction rather 
than to the symptoms. furthermore, biomarkers are required that enable characterisation 
of drug binding and target activity. We envisage the development of a biomarker-guided 
approach, by which target engagement is used as the basis for future pain research. Given 
that experimental limitations in this field cannot be completed eradicated, the success 
of such a biomarker-guided approach will also depend on scientific efforts to incorporate 
inferential methods by mathematical and statistical modelling and simulation. Biomarkers 
can be integrated in a systematic manner by pharmacokinetic-pharmacodynamic modelling, 
enabling the characterisation of exposure-response relationships and consequently 
providing a mechanistic underpinning be it for the purpose of interspecies translation or 
determination of the therapeutic dose levels in patients. 
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Neuropathic pain research remains a challenging undertaking due to the i) lack of 
understanding of the underlying disease processes and ii) poor predictive validity of the 
current models of evoked pain used for the screening of novel compounds. Common 
consensus is that experimental models replicate symptoms, i.e., have face validity but no 
construct validity. Another issue that requires attention is the sensitivity of endpoints to 
discriminate drug effects which are relevant to the disease in humans. In this paper we 
provide an overview of the pre-clinical models which can be used in conjunction with a 
model-based approach to facilitate the prediction of drug effects in humans. Our findings 
strongly suggest that evidence of the concentration-effect relationships is necessary for 
translational purposes. 







Physiologic pain usually arises as a result of the activation of nociceptive afferents by 
noxious stimuli which can lead to tissue damage, as e.g., during inflammation. Pain may 
also occur in the absence of or by sub-threshold stimulation of peripheral nociceptors. 
This type of pain is called neuropathic pain (NP). The International Association of the Study 
of Pain (IASP) defines NP as pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system [1]. following tissue injury, pro-nociceptive mediators 
are released that sensitise peripheral nerve terminals, which in turn trigger neurochemical 
and phenotypic alterations of the sensory nerves and increased excitability of spinal dorsal 
horn neurons(central sensitisation)[2]. Common causes of nerve damage and subsequent 
pain response include metabolic diseases, infection, ischemia, traumatic injury, malignancy, 
adverse drug reaction and toxins. However, the cause of neuropathic pain symptoms may 
not be easily linked to a cause in the majority of patients who experience it[3].  The lack 
of a clear aetiology has major consequences for the selection of treatments. In addition, 
it underlies some of the main hurdles in target identification and compound screening in 
drug discovery. Current efforts in research and development (R&D) therefore predominantly 
focus on the suppression of symptoms, rather than on the treatment of the primary cause(s) 
of pain [4]. In addition, these drugs often produce unacceptable side effects, making the 
clinical management of pain syndromes a major challenge [5].
The hallmark of NP is impaired sensation, with sensory dysfunction manifesting itself as 
hypo or hyperaesthesia for one or more modalities [6]. As a matter of fact, heightened 
pain perception to harmful painful stimuli (hyperalgesia) or to normally painless stimuli 
(allodynia) are often accompanied by spontaneous pains such as burning or electric shock-
like pain, paroxysms and dysaesthesia [7, 8]. Clinically, symptoms are classified into positive 
and negative.  This classification, which was primarily developed for diagnostic purposes, has 
also driven the choice of endpoints in clinical research protocols. Positive symptoms include 
mechanical and thermal allodynia and hyperalgesia, temporal and spatial summation, whilst 
negative symptoms are indicative of loss of sensory and motor function [9, 10].
Despite the symptomatic nature of drug therapy, existing treatments are suboptimal, with 
effective reduction in pain by an average of 40-50% from baseline in only 30 to 40% of patients 
[4, 11]. Available treatment options include opioids, anticonvulsants and antidepressants, 
all of which have a direct or indirect suppressant effect on neuronal activity. Besides limited 
efficacy, these compounds often cause dose limiting toxicities that, along with impairment 
in the quality of life, prevent titration to effective dose ranges [4]. from a drug discovery 
perspective, these findings are associated with a high attrition rate in the progression of 
candidate molecules. Whilst the overall probability of a candidate in development being 












































































































































































































































































































































SCREENING AND DEVELOPMENT OF ANALGESIC DRUGS
from the above, it is evident that challenges exist not only in the identification of suitable 
targets but also in predicting a priori the efficacy of compounds in humans. Given the 
gaps in the understanding of the mechanisms underlying neuropathic pain disorders, 
drugs are tested pre-clinically without a hint of which target will yield a clinically relevant 
response[11].This is further reinforced by the paradigm currently used for the screening 
of compounds, which relies on evoked-pain response associated with general positive 
symptoms such as allodynia and hyperalgesia. These models enable characterisation of the 
behavioural expression of pain processing, rather than specific features of the mechanisms 
of hypersensitisation[12, 13]. 
Advancements in this field require a clear distinction between the role of target, endpoints 
and drug properties, as primary causes of attrition. In this article we will explore the value 
of pharmacokinetic-pharmacodynamic (PKPD) modelling in conjunction with pre-clinical 
models of neuropathic pain as a tool for the translation of pre-clinical findings. This concept 
has been previously illustrated for the evaluation of the anti-inflammatory and anti-
hyperalgesic effects of different COX-inhibitors [13, 14], (figure 2.1).
Likewise, we envisage the use of model-based estimates of potency and efficacy as the basis 
for the dose rationale and improved prediction of efficacy in humans. Such an approach 
allows discrimination of drug-related factors from other causes of attrition in early drug 
development.
Animal Models and pain signalling and processing
In this review, the classification and underlying pathophysiology of pain are contextualised 
in terms of the various experimental models of evoked-pain (figure 2.2) and common 
behavioural endpoints[15]. To this end, we refer to the mechanisms of pain signalling and 
processing, which have been described as a continuum with three phases, specifically from 
nociceptive (Phase I) to inflammatory (Phase 2) and finally neuropathic pain (Phase 3). A 
correlation between the pain phases and the various models and measures is given below 
as basis for further discussions on the choices of parameterisation for pharmacokinetic-
pharmacodynamic models of pain.
The first phase within this continuum involves transient nociception and results from 
a noxious stimulus. Thus, at this stage there is minimal inflammatory response. Animal 
models of acute pain measure behavioural responses of naïve animals to noxious stimuli. 
Transmission of the stimulus occurs across A-δ and C fibres, which propagate fast and slow 
nociceptive response respectively [16]. Noxious heat is the most common stimulus applied 
in these models whereby the analgesic effects of drugs may be measured [17] 
Phase 2 pain or inflammatory pain results from tissue damage and inflammation secondary 
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to a noxious stimulus. In this phase, there is input from the damaged fibres to the CNS. 
Tissue injury causes mediator release creating an ‘inflammatory soup’, which up-regulates 
or activates nociceptive afferents. This barrage of information to the spinal cord triggers 
hyperresponsiveness of dorsal horn neurons [18]. A consequence of this hyperactivity is the 
development of symptoms such as hyperalgesia (an increased response to noxious stimuli) 
and allodynia (a painful sensation to non-noxious stimuli). Hyperalgesia and allodynia may 
be primary (i.e., close to the damaged area) or secondary (i.e., in tissues away from the 
damaged area). Secondary occurrence of these symptoms is indicative of central (spinal 
cord) sensitisation[16].  The neural pathways for transmission of this type of pain are similar 
to that for nociceptive pain. However, the spinal excitability is due to release of inflammatory 
neuropeptides from the activated C type primary afferents. Animal models that involve 
application of an inflammatory agent (formalin, capsaicin, mustard oil, carrageenan or CfA) 
elicit hyperalgesia and allodynia, thus mimicking phase 2 pain[16].
Phase 3 or neuropathic pain arises from lesions to or dysfunction of the nervous system, 
and thus all or part of the afferent input comes from damaged neurons. It manifests as 
spontaneous pain (stimulus-independent pain) as well as secondary hyperalgesia and 
allodynia [16, 18]. Animal models of NP in which phase 3 pain is elicited include partial 
or complete denervation of the sciatic nerve or of the spinal L5/6 nerves. In fact, partial 
denervation methods are widely used in NP research due to their resemblance to human 
NP. The Bennett, Seltzer and the Chung models are some of the common animal models 
used to describe this phenomenon[16]. 
Figure 2.2: Overview of commonly used experimental pain models for the screening of novel molecules in drug 
discovery and early characterisation of the pharmacological properties in drug development.






Although NP may be due to different aetiologies, all causes lead to damage of the 
nociceptive pathway [19]. However, it is important to realise that the assessment of pain in 
animal experiments remains essentially an indirect measure. There is no way to characterise 
the quality (shooting, stabbing, lancing) or intensity of pain. With the exception of aversive 
behaviour to potentially noxious stimuli (which includes vocalisation, biting, licking, shaking 
of affected limb); all measurements are based on a nocifensive reflex [16]. These models 
are potential candidates for surrogacy of human evoked pain, but are inadequate models 
of spontaneous pain which is frequently observed in patients [7]. Other endpoints such 
as latency of hind-paw withdrawal or intensity of the pressure producing withdrawal are 
applied as measures of treatment effect in both acute and chronic pain states irrespective of 
underlying differences in pathophysiology [16]. The von frey test is based on the assumption 
that a pain threshold can be reached, which reflects central hypersensitisation. However, 
in this test low threshold mechanoceptors and nociceptors are activated, indicating the 
stimulus is non-specific[17] .
Specificity of pain response and endpoints in pre-clinical models
The endpoints used in experimental models of pain can be categorised into a) pain-related 
behaviour, such as paw licking or b) threshold response, such as the latency time to paw 
withdrawal[20].The behaviour considered most indicative of pain in animals include 
autotomy or self-attack (assessed by counting the number of wounds inflicted), hyperalgesia 
(a strong withdrawal response to a moderate heat stimulus) and allodynia (withdrawal in 
response to non-noxious tactile or cold stimuli)[21]. These measures of pain perception 
involve more than just nociceptive pathways. Their effectuation requires the contribution 
of various CNS structures, which may be indirectly or directly susceptible to primary or 
secondary effects of drugs and may differ considerably from their counterparts in humans. 
Standard evaluation methods such as the hot plate or tail flick tests assess the presence 
of pain-like behaviour, but provide little information on the nature or quality of ongoing 
pain. furthermore, known differences exist in the biological substrate and natural course 
of disease associated with endpoints in different models of neuropathic pain (figure 2.3). 
for example, dynamic, brush-evoked allodynia in humans is mediated by low threshold 
fibre input, whilst allodynia in rats is static in nature, mediated by high threshold fibre input 
[22]. The tail-flick method, capsaicin or formalin induced pain model, the Bennett or Seltzer 






































































































































































































































































































































































Similar considerations apply to the repertoire of behavioural changes that are indicative 
of spontaneous pain  (e.g., increased weight bearing on the uninjured hind limb, guarding 
behaviour of the injured paw and licking of the injured paw coupled with ‘gentle’ biting and 
pulling of toe nails) [22]. In fact, endpoints classified as representative of spontaneous pain 
in humans have also been questioned as to the extent of their predictive validity. yet, whilst 
pain-like behaviour in animal models of NP is common, the corresponding symptoms are 
relatively infrequent in patients[25] .
Unfortunately, understanding of the correlation between the mechanisms of pain response 
(overt behaviour) and the underlying pathophysiology (pain signalling and processing) 
remains poor, especially if one considers the limited data on target site exposure or other 
downstream effects of drug action (figure 2.4). 
Figure 2.4: Despite evidence of peripheral hypersensitisation in the formalin-induced pain model, drug effects 
on nociceptive response are short lasting relative to the underlying pathophysiological changes, as indicated by 
the differences in the time course of pain behaviour (upper left panel) and concentrations of glutamate (lower 
left panel) in the spinal dorsal horn after administration of pregabalin[26]. Availability of pharmacokinetic and 
pharmacodynamic data is essential to explore such discrepancies in a quantitative manner and subsequently define 
a suitable dose range in humans. In this specific example, some discrepancy is observed between drug effects in 
animal models and humans. Response to pregabalin in rats occurs at levels above 4.0 μg/ml, whilst therapeutic 
levels after administration of a 50 mg dose are below 2.0 μg/ml. Reprinted with permission from [26].
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Table 2.1: Proposed relationship between neuropathic pain mechanisms and clinical symptoms and signs and 
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Sympathetic blocks α-receptor noradrenaline
Opioids Presynaptic  
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α1, 5-HT-receptors Changes of supraspinal 
descending modulation
Clonidine α2-receptors Inhibitory control
(NA, 5-HT)
5-HT, 5-hydroxytryptamine (serotonin); ASIC, acid-sensing ion channel; GABA, γ-aminobutyric acid; NK1, 
neurokinin1; NMDA, N-methyl-D- aspartate; TCA, tricyclic antidepressants. Adapted from [4, 32].






This gap prevents the use of a mechanistic approach for extrapolation of drug effect on 
behaviour into accurate estimates of analgesia in patients. furthermore, pain behaviour in 
humans is more varied and heterogeneous. In contrast to  the pre-clinical measures, the 
representation of clinical characteristics of NP has been based on (i) spontaneous, ongoing 
pain, with clear reference to pain quality and sensory loss which includes varying degrees 
of hypoaesthesia, and (ii) evoked pain, manifested by hyperalgesia and allodynia(Table 
2.1) [27]. Hence, a number of visual and numerical rating scales, such as the McGill pain 
questionnaire have been developed for the assessment of pain in clinical studies that 
capture the various dimensions of the disease [28], These scales provide information about 
the intensity, duration and location of the pain [29].
Lastly, it should be noted that integral components of pain such as the cognitive-affective 
part may not be possible to reproduce in pre-clinical species.  The differentiation between 
response features (e.g. pain relief and worsening) and mood disturbances in human pain 
cannot be replicated [22, 30]. This limitation is particularly important in chronic pain 
conditions, such as NP. Despite seeming pathophysiological similarities, none of the current 
models of neuropathy relate directly to clinical neuropathic pain conditions [23, 31].
Predictive value of pre-clinical models
Given the aforementioned differences across species, questions arise regarding the 
translational and predictive ability of pre-clinical models to describe the clinical phenomenon. 
Animal models are based exclusively on ‘pain-like’ behaviours or facilitated withdrawal 
reflexes, which in turn, are relatively infrequent in humans. In contrast, the commonest 
human complaints are tingling, paresthaesia and numbness rather than pain [25]. Therefore, 
the terms nociception and anti-nociception may be preferred in place of pain and analgesia 
[16]. It should also be unequivocal that animal models reproduce overt symptoms, i.e., they 
have face validity but are contextual in nature. for instance, paw withdrawal in response to 
a heat stimulus is observed both with inflammatory as well as neuropathic pain [33].
from a scientific perspective, the prerequisites for predictive value in experimental research 
include appropriate face and construct validity. An experimental model of disease or 
injury should be able to reproduce the symptoms observed in the clinical condition (face 
validity). At the same time, it is essential to mimic the pathophysiological changes which 
cause the overt symptoms (construct validity) [13, 34].  Commonly used animal models 
of neuropathic pain, such as the chronic constrictive injury (CCI) or sciatic nerve ligation 
(SNL), replicate elements of the pathology seen in clinical pain states, but have questionable 
construct validity with respect to specific pain syndromes, such as post herpetic neuralgia 
(PHTN) or diabetic neuralgia (DN)[24, 25]. In addition, homogenous strains are used which 
diverge from the heterogeneity of disease processes and progression in patients [35]. Such 
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an optimisation of experimental conditions may work against current efforts to predict 
treatment response in humans [12].
The failure in the development of NK1 antagonists as a putative mechanism for the treatment 
of NP illustrates the challenges in translational pharmacology research. The purported 
action of these compounds was blocking the actions of substance P, which has an important 
role in mammalian nociception. Lee et al. demonstrated that NK1 antagonists (intraplantar 
or intrathecal) attenuate NP symptoms in the SNT model. Based on their experiments, 
it was suggested that pain control methods targeting substance P and CGRP should be 
designed as new therapeutic strategies for peripheral NP [36]. However, in clinical studies, 
NK1 antagonists failed to reproduce the promise observed in animals [37].  In this example, 
the pathway selected had little relevance to the clinical disease, and the chosen endpoint 
was unable to differentiate this. Unfortunately, despite documented failures, some authors 
continue to defend the predictive validity of current animal models [22].
Target validation and new interventions
The absence of a mechanism based classification of pain syndromes consequently affects the 
selection of appropriate targets [38]. These hurdles are augmented by the lack of a process 
that ensures an integrated assessment of drug properties from target selection to proof-
of-concept [11, 14]. In the subsequent sections of this paper, we discuss the advantages 
of establishing pharmacokinetic-pharmacodynamic relationships as the basis for the 
prediction of efficacy in humans. Our objective is to show how quantitative pharmacology 
techniques can assist drug discovery in distinguishing whether the high rate of false positive 
findings in early drug development is due the lack of construct validity of animal models or 
simply because of the poor sensitivity of evoked response endpoints, which consequently 
lead to inaccurate estimates of the dose required for the evaluation of efficacy in humans. 
PKPD relationships themselves will not eliminate the issues with construct validity or 
unsuitability of behavioural endpoints. We believe however that PKPD relationships can be 
extremely useful if used as a biomarker of pharmacology, in which properties like binding, 
target activation or blockade and subsequent downstream effects are characterised in a 
quantitative manner. 
Translational Pharmacology
The high attrition rate in the development of compounds for neuropathic pain has prompted 
many investigators to revisit how pre-clinical findings correlate with efficacy data in patients 
[22, 25, 35, 39]. These reviews share a common view that evoked pain responses are 
inadequate measures of pain behaviour and do not represent pain processing in humans. 
They propose solutions ranging from modifications of current experimental models to the 
use of engineered mutant models [35, 40].  However, parameterisation of drug effect is 






presented in terms of ED50, without  accounting for the differences in pharmacokinetics 
across species and the requirements for characterisation of a dose-response curve [41]. 
finally, the duration of the effect and its relationship to target engagement is completely 
set aside [42].
Among the various publications, it is worth mentioning the attempt of Whiteside et al., 
who explored the correlations between pre-clinical to clinical data by comparing drug 
exposure in rats at the minimum effective dose (MED) for different models of inflammatory 
and neuropathic pain with clinical exposure in patients at the maintenance dose levels. 
Their conclusion is that pre-clinical animal models are predictive of efficacious exposures 
in humans [41]. However, the authors seem to overlook the fact that efficacious exposure 
ranges were considerably higher in rats as compared to humans. They indicate that the MED 
in rats for a single dose is not representative of clinical exposure, nor of the effects observed 
after repeated dosing. yet, total plasma concentrations are compared without taking into 
account interspecies differences in pharmacokinetics (i.e., drug distribution). for CNS drugs, 
the assumption that plasma concentrations reflect drug exposure at the site of action is 
often inappropriate. Another important aspect is the role of differences in metabolic rate, 
which lead to potential drug interactions if metabolites also have affinity for the target [43] 
(Table 2.1). 
Overview of experimental pain models
As shown in figure 2.2, despite the differences in the aetiology of pain in common 
experimental models, the screening for neuropathic pain compounds has also relied on the 
use of chronic inflammation models of pain [23]. In fact, the empiricism in the selection of 
compounds is further illustrated by the evaluation of anti-inflammatory drugs in neuropathic 
pain models.
In the subsequent sections, we will then explain which changes are required in the 
experimental design to allow appropriate characterisation of the concentration-effect curve 
for the screening of novel compound and translation of findings across species.
Inflammatory pain 
Ultra Violet B model 
Acute cutaneous overexposure to ultra-violet radiation (UVR) causes thermal and 
mechanical hyperalgesia in rats and humans. Using a UVB source, the plantar surface of the 
rat hind paws is irradiated to cause inflammatory reaction. This injury induces a significant 
dose-dependent reduction in both thermal and mechanical paw withdrawal thresholds, 
which peak 48 hrs after irradiation. The inflammation is caused by apoptosis of epidermal 
cells induced by DNA damage [44]. Algogenic chemicals are also released following UVR 
inflammation. The cutaneous hypersensitivity results in thermal hyperalgesia as well as 
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UVB mechanical allodynia. Spontaneous pain behaviour such as flinching, licking, excessive 
grooming or paw lifting are not seen with this model [45]. This model differs from the 
complete freund’s adjuvant (CfA) model in that it does not produce an increase in the spinal 
basal c-fos expression levels at the peak of sensory changes. There is little spontaneous 
activity in the primary nociceptors which in turn could sensitise the spinal nociceptive 
structure. This fact sets this model apart from the other algogenic models where central 
(spinal) sensitisation is observed. Hence the UVB model is sensitive to study effects of 
peripherally acting analgesics such as NSAIDs [45].
Neuropathic Pain
In neuropathic pain models, tissue injury is produced chemically or surgically, which leads 
to peripheral nociceptive sensitisation. These changes induce phenotypic alteration of 
sensory neurons and increased activation of spinal dorsal horn neurons. What follows is 
the development and maintenance of central sensitisation in the dorsal horn of the spinal 
cord [9, 18]. In persistent pain models, an algogenic substance such as capsaicin or formalin 
is introduced subcutaneously or intraperitoneally[46]. More specialised models envisage 
induction of nerve injury [47]. While they differ by locus and type of injury, all produce 
behavioural insensitivity as a result of the trauma [48].
Formalin-induced pain model (FIP)
The formalin test was developed for the screening of compounds with antinociceptive 
effects [46]. Recently it has been found to correlate with the CCI model, one of the best 
available models characterising neuropathic pain behaviour [49]. Two phases of nociceptive 
behaviour are observed following formalin injection. The first phase starts immediately after 
injection and lasts for 3-5 minutes. It is due to direct chemical stimulation of nociceptors 
and predominantly associated with activity in C fibres. Subsequently there is a quiescent 
phase of 10-15 minutes. The second phase starts 15-20 minutes after the formalin injection 
and lasts 20-40 minutes. Drugs effective in NP affect the onset and amplitude of the second 
phase (i.e. the quiescent phase is prolonged, whilst the maximum intensity of pain is 
decreased). The effect of formalin is believed to occur due to central sensitisation of dorsal 
horn neurones, as a result of the initial barrage of inputs from C fibre nociceptor afferents 
during the first phase. A role for higher brain regions in maintaining this pain state has also 
been hypothesised  [50]. The frequency of paw licking behaviour (PLB) per time interval is 
measured for NP drugs as compared to placebo [46].
Chronic constrictive injury models
 In contrast to complete transaction of the sciatic nerve, which does not reflect neuropathic 
pain pathophysiology in humans[51], these models comprise either a loose  ligature is 






placed around the entire  sciatic nerve (Benett model) or a tight ligature through half of 
the proximal sciatic nerve(Seltzer). Thermal and mechanical hypersensitivity is observed in 
both models but due to experimental complexities, the procedure is difficult to reproduce 
leading to variability in evoked responses [52, 53]. A variant to the CCI model was developed 
by Chung et al, wherein the L5/6 spinal nerves are ligated while leaving the L4 intact. In 
this way the intact dermatomes of the paw may be tested, though the L4 nerve is at risk of 
damage due to exposure [54].
Partial denervation models 
 These models were developed to further simplify technical feasibility as well as minimise 
variability associated with the degree of tissue damage. They enable the investigation of 
changes in injured primary sensory neurons and the neighbouring intact sensory neurons so 
that the relative contribution of both structures to the pathophysiology of neuropathic pain 
symptoms can be investigated. The spared nerve injury (SNI) model involves axotomisation 
of the tibial and common peroneal nerves while sparing the sural nerve [47]. The tibial nerve 
transection (TNT) represents a further modification of the SNI model. Nerve injury models 
are considered representative of symptomatically induced pain, allowing the evaluation 
of three different components of neuropathic pain, namely mechanical allodynia, cold 
allodynia and spontaneous pain. The threshold to response (withdrawal of the injured paw) 
is the primary measure for the assessment of drug effects [25, 55].
PKPD MODELLING OF PAIN RESPONSE
Translational drug research requires the prediction in a strictly quantitative manner of the 
pharmacokinetic-pharmacodynamic (PKPD) properties of drugs[56]. Assessment of PKPD 
relationships enables better understanding of how changes in drug exposure correlate to 
the pharmacological effects and overall response to treatment. To that extent, experimental 
protocols must be designed and customised accordingly to ensure that appropriate 
pharmacokinetic and pharmacodynamic data are obtained. Among other things, one needs 
to consider which dose levels to use, how long to sample and whether systemic exposure 
reflects target site concentrations .These requirements contrast, however, with current 
practice for screening protocols, which are usually performed in a standardised ‘one size 
fits all’ manner. As such these experiments are less informative, often precluding accurate 
estimation of the parameters of interest. 
Experimental requirements 
Given that behavioural models are primarily used for the purposes of screening and ranking 
of compounds, it is critical that potency estimates are accurate and expressed in terms of 
exposure (EC50), rather than dose (ED50). In this context, potency can be used as basis for 
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the scaling of PD estimates across species and/or endpoints. To that purpose, considerable 
changes to protocol design are required, which involve both modifications to the sampling 
procedures and the dosing rationale.  
Experiments suitable for PKPD modelling must therefore keep in mind some basic 
requirements regarding the time course of response. for instance, a minimum number of 
samples per animal are necessary for reliable estimation of PD parameters (e.g., baseline, Emax 
and EC50). This can be achieved by the use of sparse sampling and treatment with different 
dose levels. In contrast, PK sampling should provide enough information to characterise 
the absorption, distribution and elimination of the administered drug. Although the ideal 
situation is to have PK and PD samples measured concurrently, this may not be feasible 
in behavioural models of pain. In this case, a PK experiment can be performed prior to 
the assessment of drug effects. The advantages of this approach have been elegantly 
demonstrated by Bender et al.[57, 58]    for the analysis of drug effects in the CCI animal 
model. Another important point to consider is the observation window available for the 
evaluation of drug effects. Under non-stationary conditions, the disease process itself also 
needs to be characterised [26].  
Optimisation of Experimental Design 
In early drug development, screening of compounds ought to rely on accurate ranking of 
their pharmacokinetic (PK) and pharmacodynamic (PD) properties, yielding evidence of 
their pharmacokinetic-pharmacodynamic (PKPD) relationships [56]. However, the use of 
a model-based approach for the analysis of such experiments, while desirable, is often 
precluded by practical constraints and resources [14]. Suitable designs entail the use of 
repeated measurements that describe the time course of drug concentrations and the 
pharmacological effects of interest. feasibility considerations often limit the collection of 
repeated samples in individual animal and thus compromise the design of the experiment. 
Given the requirement for sparse sampling, appropriate sampling times become critical 
[59]. Therefore, accurate and precise model parameters estimates depend greatly on the 
experimental design.
In optimal experimental design, D-optimality is by far the most used criterion in individual, 
and population modelling studies. Herein optimisation is carried out assuming there is no 
uncertainty (imprecision around the parameters of interest) i.e. there is no uncertainty 
distribution around this parameter. This assumption does not hold true in population studies 
though it has been considered the classic approach to designing an experiment optimally 
[60, 61]. This method may not be suitable for prospective evaluation of the compounds 
during screening experiments when little data is available and prior knowledge about the 
pharmacokinetic and pharmacodynamic properties are limited. 






ED-optimality, represents an alternative for experimental data when the model parameters 
are expected to have  distributions [62]. The use of ED-optimality assumes a prior distribution 
around the parameters of interest [63]. While optimal design has been extensively used for 
optimizing different types of continuous repeated measurements, with non-linear mixed-
effects modelling, little work has been done with discrete data [64].
Data analysis requirements
Pharmacokinetic and pharmacodynamic data must be analysed in an integrated manner. 
Given the limitations to the number of samples that can be obtained per animal, nonlinear 
mixed effects modelling techniques are recommended for the assessment of concentration-
effect relationships (see box 1). Population pharmacokinetic models can be developed 
to predict systemic or target drug exposure at the time at which PD measurements are 
performed. In addition, optimal design concepts can be applied that overcome operational 
limitations to the sampling scheme, ensuring maximisation of the information gathered in 
the experiment [62]. 
In contrast to the linear regression methods applied to most dose-response curves, which 
rely primarily on observed experimental variables, nonlinear mixed effects techniques rely 
on model parameterisation which facilitates the distinction between system and drug-
specific properties. This subtle conceptual difference in data analysis gives a rational basis 
for ranking of compounds and allows preclinical findings to be translated to the clinical 
situation, assuming the model is applicable across species.
Box 1 - Nonlinear mixed effects modelling. further details on quantitative pharmacological methods can be found 
in [65, 66].
In nonlinear mixed effects modelling, two types of parameters are estimated: 
1) fixed effects, which are represented by parameters or factors usually explaining the correlation between the 
dependent and independent variables. These parameters define the structure of the model (e.g., a sigmoid 
curve) and their estimates reflect the typical value in the overall population.
2) random effects, which constitute the stochastic component of the mixed effects model. Random effect 
distributions can be identified for fixed effects with the objective of describing inter-individual and possibly 
inter-occasion variability. In addition, the residual error represents all the variability that cannot be described 
by the inter-individual and inter-occasion terms (e.g., measurement error)
 
PKPD models
Different approaches are available which account for the description of drug concentrations, 
drug effects and disease processes [67].  Direct models can be applied when plasma 
pharmacokinetics can be linked to the pharmacodynamic effects at any given time. Delays 
between response and pharmacokinetics in plasma due to slow biophase equilibration can be 
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described by effect compartment models [68, 69]. Indirect response models can be used to 
account for the pharmacodynamics of drugs that act by inhibition or stimulation endogenous 
mediators [70-72]. More complex transduction mechanisms can also be modelled by 
incorporation of a so-called transit compartment model [73]. Disease progression models 
require semi-mechanistic or mechanistic models to enable clear distinction between drug- 
and system-specific parameters [74, 75]. Various mathematical models can be implemented 
using different parameterisations for drug effect. Some of these aforementioned models 
are presented in box 2. further details on ongoing efforts in the characterisation of PKPD 
relationships are also mentioned in [41]. Interestingly, these concepts have been used more 
often for the analysis of clinical data (figure 2.5). Application of these concepts to preclinical 
models is scarce in the published literature. Recently, Bender et al. have modelled the 
effects of gabapentin in the CCI model (figure 2.6). Using appropriate protocol design and 
advanced modelling techniques, the authors demonstrate the predictive performance 
of a model describing variability in treatment effect across different dose groups for two 
different endpoints (paw withdrawal threshold and static allodynia).
Box 2 : Pharmacodynamic models [66]
Direct linear model: 






































Where baselineij and slopeij are the parameters to be estimated and and X ijk is usually a measure of drug 
exposure  (e.g.,plasma concentration, AUC) corresponding to the observed pharmacological effect yijk
Direct Emax model:






































Where baselineij, Emaxij and EC50ij are the parameters to be estimated and X ijk is usually a measure of drug 
exposure (e.g., plasma concentration, AUC) corresponding to the observed pharmacological effect yijk 
Sigmoid Emax model:
Where Baselineij, Emaxij , EC50ij and γj are the parameters to be estimate and Xijk is usually a measure of drug 
exposure  (e.g., plasma concentration, AUC) corresponding to the observed pharmacological effect yijk
 
The subscripts i, j and k indicate the individual subject i, at the time j and occasion or period k, respectively.






Figure 2.5: Predictive performance and accuracy of a pharmacokinetic-pharmacodynamic  (PKPD) model describing 
the effects of S()-ketamine in healthy volunteers. Simulations were performed with the S()-ketamine parameters 
obtained from the study data. Despite between-subject variability, it is clear from the panels that the PKPD model 
describes treatment response. (A) S()-ketamine concentration; (B) S()-norketamine concentration; (C) heat pain 
intensity; (D) electrical pain tolerance; (E) cardiac output. The lines represent the 10th, 50th, and 90th percentiles for 
simulated responses (black lines) and measured responses (gray lines). The symbols are the actual observations in 
the healthy volunteers. VAS visual analogue. Adapted with permission from [76]. 
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Figure 2.6: Time course of response for individual animals (circles) and the predicted population profiles (black 
lines) in the CCI model after administration of pregabalin alone or in combination with sildenafil. The drug effect on 
static allodynia was characterised by (A) the difference in PWT (i.e., the difference between the two paws divided 
by the difference at baseline).In both cases a continuous pharmacodynamic model was used to describe the 
concentration-effect relationship of pregabalin. The treatment groups included (1)saline,(2) pregabalin (4mg/
kg/h),(3) pregabalin 10mg/kg/h+sildenafil,(4) sildenafil,(5) pregabalin 1.6mg/kg/h+sildenafil and (6) pregabalin 
4mg/kg/h+sildenafil. Model predictions include the 90% prediction interval (shaded areas) [58]. Visual assessment 
of the random dispersion of the data within the predicted intervals provides evidence of the predictive performance 
of the model. Reprinted with permission from [58].
Scaling and dose rationale in humans
As indicated previously, one of main objectives of using a model-based approach is to identify 
parameters, which can be used subsequently to translate response from animal to humans. 
A direct application of the concept is the prediction of the efficacious exposure range and 
scaling of the dose across species. To this purpose, the concentration-effect relationships 
obtained in animals can be used to estimate the putative clinically effective dose range, 
taking into account the differences in protein binding across species. Given that differences 
in endpoints across species are not always correlated with each other in a fully mechanistic 
manner, derived parameters such as EC20, EC80, EC90 should also be considered. This concept 
has been elegantly illustrated by Huntjens et al in the evaluation of the anti-inflammatory 
pain by COX-2 inhibitors [13].
Given the complexity of pain signalling and processing, different results may be observed 
depending on which component or step is being quantified. We strongly believe that the 
answers regarding translational research lie in the use of experimental conditions which 
warrant construct validity [35, 78]. In fact, we defend a paradigm shift in the approach to 
interspecies scaling based on target/receptor occupancy. Receptor theory concepts can 
prove a useful tool for that purpose, enhancing the potential predictive value of a model-
based approach [56]. Moreover, the use of target occupancy as a marker of pharmacology 
may elucidate situations in which a mismatch exists between target activation and effect, 
as in the case of poor sensitivity of the behavioural endpoint. The cold hyperalgesia model 
is one such model wherein lowering the temperature below the threshold for nociception 
does not always provide for a better differentiation between the injured and normal paws 






of CfA rats [79]. In this context, a mismatch in the degree of target activation across species 
may explain differences in sensitivity in endpoints as well as in potency.  Hence, it would be 
desirable and useful to integrate receptor binding, which is a measure of receptor activation 
or inactivation (in case of an antagonist), with downstream markers of pharmacology and 
overt behaviour. from an experimental perspective, the use of imaging techniques would 
support the identification of differences as well as correlations across species. It should be 
noted that incorporation of the binding kinetics in the evaluation of novel compounds also 
offers an opportunity for better understanding of secondary pharmacological effects and 
adverse events. On the other hand, one should consider secondary pharmacology and safety 
findings as a proxy for target engagement when evidence cannot be derived experimentally. 
This concept is illustrated by the use of NMDA antagonists (e.g. ketamine) and alpha-2 
agonists (e.g. clonidine). Although tolerability in humans will ultimately determine dose 
selection, drug-induced adverse events are usually dose-dependent and specific markers of 
pharmacological action.
CHALLENGES AND LIMITATIONS 
It is beyond doubt that numerous challenges must be overcome to translate preclinical 
findings into predictors of clinical efficacy.  We have introduced the use of PKPD as a tool 
to bridge the translational gap but this approach itself has limitations. Animal models of 
pain are often technically laborious, making interindividual variability an intrinsic feature 
of these models[80]. Drug concentrations at the biophase are not constant over the course 
of treatment and can be altered by changes in the underlying pathophysiology or natural 
evolution of the experimental injury [81]. These variations may lead to biased estimates of 
parameters such as EC50 or Emax. Some aspects of disease are difficult to model; for instance 
NP symptoms wax and wane over time with intervals ranging from a day to as long as two or 
three months [82]. There are also feasibility limitations in terms of the number of samples 
that may be collected and of the overall duration of follow-up.
All these hurdles raise the question on whether R&D requires more extensive use of surrogate 
human models to ensure accurate prediction of clinical efficacy, forsaking preclinical 
experiments. Human models can reproduce many of the symptoms and sensory features 
in patients of NP [76]. By design however, these models lack construct validity, inducing 
acute plasticity i.e., phase 2 pain instead of long-lasting and irreversible modification of the 
nociceptive pathway, which is a hallmark of NP [83]. In other words, current human models 
mimic sensory symptoms reflective of both NP and nociceptive pain, yielding results which 




Empiricism has dominated target identification and screening of compounds for neuropathic 
pain.  Moreover, the existing models of behavioural pain response have been developed 
under the assumption that face validity suffices to translate drug effects from animals to 
humans, ignoring the requirements for accurate characterisation of pharmacokinetic-
pharmacodynamic relationships [84]. four main factors can be identified which explain 
the high attrition rate in this therapeutic area. first, the lack of sufficient understanding 
of the mechanisms of disease in humans prevents the identification of suitable markers of 
pharmacological activity. Such (bio) markers could be used in lieu of behavioural measures, 
which often misrepresent clinical symptoms in NP patients. Second, summaries of treatment 
effect are limited to qualitative estimates of drug action, most of which cannot be translated 
directly to humans. Third, experiments continue to assess dose-response curves, ignoring 
differences in pharmacokinetics across species. fourth, the duration of the effect and its 
relationship to target or biomarker engagement is completely set aside.
Our review shows that any claim regarding the translational value of a method requires 
comprehensive evaluation of the underlying PKPD relationship. Only then, is it possible 
to distinguish whether the lack of predictive value can be assigned to intrinsic limitations 
in experimental models (e.g., construct validity or poor sensitivity of the behavioural 
endpoints). We have also highlighted the relevance of the differences in the development 
of behavioural pain symptoms due to injury or noxious stimuli in these models, as compared 
to the onset and progression of symptoms observed in humans. While it takes a few weeks 
for the disease to be induced in an animal model, in patients this may take years to manifest 
[85]. A possible explanation for these discrepancies includes the differences in signalling 
mechanisms. Thus, one should accept that animal models may never be able to mimic all 
aspects of disease in humans and may be limited as a tool for qualitative distinction between 
active and inactive compounds.
In summary, the use of nonlinear mixed-effects modelling to characterise PKPD relationships 
in early drug development allows for a less empirical rationale for the selection of doses to 
be tested during first-time in human and proof of concept (POC)/Phase II studies. Model-
derived parameters may be used to estimate the effective dose range in humans assuming 
that the free concentration of the drug at the biophase can be compared across species. 
Our examples also illustrate that the translational value of a model-based approach relies on 
appropriate parameterisation. An integrated approach is needed which takes into account 
target engagement and markers of pharmacology as basis for the dose rationale in clinical 
trials.
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PKPD relationships and dose rationale in 
analgesic drug development - Scope and intent 
of investigations







The search for effective and safe compounds for the treatment of chronic pain remains 
a challenge for pharmaceutical research and development (R&D). Whilst the concept of 
an underlying dysfunction preceding overt symptoms and diagnosis is not unheard of in 
medical practice, the assessment of pain relief still prevails as the primary and often the 
only measure of efficacy in drug discovery and development. This paradigm has prevented 
the development of a more mechanistic approach for the selection and progression of 
candidate molecules for the treatment of chronic pain. In fact, one needs to realise that it 
is the dysfunction in signalling pathways that underpins the clinical symptoms of the post-
traumatic events and chronic inflammation. Such a dysfunction causes progressive tissue 
damage, including changes of neuroplasticity and synaptic remodelling when neuronal 
tissue is involved. In addition, it should be noted that the delay between the onset of the 
disease and overt symptoms may be associated with irreversible tissue changes, which 
makes the timing of any therapeutic intervention a key factor for the success or failure of 
treatment.
Hence, the evaluation of the biological and pharmacological properties of a new chemical 
entity (NCE) should provide the basis for dose selection and subsequent clinical profiling in 
clinical trials. Despite the challenges mentioned above, experimental protocols currently 
used both pre-clinically and clinically, seem to add complexity to the problem. They rely 
primarily on the suppression of symptoms and on behavioural measures of pain to define 
efficacious doses. furthermore, each  experiment is performed independently of the others. 
Experimental evidence is not generated with the objective characterising concentration-
effect relationships or to enable integration of the results from the preceding phase as the 
basis for predicting or extrapolating findings in a subsequent phase of the development 
process. The lack of data integration and the absence of suitable markers and measures 
of drug effect represent additional contributing factors to the poor decision making and 
inadequate go/no go criteria in chronic pain conditions. Undeniably, such an approach 
contrasts with the evolving understanding of disease and overlooks the role of quantitative 
tools in pharmacology and clinical pharmacology research.
In this thesis we will explore the advantages and challenges in the implementation of a 
model-based approach for the evaluation of efficacy of new chemical entities for chronic 
inflammatory and neuropathic pain conditions. More specifically, we will critically assess 
the requirements for data integration during the development process with the scope of 
facilitating the evidence synthesis and translation of findings across the different phases 
of development of a candidate molecule. Therefore, focus will be given to the relevance 
of pharmacokinetic-pharmacodynamic relationships and whenever possible to the use of 
suitable mechanism-based models. Our approach will highlight the extent to which the 
evidence obtained by empirical protocols disregards the tenets of pharmacology, making 
the discrimination of drug and system-specific parameters in a disease model very difficult. 
We will also show that the rationale for dose selection in humans must account for target 
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engagement in the population of interest. An important aspect of our work will be the 
use of mechanistic inference for the identification of key experimental requirements and 
decision criteria for the progression of a compound from early pre-clinical to late clinical 
development. 
from a drug discovery perspective, we will evaluate how to optimally integrate data and 
explore model parameterisations that potentially facilitate the translation between species 
and experimental protocol conditions. Despite the extensive discussion among drug 
developers on the development and availability of potential biomarkers, very little attention 
has been paid to the need for quantitative information about drug effects in such a way that 
parameters, rather than experimental variables can be used to characterise the implications 
of such effects in the target patient population. 
from a methodological perspective, we will challenge the current regulatory and clinical 
paradigm that imposes formal evidence of pain relief without further consideration of 
the underlying pharmacological activity. Our work will highlight how statistical methods 
such as optimal design can be used in conjunction with modelling and simulation for 
the evaluation of drug effects when noise in experimental measures and uncertainty in 
parameter estimation are high. Moreover, we will attempt to demonstrate the flaws in the 
assumption that empirical evidence from clinical trials suffices to support dose selection 
in a highly heterogeneous population. In this context, we will illustrate how differences 
in demographics as well as inclusion and exclusion criteria and protocol design which are 
applied to phases 2 and 3 trials can be evaluated in silico by clinical trial simulations. 
Our working hypothesis is that a model-based approach is required for accurate 
characterisation of candidate molecules pre-clinically and subsequently for the selection 
of the dose to be used in humans throughout clinical development. We will evaluate model 
parameterisations which take into account the underlying pharmacological effects and 
demonstrate how critical they are for the dose rationale as well as for extrapolation across 
species and phases of development.  Specifically, this thesis will evaluate existing data from 
compounds with known analgesic effects in neuropathic pain and explore the properties 
of an investigational molecule for chronic inflammatory pain to address the following 
questions:
1. Can modelling and simulation (M&S) facilitate the translation of experimental findings 
across different phases of drug discovery and development, improving the predictive 
value of experimental protocols?
2. Can historical data be integrated to support model parameter estimation and 
subsequently applied as priors during the evaluation of efficacy?
3. Which experimental and methodological requirements are critical for optimising the 
evaluation of novel compounds?






4. What is the benefit of characterising concentration-effect (PKPD) relationships as the 
basis for the dose rationale in humans?
5. Can clinical trial simulations be used for the optimisation of the dose selection and 
discriminate drug-induced effects from other confounders in the target patient 
population?
To ensure clarity and provide appropriate focus to the different questions and issues 
highlighted above, this thesis is split into three main sections. After a general introduction 
in which we revisit the pathophysiological basis of chronic inflammatory and neuropathic 
pain and describe the most common approaches currently used for the progression of an 
analgesic, we explore the technical requirements for model parameterisation and define 
the requirements for experimental design optimisation, with special focus on the use of 
binary measures of response during the screening and ranking of candidate molecules in 
neuropathic pain. Subsequently, focus is given to model parameterisations which enable 
the assessment of concentration-effect relationships as the basis for translation of the 
pharmacological properties of a molecule across species as well as for bridging across 
different phases of development. Lastly, an attempt is made to model clinical response in 
chronic inflammatory pain and establish correlations between symptom improvement and 
the underlying pharmacological effects using biomarkers. In addition to emphasising the 
role of biomarkers in drug development, our work shows how clinical trial simulations can 
be used as a design tool, enabling the evaluation of a variety of scenarios that disentangle 
the contribution of pharmacology from the confounding effects of placebo and disease 
dynamics. Our conclusions are presented taking into account the requirements for 
prospective evaluation of novel compounds where one or more of the aforementioned 
issues have to be dealt with.  
1. GENERAL INTRODUCTION: TRANSLATIONAL PHARMACOLOGY OF DRUG 
EFFECTS IN CHRONIC PAIN
In Chapter 1, an overview of the ongoing research efforts in neuropathic and chronic 
inflammatory pain is presented. focus is given to the pathophysiology of disease and to 
the notion that pain is the consequence of an underlying signalling dysfunction. In chronic 
conditions, such a dysfunction can lead to irreversible changes, which are common  to the 
course of progressive diseases in general. We discuss how early diagnosis, timing of the 
intervention and reversibility of the underlying processes ultimately determine the success 
or failure of a treatment. The identification of effective targets and therapies must account 
for these factors. The limitations and flaws in the current paradigm for the screening and 
selection of compounds in drug development are then highlighted and used as a foundation 
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for the subsequent chapters in this thesis. An approach is proposed in which the treatment 
of pain is considered from a mechanistic perspective, rather than based on the suppression 
of symptoms, which are often non-specific manifestations of the multiple nociceptive and 
cognitive mechanisms. These principles are expanded in the discussion of the predictive 
value of animal models, which resides in our ability to understand which mechanisms are 
involved and which endpoints are measured, i.e., they must have construct rather than face 
validity. Lastly, we introduce important methodological concepts pertinent to the evaluation 
of biomarkers, which are essential for the prediction of efficacy if one takes into account the 
delay between the onset of the signalling dysfunction and the development of overt pain 
symptoms. In this context, we consider the requirements for experimental design, analysis 
and interpretation of results and the relevance of mathematical and statistical models as a 
tool to describe biological system and drug properties in a quantitative manner. Hierarchical 
or population models are proposed as the basis for identifying the different sources of 
variability at individual level. Using the appropriate parameterization, these models can 
then be used for inferences about treatment effects and disease progression. 
The role of concentration-effect relationships and more broadly of modelling and simulation 
as the basis for translational research is advanced in Chapter 2, where various experimental 
models of evoked-pain and their inherent limitations are presented. Of interest is the lack 
of construct validity in most if not all experimental models used in preclinical research. 
This issue is further compounded by the use of endpoints, which usually describe pain-
related behaviour or threshold response, without evidence of a clear correlation between 
target engagement and the underlying pharmacodynamic effects that can be observed 
after drug administration. Here we also draw attention to the fact that the measures of 
pain perception currently used in experimental models involve more than just nociceptive 
pathways. Their effectuation requires the contribution of various CNS structures and can 
therefore differ considerably from their counterparts in humans, explaining partly why so 
many compounds that appear to show pharmacological activity in animals ultimately fail in 
humans. This gap prevents the use of a mechanistic approach to translate and extrapolate 
drug effects on behaviour into accurate estimates of analgesia in patients. In fact, different 
from the pre-clinical measures, the representation of clinical characteristics of chronic pain 
in patients has been derived from spontaneous, ongoing pain, with clear reference to pain 
quality and sensory loss using a number of visual and numerical rating scales. These scales 
provide information about the intensity, duration and location of the pain. 
finally, using recent examples from the published literature, we emphasise the requirements 
for the assessment of concentration-effect relationships in pre-clinical species, including 
important changes in experimental procedures in standard screening protocols. Among 
other factors, we discuss the importance of expressing potency estimates in terms of 
exposure (EC50), rather than dose (ED50). Poor experimental design can lead to inaccuracies 






in parameter estimation and consequently to biased selection and ranking of candidate 
molecules during screening. In this context, the use of optimality concepts is suggested as 
an opportunity prevent or address shortcomings in the data analysis due to inappropriate 
sampling procedures or poor dose rationale.  
 Based on a careful review of 1) the signalling dysfunction(s) underlying pain symptoms 
presented in the aforementioned paragraphs; 2) on the translational gaps in the experimental 
protocols currently used during drug screening for the selection of candidate molecules 
and  3) the empirical use of clinical scales during the evaluation of pain relief in clinical 
studies, specific issues have been identified in the current strategy for  assessment of the 
putative therapeutic dose range in humans which will underpin the scope  and intent of 
the investigations described in this thesis, as detailed here in Chapter 3. In the following 
paragraphs, we describe our endeavours to evaluate the role of historical data, protocol 
optimisation, model parameterisation and integration of biomarkers as the basis for 
statistical inference and prediction of the therapeutic dose in chronic pain.
2. MODEL BASED APPROACH FOR THE ANALYSIS OF BEHAVIOURAL PAIN 
RESPONSE IN PRECLINICAL ExPERIMENTS  
As indicated previously, the lack of suitable markers of pharmacology and absence of an 
approach that enables better data integration for the selection of candidate molecules 
contributes to the attrition rate in chronic and neuropathic pain conditions. Whilst 
the assessment of concentration-response relationships across the different phases of 
development is a sine qua non condition to accurately account for the determinants of drug 
response and variability, the evidence of PKPD relationships for a compound in itself does 
not warrant accurate statistical inference from one experiment to another, in particular with 
regard to the translation or prediction of drug effects. PKPD relationships must have predictive 
validity or value for the target population, both in qualitative and quantitative terms. Such 
considerations are not formally embedded in the requirements for evidence generation, and 
consequently lead to the implementation of experimental protocols, which are often not 
fully informative or eventually even biased.  In Chapters 4 and 5 the fundamental questions 
to be addressed are which molecules show efficacy and how this effect can be reliably and 
quantifiably demonstrated. To this end, we explore how models and model parameters 
can be used prospectively in drug screening taking into account various experimental and 
technical limitations. Using theoretical concepts in optimal design we also explore the 
requirements for experimental protocol design. Our approach is based on the assumption 
of a binary outcome as benchmark or strategy for drug screening. In addition, we evaluate 
the possibility of dissecting system from drug-specific features, allowing the introduction of 
modularity, which is essential for the assessment of drug potency as parameter of interest 
during screening. Given the limited amount of data available, optimisation methods are 
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considered, which allow incorporation of uncertainty in parameter estimation. Hence, 
ED-optimality is applied in combination with a logistic regression model describing the 
relationship between drug exposure and response to evoked pain in the complete freund’s 
adjuvant (CfA) model in rats. Here the design variables selected for optimisation include 
the dose levels and sampling times required for the characterisation of the analgesic effects 
of two paradigm compounds, namely, gabapentin and pregabalin. Moreover, a general but 
robust parameterisation is used which enables integration of historical data into the analysis. 
Information regarding system-specific model parameters and relative in vitro potency data 
are evaluated as priors during optimisation. The approach allows a shift of the efforts usually 
required for model building into relatively simple parameter estimation procedures. Our 
aim is to decrease the uncertainty on EC50 estimates as well as on the corresponding inter 
individual variability. We anticipate that these procedures will also provide the basis for the 
validation of experimental models of pain in terms of sensitivity and specificity, i.e., enabling 
the characterisation of the false positive and false negative rates.
The advantages of model parameterisations based on drug- and system-specific properties 
is further explored in Chapter 6, where we illustrate the suitability of a semi-mechanistic 
model to describe the effects of gabapentin on formalin-induced pain. In the formalin-
induced pain model, the observed behaviour in response to a painful stimulus, assessed as 
flinching frequency, is used as measure of efficacy. This behavioural measure is thought to 
reflect both the sensory and emotional aspects of pain, making it possibly one of the most 
predictive models among the available experimental models of pain. Even though differences 
are known to exist between the substrates underlying the pathophysiology of nociception 
in this pre-clinical model and in humans, it is imperative that model parameterisations are 
selected, which enable the assessment of correlations between species.
Except for a few publications, the vast majority of data arising from experimental models 
of pain are of limited value for quantitative and translational purposes, as measures of 
potency are in terms of dose or other empirical functions, which ignore systemic and target 
tissue exposure to the drug. We believe that any serious effort in translational research 
using experimental models of behavioural pain must take into account pharmacokinetic 
information as well as the time course of treatment response.  Availability of such data 
provides insight into variability in drug disposition as well into the kinetics of drug action, 
i.e., the reversibility of the effects. Consequently, one can consider a range of ancillary 
approaches, such as allometric scaling to extrapolate PKPD relationships from animals to 
humans. Lastly, we explore the relevance of parameter estimates by comparing our findings 
with published data from other experimental models of pain as well as with clinical data in 
neuropathic pain patients. Among the possible explanations for the discrepancies across 
species, we emphasise the need to carefully assess the degree of target engagement and 
drug distribution to the site of action.






yet, our endeavour to characterise the concentration-effect relationships for gabapentin 
using the inhibition of flinching behaviour as a measure of drug effect highlights the 
implications of the lack of biomarkers as an intermediate step for the translation of the 
pharmacological properties across different phases of development.  Undoubtedly, there 
is a pressing need to obtain early signals of efficacy by means of biomarkers, which can 
be used not only as a “scaling factor” to translate drug effects from pre-clinical species 
to humans, but also as a tool for extrapolating drug effects across populations during 
drug development. The requirements and points-to-consider for the implementation of a 
biomarker guided approach are the presented in the next section of the thesis.
3. LOST IN TRANSLATIONS-FROM BIOMARkER RESPONSES TO CLINICAL END 
POINTS 
As indicated in the previous paragraphs, the integration of biomarkers of pharmacology 
into drug development offers the possibility to eliminate part of the bias that arises from 
empirical evidence using nonspecific behavioural measures. In Chapter 7, we therefore 
make an attempt to show that opportunities exist for truly characterising the clinical 
pharmacological profile of novel molecules in humans when biomarkers are used as 
predictors of efficacy, enabling mechanistic insight into the exposure-response relationships 
and consequently better rationale for the therapeutic dose range.  Moreover, the assessment 
of pharmacokinetic-pharmacodynamic relationships based on biomarkers can provide a 
stronger basis for personalised medicine, a concept which has mistakenly been linked to the 
tailoring of treatment based on the use of genetic information only. 
Here we analyse data from a cyclo-oxygenase (COX) inhibitor to illustrate the concept of 
biomarker-guided dose selection and emphasise the importance of gaining insight into the 
clinical pharmacology of the compound as the basis for the dose rationale.  The choice of the 
COX-2 system as a paradigm was dictated by the various reports arising from the withdrawal 
of different drugs from the market, for which the clinical pharmacology profile was clearly 
known to determine efficacy and safety across different therapeutic areas, such as rofecoxib 
and efalizumab. By integrating pharmacokinetic data from a first-time-in-human clinical trial 
with inflammatory mediators obtained in an ex vivo assay, namely prostaglandins E2 (PGE2) 
and thromboxane B2 (TXB2), we show how biomarkers can be used to guide dose selection 
in subsequent phases of drug development. With the help of simulation scenarios we then 
illustrate how biomarkers can be used to explore the need for dose adjustment in special 
populations.
Lastly, we expand the concept of biomarker-guided dose selection to Phase 2 clinical trials, 
in which efficacy is assessed as primary endpoint in a protocol, to gain further insight into 
the relationship between biomarkers and overt pain symptoms. By applying the mechanistic 
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classification proposed by Danhof et al., it is possible to identify whether exposure-biomarker 
response relationships are drug- or disease-specific and consequently to establish whether 
they can be used as predictive and prognostic tools during the development and therapeutic 
use of novel medicines[1]. In Chapters 8 and 9, ACRn scores from a large clinical trial in 
rheumatoid arthritis patients are used to model the exposure-response relationships of a 
COX-2 inhibitor.  Whilst the utility of the ACRn as an index of clinical improvement is beyond 
doubt, its correlation with the underlying pharmacological activity following administration 
of a COX-2 inhibitor has never been established. 
An integrative approach is therefore proposed in which longitudinal data are used, i.e., 
information is derived about the time course of treatment response. This contrasts 
with current practice, in which efficacy is determined by comparing the differences in 
clinical response at completion of treatment in the active vs. placebo arms, In fact, this 
example also shows how biomarkers can be used to ensure that the appropriate level of 
pharmacological activity is achieved and maintained during the course of therapy. More 
specifically, our analysis is based on the assumption that the optimal benefit-risk balance is 
likely to be achieved when COX-2 inhibition is maintained above 80% but below 95%.  from 
a conceptual standpoint, such an approach represents a shift from the empiricism which 
dominates the design of Phase 2b and 3 trials, allowing the implementation of a learn-and-
confirm paradigm. Ultimately, a putative PKPD relationship can be derived, which forms the 
basis for the selection of the dose in efficacy trials.
4. CONCLUSIONS AND PERSPECTIVES
The final chapter of this thesis summarises the main findings and conclusions from the 
investigations presented throughout the various chapters.  In Chapter 10, we advocate the 
need for data integration in support of experimental protocols that support the assessment 
of pharmacokinetic-pharmacodynamic relationships. We provide recommendations for the 
selection of candidate molecules and prediction of the therapeutic dose range based on the 
assumption that accurate inferences can be made about drug-specific properties, if data 
generation accounts for the distinction between drug- and system-specific characteristics. 
We emphasise that whilst a distinction can be made with regard to the focus on neuropathic 
pain, at the beginning of this thesis, and chronic inflammatory pain in the later chapters, 
most of the concepts underpinning this work are equally applicable to both conditions and 
more broadly to other chronic diseases. We concede that currently available models have 
limited value. Clearly, the issue in the evaluation of neuropathic pain conditions is whether 
existing or new experimental models may ever provide us the basis for translating drug 






effects from animals to humans without evidence of common biological substrates. yet, a 
model-based approach is essential to optimise the design and interpretation of preclinical 
experiments, making them more informative. It also contributes to mechanistic inferences, 
enabling systematic integration of data and information from a vast range of resources 
available to us. Apart from considering advancements in the field of imaging and proteomics 
as possible markers of disease progression, we offer insight into novel research protocols 
and how these can be used to reduce uncertainty about the potential clinical relevance 
of candidate molecules, enabling selection of the putative therapeutic dose range and 
transition from the pre-clinical phase to humans.
A slightly different scenario is presented with regard to the challenges one faces in the 
evaluation treatment effects in chronic inflammatory pain, for which biomarkers exist and 
imaging technology is already being used. We also reiterate the importance of revisiting 
current guidelines, which dismiss the role of pharmacological activity as the basis for dose 
selection and exclude the concept of learning and confirming elegantly stated by Sheiner 
et al. in their landmark paper[2].Undoubtedly, the use of simulation scenarios will play 
an increasingly important role in the evaluation of the impact of heterogeneity in target 
population as well as of variability in pharmacokinetics, pharmacodynamics and response 
to intervention. finally, we envisage that further advancements in the prediction of pain 
response can be obtained by expanding the concepts to multiple endpoints as well as by 
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The high variability in the response to evoked pain prevents accurate ranking of compounds 
during the screening of drugs for inflammatory and neuropathic pain.  In this study, we 
explore the feasibility of introducing optimality concepts to experimental protocols, enabling 
estimation of parameter and model uncertainty. 
Pharmacokinetic and pharmacodynamic data from different experiments in rats were 
pooled and modelled using nonlinear mixed effects modelling. Pain data on gabapentin and 
placebo-treated animals were generated in the complete freund’s adjuvant (CfA) model of 
neuropathic pain. A logistic regression model was applied to  optimise sampling times and 
dose levels to be used in an experimental protocol. Drug potency (EC50) and inter individual 
variability (IIV) were considered the parameters of interest. Different experimental designs 
were tested and validated by SSE (stochastic simulation and estimation) taking into account 
relevant exposure ranges.
The pharmacokinetics of gabapentin was described by a two-compartment PK model 
with first order absorption (V2=0.118 l, V3=0.253 l, Cl=0.159 l/h, Ka=0.26 h-1, Q=1.22 l/h). 
Drug potency (EC50) for the anti-allodynic effects was estimated as 1400ng/ml. Protocol 
optimisation improved  bias and precision of the EC50 improved by 6 and 11.9.%, respectively, 
whilst interindividual variability (IIV) estimates showed improvement of 31.89  and 14.91%, 
respectively. 
Variability in behavioural models of evoked pain response leads to uncertainty in drug 
potency estimates and consequently to inaccurate ranking of compounds during screening. 
As illustrated for gabapentin, ED-optimality concepts enable analysis of discrete data taking 
into account experimental constraints.







Despite the number of compounds entering early clinical development, neuropathic pain is 
an area of high attrition rate, with most treatments failing at proof-of-concept in patients. 
This situation is critical if one considers that currently available drugs for neuropathic pain 
show less than 50% efficacy in the overall target population [1]. Among other factors, the 
lack of efficacy in humans has been assigned to the poor correlation between evoked pain 
in pre-clinical models of disease and the differences in aetiology in humans [2]. On the other 
hand, another important point which has remained less evident is the fact that experimental 
protocols in pain research are often based on empirical criteria[3] and little or no attention 
is given to basic concepts such as accuracy and precision. Poor experimental designs often 
lead to biased and inaccurate parameter estimates [4], which consequently may influence 
the selection of suitable candidate molecules for progression into humans.
In early drug development, screening of compounds ought to rely on accurate ranking of 
their pharmacokinetic (PK) and pharmacodynamic (PD) properties, yielding evidence of 
their pharmacokinetic-pharmacodynamic (PKPD) relationships [5]. However, the use of 
a model-based approach for the analysis of such experiments, while desirable, is often 
precluded by practical constraints and resources [6]. Suitable designs entail the use of 
repeated measurements that describe the time course of drug concentrations and the 
pharmacological effects of interest. feasibility considerations often limit the collection of 
repeated samples in individual animal and thus compromise the design of the experiment. 
Given the requirement for sparse sampling, appropriate sampling times become critical 
[7]. Therefore, accurate and precise model parameters estimates depend greatly on the 
experimental design.
In the current investigation, we use the CfA model, a well-known experimental animal 
model of inflammatory pain [8, 9], as paradigm to explore the feasibility of introducing 
optimality concepts in the screening of analgesic compounds. Dichotomisation of response 
is proposed as the basis for generalisation of a model-based approach in this phase of 
development. In optimal experimental design, D-optimality is by far the most used criterion 
in individual, and population modelling studies. Herein optimisation is carried out assuming 
there is no uncertainty (imprecision around the parameters of interest) i.e. there is no 
uncertainty distribution around this parameter. This assumption is also a disadvantage 
since for D-optimality to be applied, the true parameter value should be determined based 
on prior knowledge or model fitting in a previous exercise [10]. Although D-optimality has 
been considered the classic approach to designing an experiment optimally [11, 12], this 
method may not be suitable for prospective evaluation of the compounds during screening 
experiments when little data is available and prior knowledge about the pharmacokinetic 
and pharmacodynamic properties are limited. 
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Here we apply ED-optimality, an approach which has been applied in different areas of 
clinical research when the model parameters have uncertainty distributions [4]. The use of 
ED-optimality assumes a prior distribution around the parameters of interest [13]. While 
optimal design has been extensively used for optimizing different types of continuous 
repeated measurements, with non-linear mixed-effects modelling, little work has been done 
with discrete data [14]. We aimed at defining optimal design requirements for screening 
experiments, assuming EC50 and inter-individual variability as the parameters of interest for 
optimisation.
We anticipate that improved parameter precision and accuracy will contribute to better 
ranking of compounds and enhanced ability in discriminating false positives from false 
negatives during the screening of compounds for neuropathic pain.
MATERIALS AND METHODS
Experimental Procedures
In the CfA model, central sensitisation (NP) is induced following injection of an algogen. 
Allodynia or pain with a non-noxious stimulus is then measured as threshold to affected paw 
withdrawal with increasing diameter of von frey filaments [15]. The experimental protocol 
was performed according to a double-blind, randomized, placebo controlled study with 
9 animals per cohort. Sprague-Dawley rats received single doses of 0, 10, 30,100 mg/kg 
gabapentin orally. The study was approved by the Institutional ethics committee.
Pharmacodynamic measurements
The threshold to paw withdrawal to a normally non-noxious stimulus was measured as a 
marker of the anti-allodynic effect, whilst the change in threshold relative to baseline was 
selected as the PD endpoint. PD measurements were collected at hourly intervals for 4 h 
post-dose for each animal.
Pharmacokinetic experiments / measurements
PK data were obtained from 2 separate experiments in conscious rats. In the first, 
gabapentin was administered orally in the doses 0, 10, 100, 300 mg/kg in a formalin induced 
hypersensitivity experiment [16]. There were three rats per dose group, with each animal 
being sampled four times up to 6 hours post dose.  In a second experiment, 63 animals 
received 50 mg/kg of gabapentin as an IV infusion. The rats were sampled 8 times up to 24 
h post dose [17].








The threshold for paw withdrawal was dichotomised as a binary response variable, with 
response being defined as changes in the threshold for paw withdrawal were >30% relative 
to baseline. The exposure-response relationship was modelled using a logistic regression 
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Where p is the probability of an event P, x are parameters and independent variables 

















































plnlogit(p)     (2)
        
An Emax model was considered for the characterisation of the drug effect on the logit space. 
Random effects were denoted by η. This term represented both inter individual (IIV) as well 
as the random variability. Substituting for drug effects and p, the odds of an event may be 
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Drug concentrations at time points corresponding to PD measures were simulated using a 
two-compartment pharmacokinetic model with dose-limited absorption (see figure 4.1). 
The model was built using a two-step approach. first, IV data from a previous experiment 
was modelled to obtain parameter estimates. Subsequently, using these parameters, 
bioavailability estimates were obtained for oral data. Details of the PK analysis are presented 
in the appendix (supplemental material). 


























































Figur e 4.1: Two-compartment model used to describe the pharmacokineti cs of gabapenti n.
ka=absorpti on rate constant, kel=eliminati on rate constant, Cl=clearance,V2 and V3=volume of distributi on in the 
central and peripheral compartments, respecti vely, Q=intercompartmental clearance.
ED-Opti mal Design 
Since drug potency is the parameter of interest, we focused on opti mizing the experimental 
design in order to yield precise esti mates of EC50 as well as the corresponding IIV.  A summary 
of the model parameters used for the opti misati on are given in Table 4.1. Non-linear mixed 
eff ects modelling based on the maximum likelihood esti mati on method was used for 
opti misati on purposes.  Theoreti cal aspects on the opti misati on strategy are described in 
the appendix (see supplemental material).
We assumed drug exposure to be a determinant of response and thus opti mised for sampling 
ti mes and dose levels. Given that the bioavailable fracti on of gabapenti n is dose-dependent, 
the doses were opti mised taking into account such diff erences. Other experimental variables 
were kept constant keeping in mind experimental constraints. These included, sample size (9 
per cohort), number of measurements /individual (5), no of dose groups (4) and a maximum 
dose of 300mg/kg. Any predicted sampling ti mes which were identi fi ed to occur within 30 
minutes interval were moved apart from each other to ensure at least 30 min diff erence 
between two consecuti ve sampling ti mes. A diagram of the general opti misati on process is 
outlined in figure 4.2. The empirical design was the benchmark design and the parameters 
of interest were EC50 and IIV.










Central compartment volume (V1) (l) 0.118 (9.8)
Peripheral volume (V2) (l) 0.253  (4.2)
Clearance (Cl) (l h-1) 0.159 (4.1)
Intercompartmental clearance(Q) (l h-1) 1.22 (0.25)
Bioavailability fractions(F) 1, 0.75, 0.22, 0.087*
Absorption Rate constant (Ka) (/h) 0.26 (20)
Random error 0.30 (3.3)
Pharmacodynamics 
Emax (%) 97 (25)




* for doses 10, 30,100,300 mg/kg respectively
Optimization Strategy
Figure 4.2: Overview of the  general Optimisation procedures used during the analysis. 
IIV= inter individual variability, SSE=stochastic simulation and estimation, EC50=drug potency.  
Prior parameter misspecification and uncertainty was incorporated into the optimisation by 
ED-optimality. A lognormal distribution was assumed for the parameters of interest, with 
mean values fixed as the true estimate. The maximum prior parameter misspecification was 
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predetermined to be 50%. An additional scenario was simulated and optimized to account 
for the effects of linear pharmacokinetics, assuming no change in the bioavailability across 
dose levels. The standard deviation of the priors was chosen so as to take into account 
expected parameter uncertainty and was defined as a distribution rather than a point value. 
The validation of the optimised design was carried out using stochastic simulation and 
estimation (SSE). 
Stochastic simulation & estimation (SSE)
SSE was used to test the robustness of the optimal designs. In brief, during optimisation, 
gabapentin concentrations were simulated using the PK the model. The combined PKPD 
model was then used to simulate ‘optimal sampling scenarios’. The initial values of the 
PD parameters in these models were considered the ‘true estimates’ and specified as the 
upper, lower and middle points of the distribution. The simulated optimal sampling datasets 
were then fitted to a pharmacodynamic model using nonlinear mixed effects modelling to 
assess the parameter estimates yielded by the proposed design. This two-step process 
was performed 500 times for each optimal design scenario. Estimation was considered 
successful when a normal flag (minimization successful) was obtained. Values of the 500 
first successful estimations were recorded and summarised for each SSE run, along with 
their standard errors (SEs).  To prevent numerical problems causing failure of the design, 
we began by first applying the ED-optimal design criteria with point values for priors (i.e., 
D-optimality) then increased prior breadth, until they reached the relevant uncertainty.
Concordance between optimised parameters and true values
Agreement between estimated and values used for simulations (‘true values’) were assessed 
using the mean of the estimation, the mean prediction error (MPE) and root mean square 
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where Esti is the i
th parameter estimate and True is the simulation value (initial estimate) 
of the parameter. Matlab 7.9 (The Mathworks Inc., Natick, MA, 2008) and popED 2.11 
(University of Uppsala, Sweden) were used for implementation of the optimization. PsN 






3.12 (University of Uppsala, Sweden) and NONMEM 7.1 (ICON Development Solutions. 
Ellicott City, MD) were used for SSE. Data manipulation, graphical and statistical summaries 
were performed in R (www.r-project.org)
RESULTS
Pk and PkPD model parameter estimation
An overview of the estimated PK and PKPD parameters are presented in Table 4.1. As can 
be seen from figure 4.3(a), the simulated concentration profiles for all three doses of 
gabapentin are not significantly different from each other. When corrected for differences 
in bioavailability the observed exposures are equivalent to doses of 22.3, 22.5 and 27mg/
kg respectively. Relative bioavailability was found to decrease nonlinearly from 100% at 10 
mg/kg to 9% at 300 mg/ kg. The resulting logistic model for the response data is shown in 
figure 4.3(b). 
Figure 4.3: (a) Simulated plasma concentration vs. time profiles of gabapentin in rats after administration of 
10(dashed line), 30(dotted line), 100(dash-dotted line), 300(solid line) mg/kg doses. (b) Logistic regression model 
showing the exposure-response curve (gabapentin concentration vs. probability of response). Symbols depict the 
proportion of observed responses after doses of 30(open diamond), 100(crossed circle), 300(filled square) mg/kg 
whereas the curve is the model-predicted probability. 
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Table 4.2: Priors used in the experimental protocol optimisation






Misspecification % Mean Misspecification % Mean Misspecification % Mean 
EC50
# 1400 0 1400 10% 1400 50% 1400
IIV (η) 3.14 0 3.14 10% 3.14 50% 3.14
# values were applied to the logit space 
DESIGN OPTIMISATION 
As shown in Table 4.2, uncertainty in parameter estimation was explored with prior 
distributions of 10% (initial runs) and 50% (final run). As it can be seen in Table 4.3, whilst 
the same sampling scheme is used irrespective of dose in a typical empirical protocol, 
optimal designs require a different scheme for each dose. The optimised design performed 
equally irrespective of the uncertainty (i.e., 10 or 50% variance in parameter distribution). 
Table 4.3: Comparison of dose levels and sampling times for the empirical and optimised protocol designs. Dose 
levels are shown in mg/kg, sampling times are in hours (h).









0, 3.15, 4.72, 7.80, 9.93
0






0, 1, 1.5, 2, 4.9
100






0, 1.8, 2.80, 3.10, 4.10
150






0, 0.62, 1.12, 7.23, 8.23
300
0, 0.69, 1.19, 1.69, 5.67
Table 4.4:  Impact of nonlinear absorption on protocol design optimisation.
Dose level (mg/kg) 
Sampling times (h)
Empirical design Bioavailable dose level ED-optimal
(50% variance)
Dose  1 0
0,1,2,3,4
0 0
0, 2.74, 3.45, 5.78, 8.45
Dose  2 30
0,1,2,3,4
29.5 100
6.15, 6.65, 7.65, 8.15
Dose  3 100
0,1,2,3,4
41.7 150
0, 1.34, 4.79, 5.29, 5.79
Dose  4 300
0,1,2,3,4
87.6 300
0, 0.50, 1, 1.5, 2
Findings with gabapentin show that bioavailability decreases with increasing dose levels. Dose levels are shown in 
mg/kg, sampling times are in hours (h)






Comparison of parameter estimates & respective standard errors
Optimal estimates were closer to the true estimates and parameter standard errors 
decreased by more than half when sampling was based on ED-optimality concepts. figure 
4.4 reveals that improvements can be achieved not only in parameter estimates but also in 
SEs after design optimisation as compared to empirical protocol designs. furthermore, we 
show that with varying bioavailability (Table 4.4), the difference between the optimised and 
empirical protocols is more marked. As shown in Table 4.5, parameter precision increases 
and bias is lower. 
Figure 4.4: Comparison of model parameters (EC50 and IIV) and the corresponding estimates of bias and precision 
for various design scenarios described in Table 4.4. Dashed line indicates true estimate values.





Empirical 1205.5 (200-1714) 4.82 (3.30)
ED-optimality (variance 10%) 1258 (876-1601) 3.70 (2.13)
ED-optimality (variance 50%) 1252 (806-1709) 3.96 (2.30)
Empirical with varying f 319 (223-1963) 4. 62 (3.25)
ED-optimality with varying f (variance 50%) 1211(191.7-1754.90) 4.78 (3.31)
True Value 1400 3.13
unit of measurement ng /ml
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Bias and precision of parameter estimates
Uncertainty was introduced in a stepwise manner. RMSE is indicative of precision whilst 
MPE reflects bias in parameter estimates. In Table 4.6, the RMSE & MPE obtained after 
empirical and optimal designs are compared with each other.  The implications of optimised 
sampling times in experimental protocols is shown graphically in figure 4.5.  As indicated 
by the different symbols response is sampled at time points where drug concentrations are 
informative of the expected drug potency. The sampling points for the empirical designs 
describe a monotonic pattern while those for the optimal designs are different for each dose 
and distribute around the EC50. 
Figure 4.5: Selected sampling times relative to EC50 values (dashed line) based on a typical empirical protocol 
(left panels) and ED-optimal design (right panels). Based on theoretical principles, optimal sampling times should 
provide concentration values supporting the estimation of the parameter of interest. for gabapentin, our analysis 
show that variable bioavailability must be considered during optimisation to ensure accurate sampling times 
(lower panels). Symbols represent different dose levels namely; 30(open diamond), 100(crossed-circle), 300 (filled 
squares) mg/kg for all scenarios, except the top right panel where the optimal doses were, 100, 150 and 300mg/kg. 






Table  4.6: Comparison of RMSE and MPE for the empirical and ED-optimal designs.
Design Type
EC50 Omega
RMSE MPE RMSE MPE
Empirical 23.17 7.95 41.61 54.21
ED-optimal(50% variance) 11.27 2.37 26.70 22.32
Empirical with varying f 63.43 44.39 39.08 47.81
ED-optimality with varying f
(variance 50%)
22.10 7.025 41.08 52.84
DISCUSSION AND CONCLUSIONS 
The rat CfA model is typically classified as a model of inflammatory somatic pain. However 
the typical symptoms of allodynia and hyperalgesia are reproduced in this experimental 
model, which are considered indicative of central sensitization [20]. Hence this test is 
commonly employed as part of the battery of screening experiments when looking for 
analgesic/anti-neuropathic pain activity.
It is evident that challenges exist in the identification of suitable targets for the treatment of 
neuropathic pain [21]. Given the gaps in the understanding of the mechanisms underlying 
neuropathic pain disorders, drugs are tested pre-clinically without evidence as to which 
target will yield a clinically relevant response. However, this is further compounded by 
the paradigm currently used for the screening of compounds, which relies on evoked-pain 
response associated with general positive symptoms such as allodynia and hyperalgesia [22, 
23]. Ongoing research strongly suggests that evidence of concentration-effect relationships 
is necessary for translational purposes and accurate ranking of compounds [24].
Although further advancement of the field will certainly depend on the identification of 
specific biomarkers of disease, the assessment of pharmacokinetic-pharmacodynamic 
relationships remains fundamental for characterising the properties of novel compounds 
and interpreting response across species. Unfortunately, screening procedures and 
protocols do not consider the implication of empirical designs, which can result in estimates 
of drug properties such as potency, which are often imprecise and extremely variable[25]. 
As a consequence, inaccurate ranking of compounds is likely to occur during the screening 
stage, which then progress into development. Our investigation illustrates the implications 
of optimality concepts to better design experimental protocols and obtain more precise and 
accurate parameter estimates.
There have been numerous attempts in the implementation of optimal designs for 
experimental protocols [26], but most designs were explored under the assumption of no 
parameter uncertainty [27], a condition which does not correspond to the screening phase 
of novel molecule candidates. furthermore, application of optimality concepts imposes 
the availability of a model, which is unknown at the early stages of drug discovery and 
development, as is the case during the screening phase.  These conceptual constraints are 
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further complicated by practical challenges during the experiments, such as the potential 
interference of blood sampling for pharmacokinetics between behavioural measurements 
and limited sampling frequency due to habituation and other possible effects on 
pharmacodynamics.
Here we have shown how the use of a binary response can overcome technical limitations 
associated with model building, by emphasising the assessment of drug- and system-specific 
parameters. The parameterisation of drug effects in terms of EC50 allows discrimination of 
drug properties, whereas baseline and maximum response Emax reflect experimental model 
characteristics and as such can be estimated in conjunction with historical data, which are 
incorporated as parameter priors. In addition, as shown in the different scenarios, ED-
optimality also allows the inclusion of uncertainty in a formal manner. 
Our analysis focused on the simultaneous optimisation of two design variables, namely dose 
and sampling times, in a similar way to what has been previously reported by Nyberg and 
collaborators [28]. In contrast to empirical designs, the results show that the use of optimality 
concepts yields sampling at time points around the expected parameter estimate (figure 
4.5), thereby maximizing the information obtained from the an experimental protocol. Even 
in the case parameter misspecification, ED-optimality appears to provide more informative 
data than designs based on ‘best guess’ estimates.
Since gabapentin exhibits carrier-mediated absorption, bioavailability was found to be 
nonlinear, decreasing with increasing doses [29]. This effect caused an unusual situation 
in which changes in the bioavailable fraction resulted in practically the same exposure 
across the different dose levels. In such circumstances, the ‘best guess’ estimates were 
not as biased as one would normally observe. To illustrate the effect of such nonlinearity 
we have therefore investigated an optimisation scenario in which bioavailability estimates 
decreased with increasing doses but yielding wide variation in plasma concentrations. The 
results reveal that empirical protocols perform much more poorly (as defined by the bias 
and precision of EC50) than optimised designs. 
Limitations
The optimisation procedures were constrained by the effect on nonlinear absorption 
and relatively sparse availability of oral pharmacokinetic data, which prevented accurate 
estimation of the pharmacokinetic parameters of interest. Therefore, drug concentrations 
from an IV experiment were used to support the estimation of clearance and volume of 
distribution. Whilst data were accurately fitted to the model, we did not attempt to describe 
the transporter-limited absorption of gabapentin in a mechanism-based manner. Instead, 
we applied a ‘curve linearization’ approach, under the assumption that bioavailability 
decreased linearly across the dose range. 






In addition, it has been documented that optimal designs based on D-optimality have a 
tendency to cluster at parameter point estimates because model expectations is assumed 
to be the same for each individual. Apparently, this clustering effect may be minimised 
by the use of priors [30]. Regardless of the use of priors clustering was observed during 
the analysis, but this issue was resolved by imposing minimum interval between sampling 
times, as describe in the methods section. We have not performed a sensitivity analysis to 
explore the potential impact on the estimates of bias and precision obtained for the different 
optimisation scenarios.  We anticipate however that the use of stepwise iterations during 
optimisation should minimise such issues, including failure due to numerical problems. 
Lastly, it should be noted that IIV estimates were higher with varying bioavailability. It is not 
clear if these findings may have been caused by inflated random residual variability in this 
specific scenario.
In conclusion, our study reveals that experimental requirements must be considered for 
the purposes of screening and ranking of compounds. Accurate estimation of drug potency 
(EC50) entails modification to the protocol design, including specific changes to sampling 
procedures and dosing rationale, which cannot be guessed without applying ED-optimisation 
concepts. It is time for experimentalists to understand the implications of empirical 
protocols and make sure experiments are suitable for the evaluation of pharmacokinetic-
pharmacodynamic properties of novel molecules. 
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APPENDIx 1:  PK AND PKPD MODELLING DETAILS
The pharmacokinetics of gabapentin was described by macro-constants according to the 
following expression[31]:
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a21   (6)
Where ka=absorption rate constant, V1=central volume of distribution , F=bioavailability of 
the administered dose, λ1 and λ2 correspond to the initial and terminal slopes representing 
bi-exponential decline respectively and K21 is a rate transfer microconstant between 
compartments 1 and 2.                                  
Figure 4.6: Goodness-of-fit plots for the pharmacokinetic (left panel) and PKPD (right panel) models. Lines represent 
the observed data, whereas the shaded area depicts the 90% confidence intervals






APPENDIX 2: - OPTIMISATION CONCEPTS FOR BINARY RESPONSE
In optimal design, the probability density p(yi|θ) of the experimental observations yi  
depends on a vector of likelihood parameters θ, where 
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The maximum likelihood estimate θ is the value that maximises the joint log-likelihood 
function:
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As a result of a smaller covariance matrix, the lower the fIM-1 the greater is the precision, 
where fIM is defined as:
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By choosing the optimal design variables X^  that minimize fIM-1, one obtains the design 
variables that yield the smallest possible lower bound for the covariance matrix of the 
population parameter estimates [4].
Using the ED-optimality criterion, the parameters of interest are assigned a prior distribution 
and an expectation. A design XD is said to be ED-optimal if it minimises the negative expected 
(Eα) determinant of the fIM with respect to the parameter priors.
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nx = argmax [j (x)]            
          (13)  
 (13)
Laplace approximation was used for calculation of the fIM. The optimization criteria used 
was D-/ED optimal (i.e., optimizing the determinant of fIM). The Latin hypercube (LH) 
sampling was used in the MC calculation of the likelihood to speed up and stabilise the 
likelihood calculation. The number of LH samples differed between the different models 
but was between 40-200 individual samples. The fIM was calculated both using the 
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expectation of the gradient product of the first derivative of the log-likelihood with respect 
to the parameters as well as the expectation of the negative 2nd order derivative of the log-
likelihood with respect to the parameters.
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Figure 4.7: fisher Information Matrix surface versus the highest dose (300mg/kg) and sample times combination 
for ED design with 50% variance in the expected parameter estimates. The dark red surface represents the optimal 
design for this dose and sampling time’s combination.
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We have previously shown how screening experiments for neuropathic pain can be 
optimised taking into account parameter and model uncertainty.  Here we demonstrate 
how optimised protocols can be used to screen and rank candidate molecules. The concept 
is illustrated by pregabalin as a new chemical entity (NCE) and gabapentin as a reference 
compound.
ED-optimality was applied to a logistic regression (LR) model describing the relationship 
between drug exposure and response to evoked pain in the complete freund’s adjuvant 
(CfA) model in rats. Design variables for optimisation of the experimental protocol included 
dose levels and sampling times. Prior information from the reference compound was used 
in conjunction with relative in vitro potency as priors. Results from simulated scenarios were 
then combined with fitting of experimental data to estimate precision and bias of model 
parameters for the empirical and optimised designs.
The pharmacokinetics of pregabalin was described by a two-compartment model. The 
expected value of EC50 of pregabalin was 637.5ng/ml. Model-based analysis of the data 
yielded median (range) of EC50 values of 1125 (898-2412) ng/ml for the empirical protocol 
and 755 (189-756) ng/ml for the optimised design. In contrast to current practice, optimal 
design entails different sampling schedule across dose levels. 
ED-optimised designs should become standard practice in the screening of candidate 
molecules. It ensures lower bias when estimating the drug potency, facilitating accurate 
ranking and selection of compounds for further development.







Experimental protocols in pain research tend to be based on empirical criteria, in spite of 
the evidence for the advantages of a model-based approach for candidate selection and 
interspecies scaling[1]. In fact, the limitations of current screening methodologies for 
pain compounds have been extensively documented in literature [2]. In addition to the 
assumptions regarding the predictive value of behavioural measures of pain in animals, drug 
screening also implicitly rely on the accuracy of estimates obtained by standard experimental 
protocols. Unknowingly, such assumptions may lead to inaccurate assessment of compound 
efficacy and relative potency. Even when a more quantitative approach is applied to the 
analysis of the data, accurate estimation of compound potency may remain an elusive goal 
[3-5]. 
Although different pharmacological parameters may be considered as criteria during 
development (e.g., intrinsic activity, binding reversibility), it is usually potency differences 
that drives the selection of novel compounds during the screening process. yet, the EC50 
estimates of a compound are strongly dependent on the experimental conditions, which 
could affect their ranking and selection [6]. This issue is further compounded when 
pharmacokinetics is ignored and potency is expressed in terms of ED50 [7, 8]. Undoubtedly, 
poor accuracy in potency estimates can have repercussions on interspecies scaling and dose 
selection in humans, making the translation of preclinical findings a gamble rather than a 
scientific exercise. Therefore, differences in drug efficacy across pain models can be assigned 
to differences in potency and/or sensitivity only if estimates are deemed and proven to be 
sufficiently accurate [9].
Despite the potential implications of optimality concepts for experimental protocols in drug 
development, little effort has been made to demonstrate the impact of design optimisation 
on the evaluation of drug potency in experimental models of pain. In conjunction with an 
integrated PKPD approach, it would be possible to objectively  rank compounds [6], but its 
application remains eschewed by experimenters because of the different requirements for 
the experimental protocol and skills involved in model building and validation [1]. In the 
current investigation, we apply ED-optimality in the screening of new chemical entity (NCE) 
using prior information from a reference compound (REf). Putative PKPD relationships are 
used for the prospective optimisation of the experimental protocol for the NCE. Optimisation 
of the parameters of interest (EC50 and interindividual variability) is performed under the 
assumption of parameter uncertainty. To this end, we define efficacy in terms of a binary 
response, using a logistic regression model which is parameterised in terms of system and 
drug-specific parameters. Such a parameterisation eliminates the need for repeated model 
building while allowing  generalisation of a single structural model across compounds[10]. 
furthermore, this approach allows the use of historical data during the estimation of 
system-specific parameters. The main requirement is the expected point estimates of the 
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parameters and its corresponding uncertainties.  We anticipate considerable improvement in 
the selection of the doses required for screening and subsequent ranking of the compounds 
for further development.
MATERIALS AND METHODS 
Experimental procedures 
In vivo model
In the CfA model central sensitization (NP) is induced following injection of an algogen to 
the hind-paw. Allodynia or pain with a non-noxious stimulus is then measured as threshold 
to affected paw withdrawal using von frey filaments [11]. The experimental protocol was 
performed according to a double-blind, randomized, placebo controlled study with nine 
animals per cohort. Sprague-Dawley rats received single doses of vehicle, 10, 30, or 100 mg/
kg pregabalin orally. PD measurements were performed at hourly intervals from 0 to 4 hours 
post-dose for each animal. Drug concentrations at each the sampling times corresponding 
to PD measurements were simulated from a published pharmacokinetics model. further 
details of the model are described below. The study was approved by the Institutional Ethics 
Committee.
In vitro data
Based on in vitro data, we have assumed that the potency ratio between the NCE and REf 
to be equal to 2 [12].  Using the median estimated EC50 values of 1275 ng/ml from 200 
bootstrap runs for gabapentin from a previous investigation [13], the expected EC50 values 
for pregabalin were fixed to 637.5 ng/ml.
Pharmacokinetic and pharmacokinetic-pharmacodynamic modelling
Pharmacokinetic model: 
The pharmacokinetics of pregabalin was characterised by a two-compartment model 
(figure 5.1). Drug concentrations at the time points corresponding to pain measurements 
were simulated based on the parameters estimated previously [14].
PKPD modelling
 The threshold for paw withdrawal was re-parameterised as a binary response variable, where 
response was defined when differences in the threshold for paw withdrawal were >30% 
relative to baseline. The exposure-response relationship was modelled using the logistic 
regression procedures as previously described[15]. We applied different parameterisations 
to ensure the most appropriate model was used, ensuring successful minimisation and 
plausible parameter values. The logit transformation assures that the probability, pij, 






remains between 0 and 1. Assuming that pij is the individual probability at ti me j of achieving 
response (success), the general structure for this model can be described using equati on 1.
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Fi gure 5.1: Two-compartment model used to describe the pharmacokineti cs of pregabalin. 
ka=absorpti on rate constant, kel=eliminati on rate constant, Cl=clearance,V2 and V3=volume of distributi on in the 
central and peripheral compartments, respecti vely, Q=intercompartmental clearance.
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Here f  is a functi on of the typical value parameters (P), Xij the individual independent 
(design) variables at ti me j, ηi the deviati on from the typical individual. The term ηi is a 
normally distributed zero mean random variable which describes inter-individual (IIV) and 
random variability. This parameterisati on has been discussed in detail in the companion 
paper [13]. All pharmacodynamic measurements were considered to be uncorrelated for 
the purpose of our analysis, i.e. no serial correlati on was assumed.
A simplifi ed model without logit transformati on was also tested in which probability of an 
event is given directly by the by the Hill equati on. In this expression, the placebo/baseline 
and Emax vary between 0 and 1. Thus Emax =1-placebo. In this case, the individual probability 
of a response at ti me j is:
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where  Cij is the drug concentration at time j of the individual i. The random effects were 
applied to the EC50 as an additive error model. 
As can be seen from equations 1 and 2, random effects associated with IIV are parameterised 
differently in the binary response models. In the case of gabapentin,  IIV is assessed in the 
logit space, reflecting the total random variability (see companion paper), whereas for 
pregabalin, IIV is added to the EC50, yielding estimates of variability specific  this parameter.
Model Diagnostics
Model fitting was evaluated using simulation-based diagnostics, namely a categorical VPC 
and mirror plots [16]. Herein, using the final model, a number of simulated datasets are 
generated, following which the real observations are overlaid graphically on the simulated 
response (VPC) and agreement between the two is assessed. In case of mirror plots, a number 
of plots of the simulated response against the independent variable (Time or concentration) 
are made and compared with the observations against the independent variable. A total of 
100 datasets were simulated. The threshold for defining a response (successful event) was > 
0.5. Probabilities less than <0.5 were considered a failure in the VPC. Diagnostic plots were 
stratified per dose level.
Optimisation Strategy
 Our approach assumes that baseline and maximum response (Emax) are system-specific 
parameters and can therefore be considered similar across compounds. On the other 
hand, EC50 and the IIV are considered drug-specific parameters and as such represent the 
parameters of interest, for which dose level and sampling times are optimised.  The main 
assumptions for optimisation were:
· The logistic regression model can be generalised and is equally applicable to different 
compounds, i.e., the model can be applied to new compounds without recurring model 
building steps.
· IIV is expected to be of the same order of magnitude  for different compounds, and 
determined primarily by experimental procedures
· Relative in vitro data provides reliable estimates of the putative relative in vivo potency.
· The bias due to empirical protocol design is comparable across compounds.
Experimental constraints in a typical screening experiment were accounted for by limiting 
sample size to 6 animals per dose group and maximum of 5 blood samples per animal for 
pharmacokinetic analysis. Given that experimental data for pregabalin were generated 
according to a typical (empirical) experimental protocol, this design was used as benchmark 
to compare the performance of the optimised design in terms of bias and precision. for 






the sake of clarity, it should be noted that in a real-life scenario, experimental data for the 
prospective evaluation of new compounds will not be available a priori.
ED-optimality was used to optimise two model parameters, namely EC50 and the IIV. The 
design variables considered for optimisation were dose and sampling times [17]. Parameter 
uncertainty was assumed to be log normally distributed, with a 50% coefficient of variation 
(CV). for the purpose of optimisation, the true value of EC50 was set to  637.5 ng/ml (i.e., 
from in vitro data). The system specific parameters were derived from historical data on 
the paradigm compound (gabapentin) and fixed during optimisation to 97% (Emax), 2.81% 
(baseline) and 3.14% (IIV). Based on previous findings, placebo effect was considered to 
be minimal and assumed to be time-invariant during the sampling interval. Details of the 
optimisation algorithms and other theoretical concepts are described elsewhere (see 
companion paper [13, 18]). Optimisation was performed with default settings in PopED [19].
Validation
Validation procedures were implemented to assess the performance of the empirical 
and optimised designs. These included stochastic simulation and re-estimation (SSE) and 
bootstrap runs. SSE assumes that model is known and is used to compare designs [20, 21]. 
Parameter values of the 200 first successful simulations and estimations were recorded and 
summarised for each SSE run, along with their standard errors (SEs) based on the observed 
fisher Information Matrix. On the other hand, the non-parametric bootstrap is a resampling 
method suitable for estimating a parameter distribution from which various measures of 
interest (mean, median, and standard error) may be calculated. The bootstrap makes no 
assumptions about the underlying parameter distributions and thus provides confidence 
intervals of the model parameter [22]. This technique consisted of repeatedly fitting the 
model to replicates of the (simulated) data set using the bootstrap option in PsN 3.2.12[23]. 
The estimates for EC50 and the corresponding interindividual variability obtained from 200 
successful bootstrap runs were summarised as mean, 2.5 and 97.5 percentiles (denoting the  
95% confidence interval) [24].  
Comparison of Precision and Bias
Empirical and optimised designs were tested for precision and bias according to the method 
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where Esti is the i
th parameter estimate and True is the simulation value (initial estimate) of 
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The relative standard error (RSE) is given by: 
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where SE is the standard error of the estimates.
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Figure 5.2: Concept diagram for prospective optimisation and validation steps. Each box in the diagram indicates 
the data flow required for the implementation and validation of the model-based approach as a screening tool. 
NCE=New chemical entity, BR=binary response, IIV=inter individual variability, SSE=stochastic simulation and 
estimation, STD =standard, OD=optimized design.







As a last step in this exercise, binary responses were simulated for different time intervals 
according to optimised protocol design and compared with the corresponding responses 




The time course of pregabalin concentrations are shown in figure 5.3 with the sampling 
time points overlaid for both the empirical as well as optimal designs. Parameter values are 
summarised in Table 5.1.These values were used to simulate typical concentration values to 
be used for the assessment of the concentration-effect relationship.
Figure 5.3: The time course of pregabalin concentrations (population profile) with sampling time points for both 
the empirical (STD, left panel) and optimised (OD, right panel) designs. In the STD design, different dose levels are 
used, namely 10(open diamond), 30(crossed circle), 100(filled square) mg/kg, while  the OD design, relies on a 
single dose level of 100mg/kg. Dashed line indicates true estimate values for EC50.
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Table 5.1: PK Parameter estimates used for simulation.
Parameters Pharmacokinetic Parameter Value
CL (L hr-1) 0.036
V2 (L) 0.27





An overview of the fitting of the response data to the logistic regression model is shown in 
figure 5.4. Model performance is summarised in the diagnostics plots presented in figure 
5.5. The proportion of responders (number of events in which changes in pain threshold 
were >30% relative to baseline) is presented here for both observed and simulated data. 
The visual predictive check (VPC) shows that the model is more predictive for the active 
doses compared to placebo. In case of the placebo dose, observed response proportion 
varies from 10-30% while the corresponding figure for the simulated data is 10-15%. The 
final parameter estimates from the fit of experimental data are listed in Table 5.2.
Figure 5.4: Probability of response to pregabalin (measured as change >30% in paw withdrawal threshold relative 
to baseline) after doses of 10 (open diamond), 30 (crossed circle), 100 (filled square) mg/kg, as determined by the 
logistic regression model.











































































































































































































































































































Table 5.2: Pharmacodynamic parameter estimates from model fitting to the empirical protocol and priors used for 
the optimisation procedures with pregabalin. 
Parameter Estimate (SD) Priors based on paradigm compound
EC50(ng/ml) 897 (20) 637.5
Placebo(%) 14.6 (28.0) 3
Emax(%) 85.4 (28.0) 97
IIV 3 (2.04) 3.13
Design Comparison 
An overview of the design variables for the original empirical protocol and the optimised 
design is provided in Table 5.3.figure 5.6 shows the comparison of the parameter estimates 
(EC50, IIV) for the empirical and optimised designs. The percentage runs which minimised 
successfully were 50% for the empirical design, whereas all runs achieved minimisation 
according to the optimised protocol design. for the optimised design, the median EC50 value 
(range) was 755 (188-756) ng/ml, whereas considerably higher values were observed for 
the empirical design, namely 1125 (898-2411) ng/ml. Based on in vitro estimates, the EC50 
values were expected to be around 637.5ng/ml. IIV estimates for drug potency were 3.13 
and 3.00 (2.39-4.77) for the optimised and empirical designs, respectively.  These results are 
summarised in Table 5.2. 
Table5.3:Comparison of the design variables for the original versus the optimal design. Columns show the dose 
(mg/kg) and the sampling times (h).



























Figure 5.6: Comparison of the parameter estimates for the empirical (STD) and optimised (OD) protocol designs. 
Dashed lines represent expected theoretical values. 50% crashes were observed with the STD design.
The frequency distribution, median and range of the EC50 & IIV estimates obtained by 
bootstrapping are shown in Table 5.4.
Table 5.4: The RMSE, MPE, the RSE from stochastic simulation (SSE) and the bootstrap confidence intervals are 
summarised for the empirical protocol and for the optimised design.









EC50 55.13 41.76 36.06  1147(897-2196)
IIV 41.43 41.32 3.01 3 (0.00-3.00)
Optimised
EC50 19.12 18.76 6.28  213(33-763)
IIV 58.03 49.12 129.27 0.28 (0.0003-1.51)
In figure 5.7 below, the proportion of responders per time interval for both designs is 
depicted. Simulated responses are shown along observed response for the optimised 
and empirical protocol designs, respectively. As can be seen in this figure, there were 
observations in the terminal part of the response vs. time curve for the optimised design, 
including samples up to 10 hours which were not recorded for the original design.
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Figure 5.7: Sampling times and corresponding response rate for the empirical and optimised protocol designs. 
Response is shown in magenta (dark shade), whereas failure is depicted in light blue (light shade). Early, intermediate 
and late categories refer to pharmacokinetic sampling at different times after dosing. 
DISCUSSION 
Practical and scientific challenges appear to preclude the identification of suitable 
compounds for the treatment of neuropathic pain. Although further advancement of the 
field will certainly depend on the availability of specific biomarkers of disease, the assessment 
pharmacokinetic-pharmacodynamic relationships remains fundamental for characterising 
the properties of novel compounds in early drug development. Unfortunately, it has been 
shown that screening procedures and protocols do not consider the implication of empirical 
designs, which can result in estimates of drug properties such as potency, which are often 
imprecise and extremely variable [13]. 
Our results illustrate how optimality concepts can be applied to better design experimental 
protocols and obtain more precise and accurate parameter estimates, taking into account 
parameter uncertainty. Here we have shown how the use of a binary response can overcome 
technical limitations associated with model building, by emphasising the assessment of 
drug- and system-specific parameters. The parameterisation of drug effects in terms of 
EC50 allows discrimination of drug properties, whereas baseline and maximum response 
Emax reflect experimental model characteristics and as such can be estimated in conjunction 






with historical data, which are incorporated as parameter priors. In fact, using published 
literature data, we have seen that pregabalin is known to be 2 to 3-fold more potent than 
gabapentin, both in vitro as well as in vivo [12, 26]. The assumption of potency values 
(EC50) for pregabalin to be half that of the reference compound turned out to be correct, as 
indicated by model fitting of the experimental data. Both the hypothesised as well as the 
estimated value were found to lie within the same order of magnitude.
To further understand the implications of bias in parameter estimates, an overview is given 
of the maintenance doses and the corresponding exposures for a number of compounds 
used in neuropathic pain is depicted in Table 5.5 below. It can be seen that there is a 
discrepancy between the ranking of potency estimates for these compounds between 
species and between models [27].   
Table 5.5:Comparison of human and rat maintenance doses (mg/kg) and exposures (AUC, ng/ml/h) for different 
compounds used in neuropathic pain [27]. 
Compound Maintenance dose in humans Dose associated with the minimum 
efficacious exposure in rats
Amitriptyline 2.1 (2526) >100 (3540)
Milnacipran 0.7 (8673) 30 (939)
Duloxetine 0.9 (8673) 30 (584)
Lamotrigine 2.9 (208200) 10 (69754)
Carbamezapine 17 (55780) 100 (14120)
Gabapentin 26 (146000) 100 (125370)
Pregabalin 4.28 10
We believe that some of these discrepancies may at least in part be attributable to 
uninformative designs. In fact, Gabrielsson et al. have shown that compounds with a 
potential to show response, often fail to do so in preclinical experiments since the design is 
sub-optimal or non-informative and lacks sufficient information on potency and efficacy [1].
In addition, it should be noted that optimised protocols appear to impose variation in 
sampling times across dose groups. This requirement can be justified by the need to take 
differences in exposure into account. Effectively, pharmacodynamic measurements should 
yield data across the whole exposure-response curve, and in particular around the putative 
drug potency. As can be seen in figure 5.3, sample times for the optimised designs are 
distributed throughout the concentration time curve. We also showed that optimisation can 
be achieved even if experimental constraints exist. In the case of pregabalin, the sampling 
points had to be rationalised by ensuring intervals between samples of at least 15 min.
Both the bootstrap and the SSE methods showed a wider distribution around the point 
estimate for the empirical design, as compared to the optimised design. It was also clear 
that bias was present in both designs, despite improvement achieved by optimisation 
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procedures. On the other hand, these results need to be interpreted carefully, as indicated 
by the higher estimates for IIV after optimisation. The empirical design was definitely more 
unstable, as evidenced by 50% of crashed runs both in the SSE and the bootstrap. 
To compare design bias and precision, we presented RMSE, MPE and RSE. Kjellsson et al. 
have reported significant bias in parameters in modelling ordered categorical data, when 
most of the observations are found at the extreme of the possible outcomes[28]. This bias 
increases with increasing skewness of the response distribution and increasing IIV data. 
As a matter of fact, the frequency of rare events will be overestimated when simulation 
of the new data is performed using the biased parameters. Considering that the system 
specific parameter estimates as well as the IIV were derived from the prior information 
derived from gabapentin, there was a potentially unavoidable bias in the model, besides 
the evidence of physiological correlations between parameters[29]. Over and above this, 
our design was constrained by practical limitations.  We also noted that the dose was not 
an important design variable for this experimental protocol, as long as the sampling scheme 
was sufficiently robust to yield required information around the parameters of interest.
Limitations
It may be argued that we have made too many assumptions in this prospective optimisation 
exercise. However, we clarify that this methodology is applicable only in a setting of biological 
plausibility i.e. if both the paradigm and the NCE act on the same target or are of the same 
class, as is the case here. In early development, the targets or mechanisms of action are 
often obscure and hence at this stage one needs to rely on functional assays which provide 
clues to the mechanism of action of the NCEs. We hypothesise that prospective optimisation 
can be attempted even if in vitro potency ratios are calculated on such prototype assays. 
furthermore, relative potency estimates are expected to remain same irrespective of the 
bio phase.  
The use of binary responses was essential for the implementation of a model-based approach 
during drug screening. At that stage of drug development resources are limited and expertise 
for model building limited. Often, statistical arguments arise regarding the potential loss in 
information when selecting binary response variables as opposed to continuous variables. 
We believe however that this limitation is offset by opportunity to implement a model-
based approach and obtain more accurate answers regarding the selection of the most 
suitable compound to be advanced further in development.
We also acknowledge that given the absence of the true parameter values, our interpretations 
will be relative to the assumptions made initially, i.e., that the experimental data available 
can be used for validation purposes. However, despite some model misspecification, we 
showed that the experimental data from the typical empirical protocol could be fitted by 






the same model applied to gabapentin. yet, one should not overlook the fact that different 
parameterisations were used for pregabalin and gabapentin (i.e., logit and direct Emax 
model). Thus, further evaluation would be required to explore the feasibility of applying 
the same simplified model to the paradigm compound. Lastly, we should remind the reader 
that we have made an assumption that the observations were uncorrelated [30]. We could 
not test the impact of possible correlations due to large noise and wide intervals between 
successive measurements.
In summary, we showed that despite some technical challenges, the application of 
optimisation concepts for the design of experimental protocols can still prove to be more 
informative than empirical designs. Moreover, in contrast to the ‘one size fits all’ approach, 
the implementation of optimisation procedures permits the use of historical data in a 
systematic, formalised manner. Such an integrated approach ensures that differences in 
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Purpose: The formalin-induced rat model of nociception involves moderate continuous 
pain. formalin induced pain results in a typical repetitive flinching behaviour, and these 
data display a biphasic pattern characterised by peaks of pain We described the time course 
of pain response and the analgesic effect of gabapentin using a semi mechanistic modelling 
approach.
Methods: Male Sprague-Dawley rats received gabapentin (10-100 mg/kg) or placebo 1 hour 
prior to the formalin injection. A reduction in the frequency of the 2nd peak of flinching was 
used as a behavioural measure of gabapentin mediated anti-nociception. The time course of 
the flinching response was modelled using a mono-exponential function to characterise the 
first peak and an indirect response model with a time variant synthesis rate for the second. 
PKPD modelling was performed using a population approach in NONMEM v.7.1.2.
Results: The time course of the biphasic behavioural pain response was adequately described 
by the selected model, which included separate expressions for each phase. Gabapentin 
was found to reversibly decrease, but not suppress the flinching frequency of the second 
response peak only. Mean IC50 values (+RSE%) were 7510 (40.03) ng/ml.
Conclusions: A compartmental, semi-mechanistic model provides the basis for further 
understanding of the formalin-induced flinching response and consequently to better 
characterisation of drug properties, such as potency in individual animals. Despite high 
exposure levels, model predictions show that gabapentin does not completely suppress 
behavioural response in the formalin-induced pain model. 
ABBREVIATIONS
PKPD= pharmacokinetics and pharmacodynamics, RSE=Relative Standard Error, GABA= 
gamma amino butyric acid, IIV= inter-individual variability, CV= coefficient of variation, 
MOfV= minimum objective function value, VPC= visual predictive check, CI= confidence 
interval, COX-2=cyclooxygenase-2, NMDA= N-methyl d-aspartate, NK1= neuroenkephalin 1, 
MED= median effective dose.







Ideally, the evaluation of the efficacy of novel treatments for neuropathic pain should 
be based on pre-clinical models that mimic not only the symptoms of disease, but also 
consider the substrates underlying the pathophysiology of nociception in humans, i.e., show 
construct validity [1]. Nevertheless, most behavioural models of pain rely on withdrawal 
responses to evoked pain, which reflect sensory perception and consequently one’s ability 
to discriminate its intensity, localisation and modality [2, 3].  As such, these measure ignore 
other features of human pain [4]. 
Regardless of the potential limitations mentioned above, the formalin induced pain (fIP) 
model is a well-accepted screening test. The method comprises moderate, continuous pain 
due to tissue injury following injection of formalin. In the fIP model, the observed behaviour 
in response to a painful stimulus, assessed as flinching frequency, is used as measure of 
efficacy [2, 5, 6]. This behavioural measure is thought to reflect both the sensory and 
emotional aspects of pain [7, 8].  from a mechanistic perspective, the presence of common 
elements of human pain behaviour in the fIP model makes it possibly one of the most 
predictive models among the available experimental models of acute pain. These properties 
have also made the fIP model an appealing tool for the screening of compounds showing 
potential central anti-nociceptive activity [6, 9]. In fact, various compounds have been found 
to affect flinching behaviour (e.g., indomethacin and Na+ channel blockers), as assessed by 
the inhibition of  the second pain peak, which corresponds to the processes underlying 
peripheral and central sensitisation [2, 10].
In the current investigation, we evaluate the pharmacokinetic-pharmacodynamic properties 
of gabapentin in the fIP model. Gabapentin is believed to act via antagonism of voltage 
gated Ca++ channels in afferent neurons, thereby indirectly affecting GABA activity [11]. It 
has been shown to affect the amplitude of the second pain peak, whilst leaving the other 
components of the pain response largely unaffected [12]. 
Despite the widespread use of gabapentin as a reference compound in preclinical models, 
no quantitative methods have been implemented so far that allow discrimination between 
drug and biological system properties, and consequently provide a more consistent ranking 
of candidate molecules. The availability of PKPD relationships would also serve as the basis 
for translating drug (analgesic) effects across species [1]. The use of PKPD modelling offers 
an opportunity to better understand the in vivo time course of pharmacological effects, 
providing further insight into the mechanisms of action [13, 14]. Nonetheless, these 
concepts have been underutilised in pre-clinical  pain research [15]. This may be explained, 
at least partly, by the lack of pharmacokinetic information and the absence of the time 
course of treatment response [1]. 
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The primary goal of this study was therefore to develop a semi-mechanistic model that allows 
the characterisation of the time course of formalin-induced pain and assess the effects of 
gabapentin on flinching behaviour. In addition to known experimental issues such as high 
variability in response, we show that the main challenges for the characterisation of PKPD 
relationships using experimental behavioural pain models are  the lack of pharmacokinetic 
information and the absence of the time course of treatment response. Lastly, we explore 
the relevance of parameter estimates by comparing our findings with published data from 
other experimental models of pain as well as with clinical data in neuropathic pain patients.
MATERIALS AND METHODS
Experimental Design 
Protocols and experimental procedures were reviewed and approved by the Home Office, 
UK, as required per project licence. The experiments were performed following approval 
by the Ethics Committee. Sprague-Dawley rats (Charles River, UK weight range 100-300 g) 
had metal bands attached to their right hind-paws and were placed in Perspex recording 
chambers and allowed to habituate for 15 min before administration of formalin. The 
animals were then injected with 50 μl of formalin, subcutaneously in the ventral surface 
of the right hind-paw at a 2.5% conc/vol. following formalin administration, animals were 
returned to the Perspex recording chambers and the number of flinches was counted by the 
automatic teller for 1 hour. four rats could be tested in parallel using this system. All animals 
were euthanized at the end of the experiment.
Gabapentin or vehicle was administered orally at doses of 0, 10, 30, 100 mg/kg approximately 
1 hour prior to formalin administration. In 4 of the experiments, the animals were 
randomised to either the placebo of the 100 mg/kg dose group, while in the 5th there were 
2 additional dose groups who received 10 or 30 mg/kg respectively. In each experiment,8 
animals were allocated to a particular dose level. Data from five different experiments were 
pooled together, making a total of 96 animals. 
Pharmacodynamic measurements 
The total frequency of flinches was recorded at 5-min intervals, from 5 to 60 min after 
administration of formalin.








 Gabapentin concentrations were simulated using a previously published model based on 
two-compartment drug disposition and dose-limited absorption (16). The model was built 
in a stepwise manner. first, intravenous data from a previous experiment was modelled 
to obtain disposition parameter estimates, namely clearance and volume of distribution. 
Subsequently, absorption parameters (bioavailability and input rate) estimates were 
obtained for oral data. More information on these experiments can be found in the appendix. 
This pharmacokinetic model is described by the following expression [16] 
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where ka=absorption rate constant, V1=central volume of distribution , F=bioavailability of 
the administered dose, λ1 and λ2 correspond to the initial and terminal slopes representing 
bi-exponential decline respectively and k21 is a rate transfer microconstant between 
compartments 1 and 2. A summary of the PK model parameters is shown in Table 6.1.
An analytic solution to the 2 compartment model, implemented in NONMEM was used 
for the simulation and the derivation of the above expression from the estimated primary 
parameters (Volume, Clearance) and is elaborated in the appendix.
Exploratory data analysis 
Before starting model building, we performed a graphical evaluation of trends in the 
experimental data, including the time course of gabapentin in plasma,  the effect vs. time 
and the concentration vs. effect relationships. To ensure suitable model parameterisation 
and assess the existence of correlations in the data, pain response at any given point in 
time was also plotted against the preceding interval. Such correlations are of relevance for 
modelling purposes, as highly correlated data may lead to model misspecification. In fact, 
pain response (flinching frequency) at a given sampling time has been shown to correlate 
with preceding measurements [17, 18].Given that the frequency of flinches /time interval 
was high>10, we decided to model the counts as continuous data.
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Table 6.1:  Pharmacokinetic parameter estimates used for deriving simulated concentrations at the time of 
measurement of the response.
Parameter Values
Pharmacokinetic
Central compartment volume (V1) 0.118 (l)
Peripheral volume (V2) 0.253 (l)
Clearance (Cl) 0.159 (l/h-1)
Intercompartmental clearance(Q) 1.22 (l/h-1)
Bioavailability fractions(f) 1,0.75,0.22a
Absorption constant (Ka) 0.26 (h-1)
a For doses 10, 30,100mg/kg respectively
PKPD model parameterisation 
In the fIP model, there is a temporal delay between the appearance of gabapentin 
concentrations in plasma and the onset of pain response. Depending on the half-life of 
the compound, the analgesic is administered before the induction of hyperalgesia with 
formalin. Given that two pain peaks consistently occur after administration of formalin, 
this phenomenon was parameterised in terms of two independent pharmacodynamic (PD) 
compartments. The first peak (i.e., pain associated with the first phase) was described by the 
following exponential decay relationship:
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where FO= formalin-induced stimulus, kdf = dissipation constant for formalin, F3=basal pain 
load in the first PD compartment, PAIN1= total pain in the first PD compartment
The first peak of pain is almost instantaneous following algogen administration, thus the 
parameter F3 reflects pain at baseline, which wanes spontaneously soon thereafter.
The onset of the second peak of pain is after a quiescent phase and is considered to reflect 
the central hypersensitisation which ultimately manifests itself as a 2nd more prolonged 
phase of flinching. Similarly to the first peak, pain intensity increases to a maximum and 
then remits spontan ously. Given the lack of a direct correlation between the gabapentin 
concentrations in plasma and effect over time, an indirect model was deemed to be most 
appropriate to describe this ‘turnover’ of the pain response [19].
The onset of the second peak of pain is after a quiescent phase and is considered to reflect 
the central hypersensitisation ultimately manifesting as a 2nd more prolonged phase of 
flinching. After reaching peak intensity the pain remits spontaneously. An indirect model 
was deemed to be most appropriate to describe this ‘turnover’ of the pain response[19].






In these models the measured response (R) is assumed to result from factors controlling 
either the input or the dissipation of the response. The general expression to describe these 
models is given by the expression below:
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where dR/dt is the rate of change in the response over time. ksyn represents the zero-order 
rate constant for the formation of the response and kdeg  the first-order rate constant for 
loss of the response. We have replaced the response R in equation 3 with the term FL to 
make explicit reference to the time course of the flinching response triggered by the central 
sensitisation in the spinal cord following the first peak.
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Given that the pain response wanes with time i.e., there is spontaneous recovery within 1 
hour after injection of the algogen [2, 6], ksyn  was  treated as time-dependent variable. 
Depending on whether t, the time after formalin injection, was larger or smaller than Tlag 
(i.e., the delay between the occurrence of the first and second peaks of pain), different 
estimates were considered for ksyn.  Thus for t> Tlag, model parameterisation described the 
onset of the second phase of pain.  If  t<Tlag ,  ksyn=0, which meant the second phase of pain 
had not yet begun. A modified gamma function was required to describe the time course of 
ksyn and equation 4 was thus transformed to an expression representing the natural change 
in pain frequency , described by the following expression:
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Where A (response unit h-2), α (a dimensionless constant), ß (h-1) are the parameters of the 
gamma function describing the time course and intensity of the second phase of pain as 
assessed by the frequency of flinching.
As mentioned earlier, the time course of the disease is a result of the temporal change in 
the frequency of flinching   represented by FL. At the start of the study, i.e., before onset 
of the 2nd peak, the frequency of flinching was assumed to be 0.  Consequently, the generic 
equation 4 can finally be rewritten in terms of FL as follows: 
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The model was applied to simultaneously fit both placebo and gabapentin data. It has 
been observed that drug response further decreases the frequency of flinches and thus 
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it is superimposed on the natural disease process. Gabapentin effects (DEFF) were best 
described by an inhibitory Imax function, which represents the reversible counteracting 
effects of gabapentin on the algogenic action of FL, i.e., the observed flinching behaviour:
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where Imax= maximum possible inhibition of pain, Cp=plasma concentration and IC50=plasma 
concentration at which 50% of the inhibition occurs. As gabapentin only affects the second 
peak of pain, we assume gabapentin effects reflect a decrease in central sensitisation. It 
should be noted that indirect response models incorporate the Hill function directly in 
the turnover differential equation whereas we have chosen to parameterise gabapentin 
effect (DEFF) directly on the pain variable of the 2nd peak, rather than within the differential 
equation. This is because the analgesic does not alter the onset of the pain nor its eventual 
disappearance, but reversibly alters its peak intensity. In other words, the analgesic effect 
of gabapentin is a covariate on the behaviour or flinching response. A similar approach has 
been used previously to describe the effects of lumiracoxib on COX-2 inhibition  [20].
The net pain observed is the product of the gabapentin effect (DEFF) and FL or the resulting 
PD compartment (PAIN2)
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The total pain (PAIN) was described by the sum of the pain in the two model compartments:
PAIN=PAIN1+PAIN2                                     (9)
A schematic representation of this mechanistic PD model is presented in figure 6.1.  
Interindividual variability was modelled exponentially and applied serially to each parameter. 
Stochastic parameters were retained in all cases which showed significant improvements in 
the model, as defined by statistical criteria described below. Residual variability was best 
described by an additive error model.







K , Fa  




(T ) lag Total pain 




































dFL lagt Tlagt T *)**( )).(().(
        
Figure 6.1: Schematic diagram of the pharmacokinetic-pharmacodynamic model. PK compartments are displayed 
with dashed horizontal (blue) hatching, while PD compartments’ are dark shaded (grey or black). 
Model diagnostics and validation 
Model selection was based on the visual examination of the goodness-of-fit plots  using 
Xpose version 4.2.1[21], the precision of model parameter estimates is represented by the 
coefficient of variation [ (%), computed as the ratio between the standard error provided 
by NONMEM and the parameter estimate multiplied by 100, and the MOfV provided by 
NONMEM. The difference in the MOfV between two hierarchical models was considered 
statistically significant if the MOfV changed by 6.63 points which is equivalent to a p value 
of <0.01 for a χ2 distribution. The final model was further evaluated based on visual and 
numerical predictive checks and bootstrap procedures [22, 23]. Using the final model, the 
2.5th, 50th, and 97.5th percentiles from simulated pain response (n=500) were calculated and 
compared to the experimental data. 
NONMEM 7.1.2 was used in conjunction with PsN 3.2.12 for all estimation and simulation 
procedures. Modelling was based on the first-order conditional estimation method with the 
INTERACTION option [24]. R statistical software (v 2.10) was used for data manipulation, 




A nonparametric bootstrap with re-sampling was performed to estimate the confidence 
intervals for the parameters [23].  This technique consisted of repeatedly fitting the model 
to   replicates of the data set using the bootstrap option in PsN 3.2.12. Parameter estimates 
for each of the replicate data sets were obtained.  The results of successful runs from 500 
bootstraps were obtained, and the median and 2.5th and 97.5th percentiles (denoting the 




Gabapentin concentrations were obtained by simulation at each of the sampling times 
used for the pharmacodynamic measurements. A two-compartment model with first-order 
absorption obtained in a previous analysis was used for the purpose of this study. The PK 
model parameters are summarised in Table 6.1.
Exploratory Analysis
The typical concentration time profiles are shown in figure 6.2 (left panel) with the 
corresponding time courses of the flinching frequency for the tested doses (right panel). 
It can be appreciated here that gabapentin only reduces the amplitude of the 2nd peak in a 
dose-dependent manner. 
The disconnect between the two time courses are shown in the figure below with respect to 
the initiation of the experiment (formalin injection) and the PD observation window. from 
these it is clear that during the observation window, while the pain response begins and 
ends the drug is still in the distribution phase. Considerable variability in the response is 
also evident.  from these plots, it is clear that during the experimental protocol, the pain 
response begins and ends while gabapentin is still predominantly in the absorption phase. 
Considerable variability in the response can also be seen between animals.
In figure 6.4, the flinching frequency is depicted against time and gabapentin concentrations, 
stratified by dose level. from the two panels it can be seen that the concentration-effect 
relationship can be superimposed on the time course of response itself. The data suggests 
that gabapentin effects have limited effect on the time course of the second pain peak. 
furthermore, this phenomenon is further confounded by high degree of correlation 
between consecutive measurements. Details are shown in the supplemental material 
(appendix, figure 6.7). 
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Figure 6.2: Population curves for simulated gabapentin concentrations in the plasma for doses 10, 30, 100 mg/kg 
(left panel) and the observed flinching behaviour in the formalin-induced model following placebo (dot-dashed) ,10 
(solid), 30 (dashed) and 100(dash-dash) mg/kg curves (right panel). 
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Figure 6.3: Disconnect between the (observed) onset of response (right panel) and the (simulated) time course 
of concentrations in plasma following a typical dose of 100 mg/kg gabapentin (left panel). Dots represent the 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The time course of the flinching behaviour as well as the inhibitory effects of gabapentin 
following drug administration were accurately characterised by the chosen indirect 
response model. The structural model described all three components of the pain response 
to formalin. The goodness of fit plots are presented in figure 6.5.  Sample individual fits are 
depicted in figure 6.8 of the appendix. All structural model parameters were identifiable for 
the current dataset as evidenced from the RSEs (<40%) shown in Table 6.2 below.
Table 6.2: Parameter estimates from the final population PKPD model, including bootstrap estimates and 
confidence intervals.



















Basal pain load in 
1st PD 
compartment
(F3  #  counts)
126(4.38) 57.44(21.83) 16.70 132.04 122.32,139.63 0.155 0.1,34.64
*Delay between 














8.37(30.82) 67.08(78) 15 9.29 5.43,12.17 25 7.21,44.84
Degradation 
constant for 




(EC50  ng ml
-1
 ) 7510(40.33) 6380.5 3961,15390
Residual 
Error(additive)
29.09(7.8) 9.40 35.34 33.07,43.77
IIV is presented as a percentage
* T.lag is relative to the time after formalin injection
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Figure 6.5:  Goodness of fit Plots. The upper panels show the correlation between observed and population (left) 
or individual (right) predicted response. In the lower panels, the observed and predicted responses are depicted 
over time.
We have assumed the Imax to be 1, i.e., the maximum possible inhibition of pain. In practice, 
however, this is not the case, as the hypersensitisation attains different peak intensities in 
different subjects [18]. 
As can be seen from figure 6.3 and figure 6.4, there was considerable variability in the 
data. IIV was modelled exponentially and tested serially on all model parameters. The data 
supported the inclusion of IIV on the F3 parameter of the first peak, ß, and kdeg on the second 
peak, resulting in significant drops in the objective function value i.e., yielding statistically 
significant improvements in the model (p<0.01).







Model VPCs stratified by dose level are shown in figure 6.6. The model is able to describe 
both the median trends in the data as well as the distribution i.e., the interquartile ranges. 
Since there was more data available for the placebo and 100mg/kg dose, the predictions for 
these dose levels are comparatively better than for the remaining dose levels. Approximately, 
less than 5% of the observations fall outside the prediction intervals. The model predicted 
2nd peak response occurs slightly earlier than that of the real data. 
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Figure 6.6: Visual Predictive Check for the final PKPD model stratified by dose. The results are based on 500 
replicates. Open Circles are the raw data; the red and black lines denote the median of the observed and simulated 







































































































































































































































































































































































































































































































Numerical predictive checks are depicted in Table 6.3, where the median number of flinching 
counts for observed and simulated (95% CI) data is shown at four different points, with the 
objective of characterising the maximum and minimum values of the two pain phases. In 
general, predictions for the placebo and 100mg/kg doses are better as compared to the 
other two, except in the case of the trough response for peak 2 where the model seems to 
over predict the frequency of counts while under predicting gabapentin effects, for the top 
dose as compared to the other dose levels.
Bootstrap
Table 6.3 shows the results of final model parameter estimates along with the results from the 
bootstrap for 500 runs (median, 5 and 95% CI). Most model parameters were well estimated, 
with the exception of kdf , α, and Tlag as can be seen from the wide confidence intervals in 
the bootstrap. This suggests that not all parameters may be identifiable in subsets of the 
original dataset. However a sensitivity analysis showed the variation in these parameters 
did not have significant effects on the overall model fit.  Similarly, the parameters describing 
IIV were not well estimated in the bootstrap. We experienced a high minimisation failure 
rate in the bootstrap (~70%), which has caused a possible underestimation of IIV during 
bootstrapping. Therefore, all final IIV estimates are based on objective function criteria used 
during the initial fitting procedures.
DISCUSSION 
Despite its wide use in the screening of compounds for neuropathic pain, till recently no 
attempts had been made to characterise PKPD relationships in the fIP model, with the 
exception of the recent work of  Velez de Mendizabal et al. on lumiracoxib [20]. Though the 
subject of both investigations was the same (the fIP model) the applications were different. 
We are interested in describing exposure response relationships of gabapentin while they 
have studied lumiracoxib topical versus intrathecal drug interactions. 
Consequently, quantitative approaches in either case were different. Thus while we have 
explored exposure~response relationships, Velez de Mendizabal et al have used a KPD 
(kinetic pharmaco-dynamic) model. In contrast to previous investigations using the fIP 
model, the semi-mechanistic approach proposed here  fulfils two important conceptual 
requirements for the purposes of compound screening, i.e., it describes the time course of 
the disease and the gabapentin effect in an independent manner. In addition, our choice of 
parameterisation took into account the possibility and importance of generating evidence 
of PKPD properties that can be easily used to translate treatment effects across species. 
Therefore, model parameterisation has not relied on typical measures such as cumulative 
response, which despite being technically less demanding has important drawbacks. for 
instance, if data were to be modelled using cumulative flinching counts, gabapentin potency 
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would be expressed in terms of the time required to halve the maximum response. Such a 
parameter would have little physiological meaning even though many consider it suitable 
for ranking of compounds. Moreover, the use of such cumulative measures of response 
would not warrant a unique PKPD relationship (see figure 6.4).  It became clear during our 
exploratory analysis that the flinching behaviour induced by formalin produces a unique 
fingerprint which prevails over any attempt to characterise the underlying exposure-
response relationship using direct response models [26]. 
By contrast, our approach explores drug(compound) and disease properties using 
independent parameters. from a pathophysiological perspective, the first peak is caused 
by peripheral sensitisation, whilst the second may reflect central hypersensitisation. The 
same phenomenon appears to be reproduced in other species such as mice, gerbils, cats, 
monkeys [6], suggesting the opportunity for wide use of the concepts presented here. 
Gabapentin effect was therefore parameterised in terms of an indirect response model, 
which describes the changes in flinching behaviour in terms of a declining exponential 
expression. The formation rate of such response (ksyn) was further characterised by a 
gamma function, which indicates the time varying course of formalin-induced symptoms, 
and consequently modifying the classical indirect response model of Dayaneka et al. [19]. 
This function has been previously described for  endpoints where spontaneous recovery 
from inflammation can be expected [14]. Historically, negative power functions of time have 
been applied to describe clearance curves in PK studies and tracer kinetics in general, with 
a view to replacing multicompartment analysis. Though non-physiological, they require 
considerably fewer parameters and yielded more accurate predictions[27]. We have 
modified the traditional gamma function by parameterising the variable Tlag as the exponent 
of the dimensionless constant α. This led to better fits and lesser numerical difficulties 
with the minimisation routine. The time to onset of the 2nd peak was about 20 min in our 
analysis which is in agreement with the observed data and also literature estimates of 10-
20 min post formalin[2]. However, there was considerable variability in this parameter as 
can be seen from the median effect vs. time curves in figure 6.2. It should also be noted 
that the Imax was defined as the maximal change in pain intensity i.e., return to a baseline 
state, and therefore set to a theoretical maximum of 1. fixing of the parameter to a single 
maximum value was applied even though the disease process and treatment response was 
not expected to be same in all subjects. The approach has been previously applied by Maas 
et al. to describe migraine pain [18]. 
Indirect response models incorporate the Hill function directly in the turnover differential 
equation whereas we parameterise the drug effect (DEFF) directly on the pain variable of the 
2nd peak and not within the differential equation. This is because the drug does not alter the 
onset of the pain nor its eventual disappearance but reversibly alters its peak intensity. In 
other words, the drug effect is a covariate on the behaviour or flinching response. Therefore 
application of the drug effect to either kin or kout would have been non-mechanistic. This 






effect can be visualised in figure 6.2 where the typical profile for the 100 mg/kg dose 
exhibits a smaller 2nd peak compared to the placebo time course.  Velez de Mendizabal et 
al employed a similar approach to describe the effects of a COX2 inhibitor lumiracoxib on 
COX2  [20]
focus should also be given to the observed high between-subject variability in the fIP 
model, a phenomenon that is well known in clinical pain conditions [28]. Although most 
investigations consider such variability a purely stochastic process which cannot be 
assigned to any specific source or mechanism, we have tried to estimate between-subject 
variability for all relevant model parameters, such as Imax or IC50. Unfortunately, this was not 
always supported by the data. yet, it is reasonable to assume that individual differences in 
gabapentin potency do exist and occur due to the time varying effects of formalin, which 
can affect both maximum frequency of flinching behaviour as well as modulate gabapentin 
effects effects on central hypersensitisation. On the other hand, IIV could be identified for 
parameters associated with the induction of formalin-induced pain. The basal load of pain 
(F3) differed among subjects and an η on this parameter improved the fit. The waning of 
the pain phenomenon (kdeg) was also found to differ among individuals and fitting showed 
significant improvements when IIV was applied. 
Diagnostic and validation plots, such as the VPCs show the model has adequate predictive 
properties. Ideally, in such circumstances, the next step would be to fit the model to external 
datasets. Regretfully, we have not been able to identify such data. 
Limitations
A potential drawback in our approach is that the IC50 estimates appear to be beyond the 
range of observed gabapentin concentrations. This situation is caused by the use of a 
theoretical maximum (Imax), which was not reached by gabapentin. Had this been the case, 
the second peak would have been suppressed completely. However, all concentrations 
tested were in the linear part of the curve.  On the other hand, it is well documented that 
gabapentin produces partial symptomatic relief in neuropathic pain, rather than showing 
any disease modifying effects. It is therefore plausible to infer that incomplete suppression 
of the second peak reflects actual clinical effects of gabapentin [29, 30]. yet, we consider 
the ability to discriminate between compounds that cause total pain suppression and partial 
relief highly desirable and do not anticipate any bias in the way compounds can be ranked 
on the basis of their potencies.
In a situation where Cp << IC50, the DEff in equation 7 would reduce to the following 
expression:  
      







It could be argued that the IC50 would then be a linear coefficient rather than a true measure 
of potency and consequently the estimate of the IC50 would not be robust. 
It is important to mention that we assume that an ideal or an efficacious drug would 
completely suppress flinching and by fixing Imax we assume maximal response is possible in 
this biological system. The IC50   then becomes a relative parameter, conditioned on an Imax of 
1. If this is the case then this parameter can be reasonably used to compare potencies across 
compounds. Modelled parameters were not always identifiable in the bootstrap as can be 
seen in Table 6.2. This suggests that a rich dataset may be required to fit this model and here 
is where the advantages of a model based approach come in. Existing data may be used in 
combination with future data whereby the new data are used only to estimate compound 
specific parameters and existing data support estimation of system specific parameters.
We also acknowledge that the gamma function may have little physiologic basis, and thus 
future improvements to the model could be aimed at replacing this function with a more 
physiologic alternative. Such an alternative parameterisation may however require the 
availability of rich datasets. We anticipate that historical data may be used in combination 
with newly generated experimental data whereby only analgesic-specific parameters need 
to be estimated. 
Complex pathophysiological processes underlie the generation of second peak, such as the 
release of  various excitatory neurotransmitters acting through NMDA and NK1 receptors 
which then  initiate a cascade leading to central sensitisation [31]. We have parameterized 
these underlying processes collectively as FL, under the assumption that differences in the 
individual time course of neurotransmitters was not statistically different. This choice was 
made to ensure description of the observed phenomenon rather than the pathophysiology 
of the pain response.
We also highlight a few shortcomings of the experimental design in our study, which 
was performed according to standard experimental procedures. The time of dosing of 
gabapentin should have been planned taking into consideration potential differences in 
pharmacokinetic properties. If gabapentin had been administered earlier, the return to 
baseline of the flinching events might have coincided with it’s elimination phase. Secondly, 
no baseline behaviour was recorded i.e., flinching counts between the administration of 
gabapentin and that of formalin (T=0).  As explained previously, pain burden at baseline also 
showed differences between animals (η on F3).
Comparison with other pre-clinical and clinical findings
We have attempted to compare our results with other published pre-clinical and clinical data 
on gabapentin. Table 6.4 gives an overview of the EC50 and ED50 values reported for different 
pain models. Except for one pre-clinical experiment[32] and one clinical study [33] no other 
publications have applied modelling to analyse or interpret the data. Most authors used 






ED50 and MED as measures of potency with no mention of concentrations, rendering direct 
comparisons rather difficult, if not impossible [12, 34-37]. Noteworthy is the wide variability 
observed in the findings of different authors. There were other important differences such 
as the ceiling effect being observed by Iyengar et al. at a relatively low dose of 50 mg/kg 
while others reported peak effects between 100-300 mg/kg[31, 37].
Among those studies where direct comparison with our work was possible, Todorovic 
reported an EC50 of 467 nM as compared to 43 nM reported here. More consistent results for 
clinical EC50s were reported by Lockwood et al. (31.28 nM), whilst Whiteside et al. provide 
estimates for clinical MED values of 69.72 nM [38, 39]. Notably, Whiteside’s work is the only 
effort at inter-species correlations, amongst the publications we reviewed, albeit not based 
on modelling concepts.
CONCLUSIONS
In summary, differences in analgesic potency exist in pre-clinical models, which cannot 
be interpreted simply in terms of precision. A comprehensive evaluation is missing of the 
differences and similarities in the underlying mechanisms affected by evoked pain in the 
various models currently available for pre-clinical evaluation of neuropathic pain. 
Clearly, the challenges for the identification of suitable compounds for the treatment of 
neuropathic pain will not be overcome until adequate biomarkers of pharmacology are 
identified [40, 41]. yet, irrespective of such differences in pathophysiology, approaches are 
required that facilitate the translation of pre-clinical findings and provide the basis for the 
characterisation of analgesic-specific properties. A parametric, model-based approach is 
essential to ensure distinction between disease processes and analgesic effects.
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Table 6.4: Comparison of Experimental findings for gabapentin in various published preclinical and clinical studies.








fIP in rats Comparison of 
anticonvulsants with 
different mechanisms of 
action in the formalin test 
of persistent pain (rats, 
mice).
Gabapentin doses tested 
were 30-300mg/kg (IP)
In rats efficacy was seen 
across the dose range from 
30-300mg/kg
Minimal effective dose 
(MED) in rats was 30mg/kg 
for the 2nd peak of pain.
The MED for locomotor 
activity in mice was 100mg/
kg
Drug effects on 






fIP in rats A comparison of the 
effects of analgesic agents 
such as uptake inhibitors, 
tricyclic antidepressants, 
anticonvulsants on 
attenuation of formalin 
induced late phase paw-
licking behaviour.
Gabapentin was 
administered in doses of 
10/30/50mg/kg IP
Gabapentin attenuated 
paw licking behaviour in 
the doses administered. A 


















A placebo controlled 12 
week study.
A number of compounds 










The A50  (antinociceptive) 
dose was 26(16-42) mg/kg.
The peak efficacy was 






dose range of 
10-100mg/kg







Comparison of human 
Cmax at MED at daily 
maintenance dose 
(1800mg) to rat MED based 
on published literature 
The concentrations at the 
rat MED (100mg/kg)was 
191.54 nm compared to 
69.72 nm at the  human 
maintenance dose of 26 
mg/kg
We estimated 
the EC50 at 






fIP in rats The antihyperalgesic 
effects of gabapentin (10, 
30,100,300mg/kg) IP alone 
and in combination with 
ibuprofen (3, 10,30mg/kg) 
IP were tested.
An isobolographic analysis 
was used to study the 
nature of the interaction.
The ED50  for gabapentin was 
88mg/kg(51-141mg/kg, 95% 
CI) while that for ibuprofen 
was 19mg/kg (7–50, 95% CI)
Our EC50 was 
>100mg/kg






Table 6.4: Comparison of Experimental findings for gabapentin in various published preclinical and clinical studies.
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or naproxen administered 
alone or in combination 
as oral gavage was 
administered to rats.
An isobolographic analysis 
was used to study the 
nature of the interaction.
Gabapentin was 
administered at does 
ranging from 3-300mg/kg
The ED50  for gabapentin 
was 19.2mg/kg(5.5-43.1mg/
kg, 95% CI) while that for 
pregabalin was 6mg/kg 
(2.3–10, 95% CI) and for 
naproxen this was 0.48(0.05-
1.38mg/kg)
In this animal 






to that in our 
work
7. Whiteside et 
al(Whiteside 
et al., 2004)
Rat model of 
incision pain
A number of analgesic 
drugs such as gabapentin, 
indomethacin and 
morphine were compared.
Gabapentin doses were 
10,30,100mg/kg 
The MED for mechanical 
hyperalgesia was 30mg/kg, 
ED50 11.3mg/kg 
for tactile allodynia the 
MED was 11mg/kg and ED50 
3.4mg/kg 
In this animal 






to that in our 
work





model of NP. 
Anticonvulsants were 
injected intradermally into 
peripheral receptive fields 
of sensory neurons in the 
hind paws of adult rats, and 
paw withdrawal latency 
measured.
Gabapentin (5-170μg),  
phenytoin (0.1-3 μg) ,
carbamazepine (0.1-2 μg), 
ethosuximide (140-1400 
μg) were evaluated.
Dose–response data were 
fit to the function 
PI([-
DRUG])=PImax/(1+(ED50/
[DRUG])n), where PImax is 
the
maximal percentage 
increase in PWLs caused by 
a drug in the
injected vs. non-injected 
paw 10 min following 
injection, and n is the 
apparent Hill coefficient 
indicating the slope of the 
curve. 
The ED50  was 80 μg/100ml 
or 4.67 nm
The 10 fold 
difference from 
our findings 
may be, in 
part, explained, 
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Comparison with clinical/Translational  experiments







Comparison of human 
Cmax at MED at daily 
maintenance dose 
(1800mg) to rat MED based 
on published literature 
The rat MED was 191.54nm 
compared to 69.72nm for 
humans
We estimated 
the EC50 at 
43nm with a 
CV of 40%
10. Lockwood et 
al(Lockwood 
et al., 2003)




The study was placebo 
controlled, double blinded. 
Patients were randomized 
to placebo or gabapentin 
treatments.
A PKPD model (Emax) was 
fitted to data from patients 
with NP. 
The PKPD model 
was further used to 
simulate the MED for an 
investigational compound 
(pregabalin) based on in 
vitro potency information.




by us, however 
needs further 
confirmation.








Gabapentin concentrations were obtained by simulation time points corresponding to those 
when pharmacodynamic measurements were recorded. A 2 compartment PK model with 
first order absorption was used for the simulations[16]. This model was based on data from 
two different experiments in Sprague-Dawley rats. In the first experiment, gabapentin was 
administered orally to conscious rats at doses of 0, 10, 100, 300 mg/kg in a formalin-induced 
hypersensitivity experiment similar to the current one, both of which ,in turn, are based on 
standard published experimental protocols.[2, 6]. Experimental groups consisted of three 
rats per dose level, with each animal contributing with four samples over a period of up to 
6 h post-dose. The second experiment consisted of animals used in a microdialysis protocol 
receiving intravenous doses of 50mg/kg gabapentin (n=63). Each animal contributed with 
eight samples over a period of up to 24 h post-dose [42].
Published  bioanalysis of gabapentin 
Blood samples (100μl) were taken at the pre-defined time points up to 5 hours post-dose, 
namely 0, 2, 5, 15, 30, 60, 120, 180, 240 and 300 min. Plasma samples (50μl) were obtained by 
centrifugation at 4°C for 10 min and stored at -80°C until analysis. Gabapentin concentration 
in plasma was subsequently analysed by HPLC using pre-column derivatisation. Gabapentin 
and the internal standard 1-(aminomethyl) cycloheptaneacetic acid were allowed to react 
with 2,4,6-trinitrobenzenesulfone acid to form trinitrophenyl derivatives, which were then 
extracted with toluene, evaporated to dryness and reconstituted before injection. Analytes 
were resolved on a C18 reverse phase column using isocratic conditions. Mobile phase 
consisted of 58% acetonitrile in water containing 0.5% acetic acid. Ultraviolet absorbance 
was monitored at 35min. Quantification of the drug levels was based on the peak-height 
ratio. The lower limit of detection for gabapentin was typically 0.02μg ml-1 [43, 44]
Analytic Solution for the 2 compartment PK model-used for the PK simulations:
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Where kel=elimination rate constant (from the plasma compartment), k12=micro-rate  constant 
for transfer of gabapentin from the central to peripheral compartment, k21=micro-rate  
constant for transfer of gabapentin from the peripheral to central compartment, V1=central 




from the above the coefficient A may be calculated
A=k12+k21+kel
from A, the two macro-constants or λ1 and λ2 (corresponding to the initial and terminal 
slopes representing bi-exponential decline respectively) may be further derived as follows
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from these above the expression in equation 1 of the main text– for plasma concentrations 
is then derived. 
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Figure 6.7: Correlations between observations at successive observation intervals. In the 4 panels, flinching counts 
at a particular interval are plotted against the corresponding counts in the next interval. Due to correlations 
between successive observations, the flinching patters show trends, towards decreasing frequency in the upper 
two panels and increasing in the lower panels.






Figure 6.8: Example of randomly selected observed individual profiles (shaded circles) with the corresponding 
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Lack of efficacy is one of the major causes of attrition in early clinical development. This is of 
particular concern in areas of high unmet medical need such as chronic inflammatory pain, 
where measures of efficacy cannot be quantified directly in healthy subjects. The evaluation 
and selection of an effective dose range for COX-inhibitors has been a matter of debate 
over the last decade. yet, a systematic approach has not been fully implemented that 
enables the use of pharmacodynamics as a biomarker in a mechanistic manner to support 
the development of anti-inflammatory compounds. Here we apply PKPD modelling and 
simulation to assess the pharmacodynamic effects of a selective COX inhibitor across various 
clinically relevant scenarios and use biomarker response rather than drug exposure as the 
basis for dose selection in subsequent efficacy trials. Thereby, we are able to personalise 
and optimise the effective dose range in different patient sub-populations. 







A landmark study on attrition rates in drug development revealed that the major dropouts 
occur in Phase 2 and 3 [1]. In some therapeutic indications, such as chronic pain, such 
challenges are also observed during proof-of-concept (POC) studies. Potential explanations 
for these findings are species differences in target pharmacology or tissue distribution, 
poor tolerability due to inaccuracy in predicting the therapeutic index, insufficient target 
engagement, timing of the intervention relative to the onset of disease and trial design 
factors[2]. Whilst all the aforementioned factors can play a role in the results of a trial, target 
pharmacology and target (tissue) distribution have been considered a matter for basic 
rather than clinical pharmacology. yet, they are essential for the characterisation of efficacy 
and safety and as such underpin the rationale for dose selection. In fact, as illustrated by 
Morgan et al., development programs that have a positive readout at clinical POC also 
clearly express the pharmacology of the compound in humans [3]. Nevertheless, despite the 
increasing appreciation of the role of pharmacodynamic markers in clinical development, 
Phase 1  trials, including first-time-in-humans studies are typically designed to evaluate, 
systemic pharmacokinetics and tolerability[4]. These studies may be complemented by data 
from experimental models of pain, but measures of pain such as global pain scores are 
not integrated to pharmacokinetics or pharmacodynamics, and consequently, doses are 
selected without quantitative evidence about the extent and rate of target engagement [2]. 
These findings then become the reference for designing dose ranging studies in Phase 2 and 
defining the therapeutic dose(s) in Phase 3. 
Undoubtedly, there is a pressing need to obtain early signals of efficacy and safety to prevent 
high attrition at late stages of development. This prerequisite is key for areas of high unmet 
medical need such as chronic pain and other immunoinflammatory conditions [5]. In these 
conditions inadequate decisions regarding dose selection during Phase 2a can propagate 
undetected into late development and have a disastrous impact on the life cycle of a novel 
molecule. Despite our evolving understanding  of pharmacodynamics (PD), the evaluation of 
what constitutes a clinically relevant dose still relies primarily on empirical evidence, without 
any quantitative consideration of the underlying pharmacology or target engagement (e.g., 
receptor occupancy levels) in the patient population[3]. Currently, opportunities exist for 
truly characterizing the clinical pharmacological profile of novel molecules in humans, 
enabling mechanistic insight into the exposure-response relationships and consequently 
better rationale for the therapeutic dose range. Integration of biomarkers of pharmacology 
into drug development therefore becomes an opportunity to allow the implementation of 
the aforementioned concepts, eliminating part if not all the unobserved bias that arises 
from empirical evidence. Moreover, the assessment of pharmacokinetic-pharmacodynamic 
relationships based on biomarkers of pharmacology can provide a  stronger basis for 
personalised medicine, which is often restricted to tailoring of treatment based on the 
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use of genetic information only[6]. By applying the mechanistic classification proposed 
by Danhof et al. [7], it is also possible to identify whether such relationships are drug or 
disease-specific and consequently to establish whether they can be used as predictive and 
prognostic tools during the development and therapeutic use of the drug. 
In the current investigation we use data from a cyclo-oxygenase (COX) inhibitor to illustrate 
the concept of biomarker driven dose selection and emphasise the importance of gaining 
insight into the clinical pharmacology of the compound as the basis for the dose rationale 
and other relevant labelling information.  The choice of the COX-2 system as a paradigm 
was dictated by the various reports arising from the withdrawal of different drugs from 
the market,  for which the clinical pharmacology profile was known to determine efficacy 
and safety across different therapeutic areas, such as rofecoxib (2004), rimonabant (2008) 
and efalizumab (2009) [8-10]. Although complex interactions in mechanisms underlie the 
pathophysiology of chronic inflammatory conditions, the role of the COX-2  enzyme in the 
production of inflammatory mediators such as thromboxane B2 (TXB2) and prostaglandins 
(PG) has been clearly elucidated [11]. Selective COX-2 inhibitors are known to primarily 
inhibit  PG synthesis [12]. 
Based on the aforementioned classification [7], PGE2 and TXB2 rank as biomarkers that 
reflect target engagement. Notably, the therapeutic dose range for chronic inflammatory 
pain for most non-selective and many of the selective  COX-inhibitors has been defined 
according to empirical evidence of pain relief and analgesia after administration of discrete 
dose levels in clinical trials, regardless of the underlying pharmacology[13, 14]. It has been 
demonstrated, however, that pain relief appears to occur at PGE2 inhibition levels of  around 
80%, i.e., complete suppression of COX-2 activity is not required to translate pharmacology 
into clinical improvement [15]. from these findings it can also be inferred that analgesia will 
also be observed at still higher levels of COX-2 inhibition, but such levels will lead to long 
term disruption of the normal physiological and homeostatic functions of the prostacyclin 
system, including tissue repair [16].
We use data from GW406381, an investigational and potent COX-2 inhibitor with 
demonstrated pre-clinical anti-inflammatory and analgesic activity [17, 18], to show that the 
study of such a mechanistic biomarker should be at the cornerstone of analgesic and anti-
inflammatory drug development. The compound’s pharmacokinetics as well as its effects on 
PGE2 and TXB2 were evaluated in an ascending dose study in healthy subjects, allowing the 
use of a biomarker-driven approach to select the doses for a Phase 2 study [19]. With the 
help of simulation scenarios we illustrate how biomarkers can be harnessed to explore the 
need for treatment personalisation (e.g., hepatic impairment) and quantitatively evaluate 
the rationale for the dosing regimen (e.g., optimised benefit-risk ratio). 








Data from a human pharmacology study in healthy male subjects from the GSK 
(GlaxoSmithKline) clinical trial repository was used for the purposes of our analysis. This 
was a randomized, placebo controlled, double blind dose escalation parallel group study 
aimed at the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics 
of GW406381. Treatment consisted of a single dose followed by a 10-day repeated dosing 
phase (n=9 for the active and n=3 for the placebo arm).  Data from placebo, 35 and 70 mg 
dose arms after the single dose phase and 35 mg dose arm after repeated dosing were 
used in our analysis. The study was conducted according to the principles of good clinical 
practice (GCP) and the declaration of Helsinki pertaining to research on human subjects 
[20, 21]. All subjects provided their written informed consent for participation and the 
study was approved by the Institutional ethics committee. further information on subject 
demographics and the study protocol is provided in Table 7.3 (see appendix).
Pharmacokinetic-pharmacodynamic modelling
To guide the model building, exploratory analysis was carried out by plotting the time course 
of the biomarker levels as well as the drug concentration vs. biomarker levels profile. The 
PKPD   analysis was subsequently carried out sequentially in two steps, with modelling of 
PKPD data after completion of the pharmacokinetic analysis. Details on the pharmacokinetic 
modelling can be found in the appendix to this manuscript. All modelling was performed 
in NONMEM®, version 7.2 (Icon, Dublin Ireland), using the fOCE (first order conditional 
estimation) method. PsN 3.5.3 was used to run NONMEM, whilst data manipulation and 
plots were performed in R 2.13[22].
Both for the PK and PKPD analysis, a parameter Θ for an individual i was described by the 
following expression:
ηi
TVi exp*ΘΘ         (1) 
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Where ΘTV is the typical (population) value of the parameter, η is a random variable with 
zero mean and a variance ω2.
Inter-individual variability (IIV) was parameterised using an exponential distribution 
model. The square root of the variance is reported for IIV, as this is an approximation to 
the apparent coefficient of variation of a normal distribution on log-scale. The residual 
variability comprising measurement and model misspecification errors was described with 
an exponential model, thus for
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Where Y is the jth observed concentration in the ith individual.
F is the predicted concentration and ε  is a random variable with zero mean and variance σ2.
The concentration-biomarker response relationships were described by the following 
equation/expression for the sigmoid Imax model
ηi
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Where Imax represents the maximum inhibitory response to GW406381 plasma concentrations 
(C), I0 is the baseline production of PGE2 and γ is the Hill factor. The covariate effects of 
baseline PGE2 on the parameter I0 was tested according to the following expression
ηi
TVi exp*ΘΘ         (1) 
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where I0i represents the parameter value for the i
th individual, I0TV is the population value of 
the parameter, BASi and MED represent the individual and median values of the  baseline 
PGE2, respectively.
Model evaluation and validation procedures
Parameter inclusion and thus final model selection was based on the likelihood ratio test, 
parameter point estimates and their respective 95% confidence intervals (CI) as well as 
goodness of fit plots. for the likelihood ratio tests, the significance level was set at 0.01 
which corresponds with a decrease of 6.63 points after the inclusion of one parameter 
in the minimum value of the objective function (MVOf) under the assumption that the 
difference in MVOf between two nested models is χ2 distributed. Visual goodness of fit 
plots comprised individual vs. population or individual predictions, and weighted residuals 
vs. time or population predicted values. Minimisation was considered successful in case the 
minimisation occurred with a positive covariance step and no associated error messages.
Validation 
The precision of estimated model parameters was assessed using a non-parametric 
bootstrap. Two thousand bootstrap samples were generated in PsN 3.5.3 [23]. Results 
were used to assess model stability and obtain estimates for the coefficient of variation 
for relevant model parameters. The mean and standard errors of the parameters obtained 
from bootstrapping were subsequently compared with those obtained by fitting the 
model to the original dataset. finally visual predictive checks were used to visually inspect 
the concordance between simulated data and real observations. Using the final model 
parameters, 2000 datasets were simulated and the simulated data overlaid with the real 
observations.







The last part of this work was to simulate analgesic doses in patients based on biomarker 
inhibition data from human subjects, under the assumption that pharmacodynamics in the 
target population are comparable, other than differences in baseline levels of inflammatory 
mediators due to differences in disease conditions. Most importantly, it was assumed that 
the analysis was  based on the premise that PGE2 inhibition represents a causal step in the 
pain cascade [24]. The drug effect was parameterised in terms of ICn as per the following 
expression [15]. 
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where n = the degree or extent of COX-2 inhibition in percentage.
Using the final PKPD model, concentration-biomarker response profiles were simulated for 
a number of clinical scenarios are presented in Table 7.1 below.




Liver dysfunction Cl: -25%
Cl: -50%
Cl: -75%
Mild, moderate and severe liver 
dysfunction-as per Child Pugh scores







 Significant interferon inhibitory activity 
attributed to increased levels of soluble 
interferon receptors, PGE2 levels and 
interferon inhibitory protein
Ambrus JL, et al. 
1997[26]
CyP3A4 induction Cl: +25%
Cl: +50%
 Induction of CyP3a4 Maronpot et al. 2009[27]
Hewitt et al. 2007[28]
Combination of liver 
dysfunction and 
general inflammation
Cl: -25% - I0: +30%
Cl: -50% - I0: +50%
Lower clearance with general 
inflammation
 Vet, N et al. 2011[29]
Once vs. twice daily 
dosing
 None  The same regimen was compared as 
once vs. twice daily doses
NA
for each scenario, concentrations at steady state were generated for 50 subjects per dose 
group, assuming treatment for two weeks using a q.d. regimen. The dose range used for 
these scenarios was  0, 20, 35, 70, 100, 150, 250 and 400 mg. Samples were collected on 
the first and last treatment day before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 h after 
administration.
The simulated scenarios were based on the anticipated clinical relevance (i.e., safety and 
efficacy), of different levels of COX inhibition. A summary of the simulation algorithm is 
depicted in  figure 7.1.
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Final validated  
model  
 
•Dose range from 20-400mg/day 
•50 subjects /dose group 
•2 week dosing (steady state concentrations) 
•Rich PK and BM sampling on day 1 and day 




normal organ  









OD Vs BD Dose 
Simulated Cmin compared  
to IC80-95 
Dosing Recommendation 
Figure 7.1: Diagram depicting the simulation protocol. five different clinical scenarios were simulated; each having 
the characteristics shown in the box above the simulated profiles. The simulated trough (Cmin) concentrations were 
compared to the estimated IC80-95 to assess deviations from the putative therapeutic window.
The simulations were also used to calculate the putative therapeutic windows at dose level. 
for each dose, trough concentrations at the steady state (Cmin) were simulated and compared 
to the benchmark values, namely IC80 (efficacious levels), IC90 (maximum desirable response) 
and IC95 (potential safety risk). A ratio of 1 represented optimum desired concentrations 
while IC90/Cmin of 2.5 was assumed to be the upper margin of the therapeutic window. 
At concentrations of around or greater than the IC95, safety events were assumed to be 
expected. Therefore, effective but non-toxic doses were defined as those at which the Cmin 
values at steady state were around the IC80, while the Cmax was below the IC95. In addition, 
given that for meaningful analgesic response, i.e., not only the attainment but also the 
maintenance of pain relief is important, the time span during which  drug concentrations 
remained within the therapeutic window (i.e., between IC80 and IC95) was evaluated for 
twice daily dosing and compared with the standard q.d. regimen.
RESULTS
Pharmacokinetic Analysis
A two-compartment model with first order absorption and elimination best described the 
PK of GW406381 in adults. Due to high variability in the data, higher concentrations were 






found to be slightly under predicted. This discrepancy may be due to the absence of data 
on influential covariates, which means that not all of the observed variability could be fully 
characterised. Nevertheless, interindividual variability (IIV) was identified on the peripheral 
volume (V3), clearance (CL), absorption rate constant (ka) and bioavailability (f1). Residual 
variability was best described using an exponential error model. The PK parameters from 
the final model as well as the results of a non-parametric bootstrap are presented in Table 
7.2.
Table 7.2: final pharmacokinetic and pharmacodynamic model parameter estimates and the results of a non-
parametric bootstrap (n=2000).
Model estimates Bootstrap Results
Parameter Final Model 
estimates
CV% Median %5 CI 95% CI
V2 (L) 252.38 35.06 242.93 160.39 416.84
V3(L) 959.78 60.54 954.25 476.81 2115.03
CL (L/h) 30.21 43.97 29.89 17.86 58.61
Ka (h
-1) 15.24 78.7 10.83 3.92 35.81
Q (h-1) 37.28 35.82 35.6 23.83 62.44
Lag time (h) 0.47 6.05 0.47 0.41 0.49
F1 35 1.00 FIXED FIXED FIXED FIXED
F1 70 0.49 44.2 0.48 0.25 0.93
IIV V3 93% 73.05 98% 30% 145%
IIV CL 56% 76.4 53% 32% 84%
IIV Ka 198% 48.84 166% 98% 258%
IIV F1 95% 50.58 91% 53% 133%
Residual error 0.11 58.99 0.1 0.05 0.23
PD parameters PD  Bootstrap Results
I0 (pg/ml) 63196.80 9.74 63077.60 53861.30 73871.50
Imax (pg/ml) 479.00 FIXED FIXED FIXED FIXED
IC50 (ng/ml) 43.25 12.22 43.69 36.04 53.21
Hill factor 1.59 10.37 1.61 1.42 1.94
IIV I0 44% 28.63 42% 33% 54%
IIV Imax 272% 107.38 241% 0% 343%
Residual error 0.002 10.91 0.002 0.001 0.002
Where V2 and V3 =central and peripheral volumes of distribution respectively, Cl=clearance from the central 
compartment, Q=intercompartmental clearance,F1=relative bioavailability
Although the coefficient of variation for some of the parameter estimates was high, all 
findings were comparable to the bootstrap median results except for Ka, which showed 
50% higher variation than the bootstrap median. The observed profiles and model fits are 
presented in the supplemental material (figure 7.6), along with diagnostics of individual 
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and population predictions as well as an individual predicted profile. The high IIV was 
reflected in the visual predictive check. The medians of the predicted and observed data are 
very similar, however, the uncertainty around the predictions, is maximum above the 95% 
quartile, especially in the multiple-dose-phase for the 35 mg dose group (see figure 7.7).
PKPD analysis
GW406381 did not have any effect on TXB2 levels. Therefore, only PGE2 data were analysed. 
The Imax model was fitted using the PK parameters estimated during the PK analysis. The 
PKPD model was able to describe the data adequately, as assessed by the basic goodness of 
fit plots (see right panel figure 7.6, in the appendix). High variability was seen in the baseline 
(I0) PGE2, which is most conspicuous in the placebo group. Interindividual variability was 
modelled exponentially and IIV identified only on two parameters. Not all subjects showed 
high concentrations due to highly variable exposure, whereas maximum PGE2 inhibition was 
observed in only 3 subjects. A summary of the PD parameters from the final model along 
with the estimates from the nonparametric bootstrap estimates are presented in Table 7.2. 
from the visual predictive checks, it can be seen that variability is inflated at the upper 
boundary of the confidence interval (see figure 7.7 in the appendix).
Simulation scenarios
We have assumed that effective analgesic and anti-inflammatory effects could be achieved 
and maintained when PGE2 inhibition are kept above 80%, but below 95%.  Based on the 
predicted potency estimates, a range of doses from 20-400 mg/day was investigated. from 
a physiological perspective, two parameters were considered to fluctuate in the target 
population, depending on intrinsic or extrinsic factors, such as differences in metabolism 
and disease conditions, namely CL and I0. 
Patients with Normal Organ Function
Patients with normal organ function were used as a reference for the other scenarios. The 
objective of this scenario was to provide the range of doses which provide clinically relevant 
target engagement. As can be observed from the concentration vs. time profiles, the median 
peak concentrations lie below the IC95 after a dose of 100 mg daily. Biomarker response 
increases in a nonlinear manner, with trough concentrations reaching IC80 values after 250 
mg given as a once daily dose regimen. However, at this dose level peak concentrations are 
above IC95. Consequently, to remain within the proposed therapeutic range (i.e., >80% and 
< 95% inhibition), the median effective therapeutic dose appears to lie between 70 mg and 
<250mg/day. (See figure 7.2).







Figure 7.2: Patients with normal organ function. (Left panel) GW406381  concentration vs. time stratified  by dose 
group.  Black solid line depicts median concentrations in patients with reference parameter values whilst the 
shaded area represents the 90% confidence interval (right panel). forest plots showing drug response associated 
with different dose levels. X-axis shows the concentration at trough, relative to the IC80 of GW406381 stratified by 
dose group. The solid black circles depict median concentration whilst solid lines represent the 90% confidence 
interval. Green solid line: IC80. Orange dashed line: IC90. Red dotted line: IC95. 
Patients with hepatic impairment
Given the metabolic elimination route (CyP3A4) of GW406381, patients with hepatic 
impairment are likely to show decreased clearance of the drug. In this scenario, we explored 
how changes in clearance alter drug exposure and consequently biomarker response. 
Patients with severe liver impairment needed a longer time to reach steady state (>5 days), 
especially in the higher dose groups. furthermore, the trough concentrations were found 
to be higher than IC95 values for the dose groups receiving >250mg. The forest plot (figure 
7.3) reveals that the median trough concentration reached the IC80 for the mild, moderate 
and severe forms of liver impairment at doses of 150, 100 and 35 mg, respectively. Based 
on these findings, the doses of GW406381 to be used in mild hepatic impairment should be 
between 100-150mg, whilst for moderate and severe impairment further reductions should 
be considered (i.e., from 70-100 mg and 20-35 mg respectively).See figure 7.3.
Metabolic (CYP3A4) induction
The dose required to reach IC80 trough concentrations was higher in this scenario, as 
compared to patients with normal organ function. GW406381 concentrations were overall 




Figure 7.3: Patients with decreased liver function. Panel (a-left) GW406381 concentration vs. time stratified by 
dose group. Black solid line depict median concentrations in patients with hepatic impairment, whist the shaded 
area represents the 90% confidence interval. Panel (b-right) forest plots showing the different dose levels. X-axis 
indicates drug concentrations at trough, relative to the IC80 of GW406381 stratified by dose group.  Percentages 
reflect the predicted change (%) in hepatic function. Solid black circles: median concentration. Solid lines: 90% 
confidence interval. Green solid line: IC80. Orange dashed line: IC90. Red dotted line: IC95. 
Figure 7.4: Metabolic enzyme (CyP3A4) induction, with 25% CL and 50% increase in CL. Panel (a-Right) Concentration 
vs. time stratified by dose group. Panel (b-Left) forest plots showing the different dose levels. Percentages reflect 
the predicted change (%) in hepatic function.






The difference between 25% and 50% increase in clearance are negligible, as evident from 
the forest plots. The overall trough concentrations relative to the IC80 are lower than what 
was observed in the reference groups with normal organ function. IC80 values are reached 
at trough levels for doses between 250 and 400 mg when total clearances increased by 
25%. Median plasma concentrations of GW406381 were below IC80 values throughout the 
simulated dose range when 50% increase in clearance was considered. See figure 7.4.
Inflammatory conditions
A scenario was considered in which symptoms worsen as compared to standard inflammatory 
diseases such as in systemic vasculitis or generalised septicaemia. Interestingly, the dose 
range required to yield effective exposure in these patients remained the same as in 
patients with normal organ function. Elevations in baseline PGE2 did not appear to alter 
the concentration-effect relationships. Consequently, these findings indicate that no dose 
adjustment is required in patients showing variable degrees of inflammatory response. 
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Figure 7.5: Time above the IC80,90,95 respectively for once daily (OD, left panel) and twice daily  (BID, right panel) 
stratified by dose group, in patients with normal organ function. Red bars depict the 5 and 95% Confidence intervals 
respectively.
Once daily (q.d.) vs. twice daily (b.i.d.) dosing regimens
Given the proposed therapeutic range (i.e., >80% and < 95% inhibition), it was found that a 
b.i.d. regimen allowed peak concentrations to remain above the IC95 for a shorter time and 
at much higher dosages, without significant effect on trough concentrations, which were 
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comparable to those achieved with an q.d. regimen. furthermore, important differences 
can be noticed in the total time plasma concentrations remain above IC80, IC90 and IC95.  
Whilst no differences are observed for the ratio between trough concentrations to IC80, the 
total time above IC95 was significantly lower (see figure 7.5).
DISCUSSION
The rationale for the therapeutic dose range has always been a difficult aspect of drug 
development. Recommended doses and dosing regimens are often defined early on in 
development when information on the drug’s pharmacology is scarce. As can be deduced 
from the number of drugs for which the recommended dose has undergone revisions, dose 
selection remains a point of concern in even in the post marketing phase[30]. The possibility 
of generating data on a compound’s pharmacology represents an opportunity to optimise 
and personalise treatment during the development programme.
Phase I studies have traditionally been designed with the aim of evaluating the maximum 
tolerated dose (MTD) in humans [4, 31] . Even though the scope of these studies has 
expanded in recent years to allow the early evaluation of pharmacodynamics, challenge 
models in healthy subjects, similar to animal models of pain, reproduce symptoms rather 
than expressing the pharmacology of the compound[32]. In fact, their translational relevance 
is questionable. Data from these models  have been documented to be non-specific and can 
at times yield contradictory results [33]. 
Conceptually, dose selection and optimisation of pain control have been primarily 
determined by techniques such as titration to effect [13]. In addition,  subjective scales have 
been endorsed as clinical endpoints of choice for  the evaluation of analgesia in regulatory 
guidance documents for neuropathic as well as nociceptive pain[34, 35].Not surprisingly, 
there is little evidence in the published literature of clinical trials in which the dose selection 
for appropriate analgesia has been based on pharmacological activity. Here we  have 
illustrated the concept of biomarker driven dose selection and emphasise the importance 
of gaining insight into the clinical pharmacological properties of a compound to ensure 
accurate assessment of  safety and efficacy early in the clinical development programme. 
Specifically, we show how such biomarkers can be used in a quantitative manner to guide 
the dose selection and identify the conditions requiring dose adjustment. With the help 
of simulation scenarios, we show how the scope of Phase I studies may be expanded to 
understand the pharmacology of candidate compounds, taking into account different 
characteristics of target sub-populations, who would be likely recipients of  the drug later in 
the clinical development programme. 
from a methodological perspective, even in circumstances where high variability exists 
in the data, the use of a model-based approach in conjunction with biologically relevant 






model parameterisation allows one to explore the impact of individual differences in 
pharmacokinetics and pharmacodynamics and quantify the overall consequences (i.e., 
uncertainty or true interindividual variation) of variability on dose selection for different 
groups in the target patient population. In our example, the variability in the actual data 
was attributable firstly to the hepatic metabolism of GW406381, as it is a CyP3A4 substrate 
[17, 36]. It is well known that CyP3A4 substrates show high IIV in metabolism [37]. Secondly, 
considerable IIV has been reported in the degree of COX-2 inhibition and selectivity in 
similar assays of enzymatic activity in healthy subjects [38]. The high variability observed 
in healthy subjects also exposes a limitation of using in vitro potency as a benchmark to 
compare compounds in early clinical development, which does not reflect differences in 
selectivity or metabolic activity in vivo. In fact, fries et al. showed that despite the higher 
potency of rofecoxib relative to celecoxib in vitro, their in vivo selectivity is likely to be the 
same [38]. Likewise, the in vitro potency of GW406381 was estimated to be approximately 
30 times as high as rofecoxib[39]. However, the optimal recommended dose range proposed 
from our simulations lies between 150-250 mg, while that for rofecoxib is 25-50mg[40]. 
This is mostly explained by the inter-individual differences in pharmacokinetics and enzyme 
activity described above. 
We acknowledge that such an exercise presumes the availability of biomarkers of 
pharmacology, which may not always be readily measurable in a different disease or 
therapeutic indication. yet, there are some general principles of basic pharmacology that 
can be extended to clinical pharmacology studies, i.e., that target engagement determines 
therapeutic response and as such needs to be taken into account for the purposes of dose 
selection [2, 3]. Evidence of clinical efficacy and safety without further characterisation of 
the underlying pharmacological activity is misleading. Of particular relevance in the case 
of COX-inhibitors for the treatment of chronic inflammatory pain is the fact that clinical 
response is reached below maximum target engagement [24, 41]. Similarly, the use of target 
engagement or target receptor occupancy may be applied to the evaluation of various 
other drugs (e.g., antibodies, cannabinoids and centrally acting analgesics), subject to the 
availability of a suitable mechanistic biomarker of response. 
In chronic pain, hypersensitivity is the result of downstream effects of COX-2 production 
which, in turn, is mediated by PGE2 and TXA2 [11, 42]. However, pain scales are considered 
pre-requisites for demonstrating evidence of analgesic and anti-inflammatory response ,[43, 
44]. Various issues arise from such an empirical, fragmented approach to drug development; 
the most important one being the inability to define the true therapeutic window. By 
contrast, the use of a biomarker-driven approach provided us insight into the therapeutic 
window. Under the assumption that drug exposure levels leading to > 95% inhibition in 
biomarkers (i.e.,IC95) is above the therapeutic margin, we could  show how the risk of 
adverse events (AEs) can be mitigated by ensuring drug levels at doses yielding exposure 
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within IC80-IC95 values. This therapeutic window is based on the investigation of Huntjens et 
al. who have shown that analgesic therapeutic plasma concentration is directly correlated 
with IC80[45]. At COX-2 inhibition >90%, treatment effects suppress the physiological levels 
of COX-2, which are also present under healthy conditions. In addition, for some drugs, COX-
2 selectivity may also be lost, which would then result in adverse events associated with 
COX-1 inhibition. This subtle balance has been highlighted by Capone et al. who have shown 
that a correlation exists between COX-2 inhibition greater than 90% and elevated risk of 
cardiovascular events [46]). Clearly, our work illustrates how the pharmacodynamics of this 
class of compounds can be used as a proxy or predictor of clinical response.
In contrast to traditional non-steroidal anti-inflammatory drugs, selective COX-2 inhibitors do 
not alter TXB2 levels, which act as a pro-coagulant [12, 47]. In fact, concerns about the safety 
of selective COX-2 inhibitors arise from the pharmacological activity on its primary target 
[48-51]. As can be seen from our simulations, the  reported cardiovascular events with this 
class of compounds is likely to be the result of an inappropriately high dose, the selection of 
which was not based on pharmacological activity, but rather on the statistical significance 
of the differences between active and placebo treatment arms [52-55]. McGettigan et al. 
have proposed that there exists gradient of cardiovascular risk for COX-2 inhibitors which 
runs from protective to risk-inducing, i.e., lower doses are cardio protective, becoming risk-
inducing at higher doses[56]. furthermore, additional evidence points to a time-dependent 
effect, suggesting that it’s the prolonged suppression of COX-2 activity that may ultimately 
determine adverse cardiovascular outcome [57].
Lastly, we have attempted to show how different dosing regimens affect the therapeutic 
window in clinical practice. Our analysis reveal that optimal exposure to GW406381 can 
be achieved by constraining drug concentrations to fluctuate within the range comprised 
between IC80 and the IC95 values. Such a requirement can be met by the administration of 
GW406381 according to a twice daily dosing regimen. This finding can be partly substantiated 
by the safety profile of celecoxib, which is also prescribed as b.i.d. regimen [58].
Methodological   Limitations
Our exercise had some limitations, which for the sake of clarity are worth mentioning. We 
assumed that PGE2 inhibition is required not only for the onset but also the maintenance 
of pain response. The role of secondary, downstream mediators known to contribute to 
the inflammatory process has been excluded from our analysis [59]. In addition, the data 
available for this exercise did not include any other intrinsic factor or covariate that might 
contribute to further changes in response to COX inhibition, such as differences in receptor 
density or other mediators that might antagonise the effects of COX-2 inhibition. We have also 
assumed that the disease status and processes do not alter during the time span considered 
for the simulation scenarios. However, it has been shown that in certain conditions, such as 






systemic inflammation (vasculitis or rheumatoid arthritis), other circulating mediators such 
as cytokines vary over time and  may therefore influence pain response over time [60]. 
Another obvious criticism is the lack of prospective validation of the simulation scenarios 
and availability of data confirming the suggested dose recommendations. As this is the crux 
of matter in terms of the concepts implemented here, we refer the reader to a few examples 
from published literature in which population-based approaches have been used for dose 
selection and extrapolation purposes [61-63].  The most compelling example is provided by 
the work of Huntjens et al. With the help of PKPD modelling, they have analysed human 
in vitro and ex vivo PGE2 inhibition data and were able to demonstrate that IC80 estimates 
for fenoprofen were similar between healthy subjects and patients with systemic lupus 
erythematosus (SLE)[64]. Subsequently, based on simulations the authors conclude that 
doses above 600-800 mg/day yield concentrations above IC80 for at least 80% of the dosing 
interval (24hrs). This compares favourably with the recommended total daily analgesic 
fenoprofen dose of 800-1200 mg for the relief of mild to moderate pain in adults [65]. 
The common denominator in all these examples is that the biological substrate across the 
populations or experimental groups is the same.
In conclusion, the role of biomarkers expands beyond the potential diagnostic and 
prognostic value currently perceived by most investigators in industry and academia.  In 
contrast to many of the translational efforts using pre-clinical species [66], biomarkers 
offer a mechanistic basis for the characterisation of PKPD relationships and as such provide 
valuable guidance for the dose selection as well as for the design of subsequent studies 
during drug development. Moreover, this approach contributes to further dismantling of 
an entrenched belief that still pervades the field of clinical pharmacology, i.e., that the 
maximum tolerated dose should be evaluated in subsequent efficacy trials, irrespective of 
any evidence of underlying target engagement.
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Figure 7.6: Diagnostics (goodness-of-fit plots) for the pharmacokinetic (left panels) and pharmacokinetic-
pharmacodynamic (right panels) models. The upper panels show the observed data, the individual and population 
predictions vs. time (PK panels) or concentration (PD panels). The lower left graph shows the observed data vs. 
individual predictions, whereas the lower right graph depicts an individual predicted profile.
Figure 7.7: Visual Predictive checks of final pharmacokinetic model (left  panels) and PKPD model (right panel). The 
dots represent the actual observations, whereas the lines represent the median (solid line) and the 5th and 95th 
percentile (dashed line) of the real data. for the VPC on the right, the black lines represent the 5th, 50th  and 95th 









Figure 7.8: Two-compartment pharmacokineti c model with fi rst order absorpti on used to describe the 
pharmacokineti cs of GW406381 in plasma.
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Objective: In the current investigation, we characterise the exposure response relationship of 
GW406381, an investigational selective COX2 inhibitor, in patients with rheumatoid arthritis. 
Using the change in core set of outcome measures (ACRn) as an index of improvement, we 
aimed to predict the effective dose range required for a future Phase 3 study.
Methods: Demographic and efficacy data from a Phase 2b study,  in which four different 
treatment arms (0, 10, 35 and 50mg) were tested, were available for the purposes of the 
analysis. first, a Weibull function was used to describe the natural time course of ACRn in 
individual patients. Treatment effect was then characterised by an Imax model in which the 
predicted drug exposure as well as biomarker activity are used to assess the underlying 
exposure-response relationships. In addition, patients were divided into responders 
and non-responders in order to evaluate the impact of interindividual variability in 
pharmacodynamics and in pain response. Response was defined as a change > 25% in scores 
of at the end of the study, as compared to baseline.
Results: Both the placebo and the pharmacokinetic-pharmacodynamic model described the 
data accurately. The percentage of responders was 54, 70, 59 and 69, across the various dose 
groups, indicating that there was little discrimination amongst the doses. Despite the wide 
distribution observed for IC50 values, no covariates were identified, other than significant 
differences between the responder and non-responder phenotypes.
Conclusions: ACRn scores can be accurately described by a Weibull function despite 
fluctuations in individual response profiles during the course of treatment. Albeit empirical 
in nature, the proposed model illustrates how further understanding of the underlying 
exposure-response relationships can be used to explain heterogeneity in response and 
support the rationale for dose selection in subsequent trials.
 







Clinical scales are the preferred endpoint for the evaluation of efficacy during the development 
of analgesic and anti-inflammatory drugs. Doses in Phase 2 and 3 trials are usually selected 
based on treatment response without taking the underlying pharmacological activity into 
consideration. This practice is often accompanied by a reluctance to collect information on 
drug exposure in patients, and consequently reliance on the nominal dose for the analysis 
of the efficacy [1], which prevents the quantitative characterisation of exposure-response 
relationships. Although clinical and regulatory guidelines  endorse the use of physician and 
patient reported scores [2, 3], this empirical dose selection raises the following questions: 
1) which doses would be selected if direct evidence were available of the underlying 
pharmacological activity? 2) Is it plausible to expect clinical improvement after maximum 
pharmacology has been reached and contrarily 3) can clinical response occur in the absence 
of target engagement?
A number of scales are currently available in clinical practice [4], such as the visual analogue 
scale (VAS) or numerical rating scale (NRS), which are easy to administer in an out-patient 
setting. However, they suffer from important drawbacks in that it has been shown that most 
often than not, no clear link has been identified between pharmacology and clinical response. 
This is partly due to the fact that different scales differ in sensitivity, and do not always 
correlate with one another or with other aspects of the disease such as functional disability 
[4],[5]. Most importantly, they do not provide any clue about how drug interventions alter 
the underlying pain signalling pathways. 
In a previous investigation with a selective COX2 inhibitor GW406381 in  healthy subjects, 
we showed that it is possible to correlate target engagement (i.e., the extent of COX-2 
inhibition) with a biomarker of pharmacological activity, namely prostaglandin E2 (PGE2)
[6].  Additionally, published literature shows that there is a relationship between COX-2 
inhibition and therapeutic drug levels associated with pain relief in a range of chronic and 
acute inflammatory conditions [7]. Hence, we envisage the development of a biomarker-
guided approach for analgesic drugs, in which target engagement is used to guide the dose 
rationale. 
Rheumatoid arthritis is a chronic relapsing remitting systemic autoimmune disorder 
characterised by inflammation and joint cartilage destruction [8]. In clinical trials a number 
of scales have been used to assess disease activity or measure/evaluate treatment response. 
Amongst these are the ACR-20, the DAS-28 and the ACRn [9]. The ACRn represents an index 
of improvement, combining a continuous scale of percentage improvement with traditional 
categorical response scales such as the ACR-20, ACR-50 or the ACR-70 [10]. It is considered a 
robust indicator of treatment response since it is a continuous measure of different elements 
of the disease and can thus detect small effect sizes [10]. Although it has been considered 
to show construct validity when compared to other scales used in pain research, it is not 
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symptom or mechanism specific, as exemplified by its use in the evaluation of efficacy for 
different drug classes [11-13]. 
Even though the therapeutic dose range of many of the selective COX-inhibitors used for the 
treatment chronic inflammatory pain in rheumatoid arthritis has been defined according to 
empirical evidence of pain relief  after administration of discrete dose levels in clinical trials, 
in the current work we attempt to illustrate the concept of biomarker-guided dose selection 
by evaluating how exposure to GW406381 correlates to clinical response in rheumatoid 
arthritis, as assessed by the time course of ACRn scores. Despite some limitations imposed 
by the typical experimental protocol in chronic pain, inferential methods are used to explore 
and predict the underlying pharmacological effects in patients. This exercise is also aimed 
to show how target engagement can be used to select the effective dose range in the 
patient population and ultimately improve the overall benefit-risk balance of a treatment by 
ensuring that the appropriate level of pharmacological activity is achieved and maintained 
during the course of therapy. from a conceptual standpoint, our approach represents a shift 
from the empiricism which has dominated the design of Phase 2b and 3 trials, allowing the 
implementation of a learn and confirm paradigm [14]. The putative PKPD relationship will 




Study data was obtained from a multicentre, randomised, double-blind placebo and active 
controlled phase 2b parallel group dose ranging study in patients with rheumatoid arthritis 
[15]. Information was available from a total of 541 patients who completed at least one trial 
visit. Patient demographics are presented in Table 8.1
Table 8.1: Demographic overview of the patients enrolment into the trial





















No of centres 77
Mean (SD) Baseline scores for the core set measures. 35.28 (11.28)






Protocol and study procedures were approved by the respective institutional ethics 
committees of the participating institutions. Included patients gave their written informed 
consent prior to enrolment into the study.
Study design
for randomisation, subjects had to meet the following disease activity criteria at baseline 
when compared to their screening visit:
- A minimum of 6 tender/painful joints and an increase of at least 2 tender /painful joints 
(or a 20% increase whichever was greater).
- A minimum of three swollen joints at baseline and an increase of at least two swollen 
joints (or 20% increase, whichever was greater).
- A visual analogue scale (VAS) of at least 40 mm at baseline and an increase of 10 mm (or 
20% increase, whichever was greater).
All subjects who were randomised received the study drug for a period of 42 days with 
follow-up visits scheduled on days 7, 14, 28, 42 and 49. The subjects were allowed to 
continue with their standard DMARD(disease modifying anti-rheumatoid drug)  therapy, as 
well as paracetamol up to a maximum of 300 mg per 24 hour period as rescue analgesic 
medication. An overview of the enrolment and randomisation scheme is presented in figure 
8.1 (left panel).
Summary of the data available for the PKPD analysis
for the included patients, the  number of recorded visits was 2737, representing 84% of the 
maximum scheduled visits. Stratification of the data by dose group shows that the drop-out 
rate was unrelated to the dose, with the total number of visits being 80% , 86% , 82%  and 
88 % in the placebo, 10 mg, 35 mg  and in the 50 mg groups respectively.
Outliers
Data from all patients who had at least one visit after the start of the treatment were to be 
included in the analysis, with exception of two subjects, whose ACRn at the end of the study 
was >100. One was on placebo the other received 35 mg of the study drug. It is possible 
that in both cases, ACRn truncation was not performed as per protocol or that these results 
were data entry errors.
The ACRn
The ACRn is an improvement index that synthesises in a single number the percentage of 
improvement from baseline that a patient has experienced in analogy to ACR20, ACR50 and 
ACR70 responses[10, 16].It is the lowest of the following three disease cores set measures 
(CSM), indicating the least improvement, 1) the percentage change from baseline in tender 
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joint counts; 2) the percentage change from baseline in swollen joint counts; and 3) the 
median percentage change from baseline in the following five assessments:
- The patients’ assessment of pain, as measured by a visual analogue scale (VAS)
- The patient’s global assessment of disease activity (VAS)
- The physician’s global assessment of disease activity (VAS)
- The patient’s assessment of physical function, as measured by the health assessment 
questionnaire
- C reactive protein/acute phase reactants
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where CSMEOS, CSMBAS represents the CSM score at the end of the study (EOS) and at the 
baseline (BAS) respectively, in the original scale.  The ACRn is simply the value representing 
the least improvement in any one of the core set measures among the individual scales listed 
above. Since it is a δ or change relative to baseline, the ACRn is by definition only a measure 
of response and conveys no information about the status of disease activity. furthermore, 
the results are dependent on the state and accuracy of baseline measurements. It should 
also be noted that by aggregating information across a number of measures, it is not 
possible to discriminate between the changes of the actual measures (scales) making up 
the response [17] [18].
The ACRn may be presented in such a way that increasing values indicate improvement on 
a scale from 0 to 100, or in terms of percentage improvement [9]. It may also be presented 
as in our study where the scores ranged from -100 to +100, with -100 indicating maximum 
relief and +100 indicating a 100% increase in pain relative to baseline scores.
Withdrawal and handling of drop-outs
In the original statistical analysis plan, data analysis for subjects who dropped out during 
the study was based on imputation by LOCf (last observation carried forward) to the last 
planned study visit, i.e. day 42. for the purposes of our PKPD analysis, however, the actual 
time corresponding to the visit when drop-out occurred was noted together with the 
corresponding clinical response. 
figure 8.1 shows the number of drop-outs stratified by visit. from this graph, it appears 
that drop-out was non-informative. Since subjects were missing at random (MAR), we have 
decided that a drop-out model was not required. 







In view of the lack of additional information on treatment compliance, adherence to the 
prescribed dose was assumed to correspond to the number of completed visits. Subjects 
received 7 days of trial medication at baseline and on day 7, while on days 14 and 28 trial 
medication was provided for a 2-week period. Therefore, it is assumed that if a subject 
missed the visit on day 7, he/she could be considered 83% compliant, whilst a subject who 
missed the visit on day 14 or day 28 would have missed 14 doses, and therefore has a 
compliance of only 63%.
  
Figure 8.1: A (left panel) Overview of patient recruitment stratified by dose level and treatment completers. 
A completer was a subject who remained in the trial until completion of his/her last (5th) scheduled post-
randomisation visit. B (right panel) Bar diagrams show the frequency of drop-out per dose level at each visit.
Late follow-up
All randomised subjects were on treatment from day 1 to day 42 post randomisation. 
Thereafter as per protocol, there was one post-treatment follow-up visit, planned on day 
49. Of all patients, eleven subjects followed up after day 42 of which 10 on day 49 (visit 6) 
and one on day 56.All these subjects were analysed with the assumption that none were on 
rescue medication during the follow-up phase.
Simulation of systemic drug concentrations
Our investigation presupposes that estimates of treatment potency, and consequently 
of the drug levels associated with efficacy, are more accurate when exposure response 
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relationships can be derived, as compared to the traditional dose-response curves. However, 
in the current study, pharmacokinetic data were not collected. Instead, drug concentrations 
were simulated to subsequently characterise the concentration-response relationship. 
Mean steady state concentrations were simulated at the time points at which the clinical 
response was recorded. for this purpose, a population pharmacokinetic model based on 
healthy volunteer data was used [19].The pharmacokinetics of GW406381 in adult male 
subjects was best described by a two-compartment model with first order absorption and 
elimination. Given the absence of covariate effects on the pharmacokinetics of GW406381 
in healthy subjects, it was assumed that rheumatoid arthritis has little or no effect on drug 
disposition. A summary of the pharmacokinetic model parameters are presented in Table 
8.2 in the appendix.
Model building strategy
The time course of the ACRn was plotted along with the corresponding core set measures 
(CSM) and used as the basis for subsequent model parameterisation. Placebo data was 
evaluated first to ensure accurate characterisation of the within and between-subject 
variation in response. The exploratory plots are depicted in figure 8.2. 
Pharmacokinetic-pharmacodynamic analysis
To describe the drug effect, assumptions were made with regard to the disease status of 
the patients entering the trial [20]. More specifically, it was assumed that the analgesic 
and anti-inflammatory effects of GW406381 were additive to the natural time course of 
response, as observed in the placebo group. Given the short duration of the trial disease 
progression was considered undistinguishable from placebo response and was therefore 
considered a single entity [21]. In addition, it was assumed that the disease remained stable 
over the short observation time of six weeks. Therefore the contribution of concomitant 
medications (particularly DMARDs and prednisolone) to the reduction in pain symptoms 
could be considered constant throughout the course of treatment. furthermore, parameter 
estimation was performed was under the assumption that 1) DMARD use was equally 
prevalent across all dose groups and 2) the effect of rescue medication could be neglected 
as it caused only transient benefit.
Structural model building was performed in a stepwise manner. first the placebo model 
was built using the placebo data. Drug effects were then characterised using fixed placebo-
related model parameters. Eventually the combined placebo and drug effect was fitted to 
the total dataset.







Despite some erratic trajectories, the Weibull function was considered appropriate to 
describe the non-linear decrease in the scores from baseline, which reaches a plateau prior 
to completion of the treatment [22]. In fact, a steady state placebo effect appears to be 
reached no later than the third week of the trial. Despite its empirical nature, the use of 
a Weibull function was deemed one of the best choices to describe the observed profiles. 
This model can take into account both placebo responders as well as those with a flat (zero) 
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where Pdt is the clinical endpoint at time t, Basl=baseline value of the clinical endpoint, Pcsm 
is the estimate of the CSM with placebo treatment, td= time to reach the maximum placebo 
effect, α=shape parameter [23]. from Basl and Pcsm we calculate a derived parameter, Pmax 
or the magnitude of the placebo effect which is the difference between the two given as: 
Pmax= Basl-Pcsm
In order to describe the time course of ACRn, modifications to the basic equation were 
required to constrain ACRn to be 0 at baseline, as per clinical definition. Therefore, instead 
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where ACRn t0=ACRn at time=0, Bas_Sc= core set measures at baseline (time=0).
This modification was necessary because the use of a Weibull function implies a finite non-
zero parameter representing baseline conditions at time=0.The proposed modification 
does not however influence the model predicted time course of ACRn. Substituting OFF in 
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During model building we also considered the inclusion of an additional term to equation 
4 to describe worsening of the disease after initial improvement. Although the Weibull 
function eemed a good descriptor of a stable placebo response, it does not allow for late 
fluctuations in the individual trajectories [22]. Gomeni et al. have previously proposed an 




























    (2) 
 
 
Pmax= Basl-Pcsm      geen  num 
 
 






































































This modified version of the model was tested for subjects who had late follow-up, at visits 
6 or 7.
Drug Effect Model
The effects of GW406381 on the ACRn were best described using a standard Imax model, as 
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where Imax represents the maximum inhibitory effect, IC50 is the drug potency and Conc the 
systemic drug concentrations. The net effect on the time course of the ACRn at time t, was 
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Dichotomisation into Responders and Non-responders
To explore treatment and patient characteristics underlying clinical response across the 
different dose groups, subjects were split into responders (R) and non-responders (NR). A 
trial subject was categorised as a responder if he/she had decrease in ACRn > 25% relative to 
baseline at the last study visit (i.e., completion of treatment). A comparison was then made 
between model-predicted and observed median response profiles.
This approach was deemed necessary to further investigate a putative correlation between 
pharmacological activity and clinical response. An assumption is made with regard  to 
the clinical response itself, in that response implies disease activity susceptible to COX-2 
inhibition, whereas a non-responder presupposes not only limited drug action (e.g., low 
dose), but also refractoriness to COX-2 inhibition mechanisms. Given that these definitions 
are irrespective of the treatment allocation, the dichotomisation into responders and non-
responders should yield different estimates of drug potency for each population. Therefore 
separate, model fitting was performed for either sub-population. Another important 
assumption here was that there was no misclassification for a drop-out. Thus, a subject who 
had dropped out earlier in the study would have continued to exhibit the same response he/
she did at the time of dropping out.







Inter-individual variability (IIV) in model parameters was assumed to be log normally 
distributed. The square root of the variance is reported for IIV, as this is an approximation to 
the apparent coefficient of variation of a normal distribution on log-scale. A parameter value 
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where ΘTV is the population value of the parameter, η is a random variable with zero mean 
and a variance ω2.
The residual variability was described by an additive error model. It was assumed to comprise 
measurement error and any model misspecification:
Yij = Fij + εij     (9)
Where Y is the jth observed response in the ith individual. F is the predicted response and 
ε is a random variable with zero mean and variance σ2.
Covariates 
To explore the potential influence of demographic covariates on response, post-hoc estimates 
were plotted against the respective covariate vectors. In case a linear covariate parameter 
relationship was identifiable, non-linear relationships were further tested. Covariate factors 
included race, sex and age. 
Model evaluation and validation procedures
The pharmacokinetic-pharmacodynamic analysis was performed using nonlinear mixed-
effect modelling in which the typical values of the parameters as well as their inter-
individual variances were estimated. Parameter inclusion and model selection were based 
on the likelihood ratio test, parameter point estimates and their respective 95% confidence 
intervals (CI) as well as on the visual inspection of goodness of fit plots. for the likelihood 
ratio tests, the significance level was set at p<0.01, which corresponds to a decrease of 6.63 
points in the minimum value of the objective function (MVOf) after the inclusion of one 
parameter under the assumption that the difference in MVOf between two nested models 
is χ2 distributed. Minimisation was considered successful when runs were completed with a 
positive covariance step and no associated error messages.
The precision of model parameters was assessed using a non-parametric bootstrap. Two 
thousand bootstrap samples were generated in PsN 3.5.3 [25]. The model was fitted to 
the replicates and a distribution of the parameter estimates hereby obtained. The relative 
standard error (RSE) of the bootstrap estimates was then calculated. The bootstrapped 
parameter estimates were then compared to the final model parameter estimates. 
Secondly, visual predictive checks were used to visually inspect the concordance between 
Chapter 8
188
simulated data and real observations. Using the final model parameters, 2000 datasets were 
simulated and the simulated data overlaid on the real observations. In addition, mirror plots 
were generated to assess the predictive performance of a model when used for simulation 
purposes. Mirror plots depict fitting profiles using simulated data, which provide information 
about the variance-covariance structure of the  model [26]. These plots are based on the 
principle that the selected model should accurately describe the variance pattern observed 
in the original data.
Separate validation procedures were performed for the analysis of responders and non-
responders, which included visual predictive checks (n=1000) and NPDE (normalised 
prediction distribution errors), which are based on the assumption that the normalised 
(decorrelated) prediction distribution errors (discrepancies) are normally distributed [27]. 
One hundred datasets were simulated using the final model, which was then tested for the 
assumption of normality of the prediction distribution errors. 
Software 
All analyses were performed using non-linear mixed effects modelling, as implemented 
in the NONMEM version 7.2 (Icon, Eliott City, Maryland USA). The first order conditional 
estimation method (fOCE) with INTERACTION was used to estimate all parameters. PsN 
3.5.3 was used to run NONMEM. Data manipulation, graphical and statistical summaries 
were performed in R 2.13 [28].
RESULTS
Exploratory analysis
The population used for modelling of the exposure-response relationship comprised 541 
patients who received placebo (n=132) or active treatment, namely 10 mg (n=133), 35 mg 
(n=139) or 50 mg (n=137) mg doses of GW406381. Visual inspection of the data showed 
an exponential decrease in the ACRn score, indicating pain relief over the first few weeks 
of therapy, which tended to plateau, typically after the third week of the trial. Exploratory 
plots of the time course of the observed ACRn are shown in figure 8.2, stratified by dose 
level for responders and non-responders. for the sake of clarity, the time course of the 
corresponding core set measures is also presented for the overall population in the same 
figure. The trajectory of the core set measures provides insight into the individual response 
pattern and its variability. As shown in figure 8.6 (appendix), the distribution of baseline 
scores was comparable across dose levels, suggesting no trends due to different disease 
status at the start of treatment.






Simulation of systemic drug concentrations
As pharmacokinetic samples were not collected during the trial, mean concentrations of 
GW406381 in plasma were simulated for each patient, under the assumption of random 
interindividual variation around the population mean. 
 
Figure 8.2: (Upper panel) Time course of the observed ACRn stratified by dose level for responders and non-
responders. (Lower panel) Time course of the core set measures (CSM) for the overall population.
Table 8.2: final parameter estimates for the Weibull model used to describe the exposure response relationship for 
GW406381, including the results of a non-parametric bootstrap (n=2000).
Exposure-response model Bootstrap Results
CV% Median %5 CI 95% CI
Bas_Sc (%) 36.5 1.5 36.50 34.31 38.44
Pcsm (%) 2.05 9.04 2.024 1.760 3.75
Kon* 0.386 25.40 0.306 0.413 0.423
α 0.351 40 0.32 0.380 0.79
Imax(%) -100 FIXED FIXED FIXED FIXED
IC50(ng/ml) 7780 38.20 113 7848 16763
IIV Pcsm (CV%)  38.3 5.80 30.65 38.21 46.71
Residual Error(%) 17.46 32 16.80 17.35 18
where Pcsm is the estimate of the CSM after placebo treatment, * This is the reciprocal of td, td= time to reach the 




As described in the methods section, the baseline CSM was estimated along with the 
ACRn scores. The exposure-response population for model development comprised 2737 
observations from 541 patients. A Weibull function was found to best describe the time 
course of ACRn scores in placebo treated patients and was subsequently used as the basis 
for characterising drug effects. Despite some individuals showing symptomatic worsening 
at the end of treatment, the inclusion of an additive term to the Weibull function did not 
result in further improvement of the fitting. The estimated placebo response for the core set 
measures in a typical patient was 2.05 (9.0) % on the normalised CSM scale. This corresponds 
to a maximum improvement due to placebo response (Pmax) of 34.4 %. 
Drug effects could be described adequately by the Imax model, as assessed by the basic 
goodness-of-fit plots (see figure 8.7  appendix). No unexpected trends could be determined 
in the individual predictions (figure 8.8, appendix). Given that maximum pain relief was not 
achieved in the study, a linear model was found to equally describe the data. However, the 
Imax model was selected to ensure a clear pharmacological interpretation of the drug effects. 
In addition, from a pharmacological perspective, the maximum expected relief observed for 
this class of drugs can be anticipated. Imax was therefore fixed to -100, which is the maximum 
decrease relative to baseline scores. final model parameter estimates are shown in Table 8.2.
Despite the large variation in ACRn, inter-individual variability (IIV) was found to be 
identifiable only on Pcsm, indicating clear differences in the time course of the core set 
measures (p<0.001) between subjects. The remaining residual variability could be modelled 
accurately using an additive error term. Additional efforts to identify covariates did not 
reveal any trends or correlations with demographic or disease covariates that could explain 
variability in the data.
 
Dichotomisation by response level 
In view of  the role of placebo response as well as the known interindividual differences in 
susceptibility to pain relief, patients were further split into responders and non-responders 
according to the extent of changes in ACRn scores at completion of treatment (figure 8.3). 
The number of observed responders per dose level was 54, 70, 59 and 69.3% in the placebo, 
10, 35 and 50 mg treatment groups, respectively.
Overall the model was able to predict median trend in the observed data for both responders 
and non-responders, except for the late study upswing, as shown in the lower panels of 
figure 8.3. These fluctuations in ACRn can be explained by the late follow-up, i.e., these 
patients were off-trial medication at the time of their last visit. In addition, it should be noted 
that response level observed here differs from the estimated maximum placebo response 
because of the clinical definition of response used for dichotomisation of the population 
into responders and non-responder.






Dichotomisation of the population into responders and non-responders has not only 
shown evidence of different susceptibility to the treatment, but also provided estimates 
of apparent IC50 values for each group, with parameter values suggesting that the fitting of 
the entire dataset is more likely to represent drug potency in the so-called non-responder 
population. In fact, the distribution of IC50 values obtained by bootstrapping seems to reflect 
the sensitivity of the two populations to the drug effects (figure 8.9 appendix). Thus, the 
IC50 (CV%) value estimated for responders was 2,853 (19.14%) ng/ml. This was obtained 
after fixing the IC50 for non-responders to the value obtained for the entire population i.e. 
7774 (38.09%). Conversely, the data did not support estimation of a non-responder IC50, 
with bizarre estimates being produced. We also tried to estimate separate IC50s for the two 
phenotypes, without success. 
 
Figure 8.3: Median time course of observed (solid) and predicted (dashed) ACRn score in responders (R) and non-
responders (NR) stratified by dose level.
Model validation
The visual predictive checks suggest that the Weibull function can be used to adequately 
describe the time course of the pain response (see figure 8.4), except for the fluctuation 
observed in the last 2 visits, a limitation which is reflected in the broader prediction intervals 
at those time points. Despite these discrepancies, it should be noted that less than 10% of 
the observations lie beyond the prediction intervals, indicating good agreement between the 
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observed data and model predicted response. further stratification of the population into 
responders and non-responders (figure 8.5)  reveals that the model predicts the time course 
of ACRn in responders better than in non-responders. In addition, the bootstrap procedures 
for the overall population show parameter values comparable to the parameter estimates 
obtained with the final model. Estimates also showed a low coefficient of variation, with the 
exception of the exponent (α) and IC50. As indicated previously, this apparent imprecision 
is more likely to be a reflection of the differing susceptibility of the two populations to the 
treatment response. The distribution of IC50 values and the corresponding standard errors 
from 1000 bootstrap runs is depicted in figure 8.9 (appendix). 
In addition to the numeric and visual predictive checks, mirror plots were obtained to 
demonstrate model performance in subsequent simulations. These plots reveal no trends 
in the individual profiles, indicating accurate characterisation of the variance-covariance 
structure. (figure 8.10, appendix). yet, some of the predicted ACRn scores reach values 
below -100, which is probably explained by the use of an additive random error. Lastly, 
model performance in subsequent simulations was evaluated by NPDEs, which clearly show 
that apparent potency estimates are required to best describe the population of responders 
and non-responders (figure 8.11, appendix). 
Figure 8.4: Visual Predictive Check by Dose for the final response model. Red lines represent the median, 5 and 
95% confidence intervals for the real data and the black lines for the predicted data. The open circles are the 
observations.






Figure 8.5: Visual predictive check for responders (left panels) and non-responders (right panels).
DISCUSSION
To our knowledge, this is the first time that nonlinear hierarchical modelling has been used 
to analyse clinical response to a selective COX-2 inhibitor in rheumatoid arthritis. Similar 
concepts have been used previously for the evaluation of the effects of gabapentin in patients 
with neuropathic pain. In that instance, a Weibull function was also deemed suitable to 
describe the time course of pain [29]. Despite the empirical nature of the Weibull function, 
our analysis shows how modelling can be used to describe drug effects on core set measures, 
as assessed by the changes in ACRn. We also emphasise that whilst other modelling efforts 
in pain research have relied on individual clinical scales, not much work has been done 
on   composite measures such as ACRn [12]. The ACRn captures both worsening as well 
as improvement of the symptoms, making it a sensitive measure of treatment response 
in rheumatoid arthritis [30], [31]. Such characteristics support our modelling strategy, in 
that lack of response may be reflective of differences in individual susceptibility to the 
mechanism of action, i.e., COX-inhibition, as well as of insufficient exposure to the drug. 
Stratification of the population into responders and non-responders allowed us therefore to 
identify differences in drug-specific parameters (i.e., apparent potency), whilst taking into 
account the putative differences in drug exposure.
from a modelling perspective, another important point to consider was the nature of the 
pharmacological activity and choice for the descriptor of drug exposure. first, it should be 
highlighted that a direct response model was considered the most appropriate choice to 
describe improvement in core set measures.  This choice was based on the fact that selective 
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COX-2 inhibition is immediate and the overall treatment duration was relatively short in 
comparison to the rate of disease progression in rheumatoid arthritis. This contrasts with 
the use of indirect response models, which have been considered the preferred approach 
for modelling the effects of DMARDS in rheumatoid arthritis [13],[16]. We have also decided 
on instantaneous drug concentrations, i.e., C(t) instead of other summary measures such 
as, Cmin or AUC for similar reasons. Although parsimony rules ought to be taken into account 
when defining model parameterisation, drug effects were described according to an Imax 
model, instead of relying on a linear function, which was also able to describe the data 
accordingly. This choice was essential to ensure appropriate interpretation of the drug-
specific effects and subsequent differentiation between individual susceptibility and the 
potential impact of pharmacokinetic variability.
Despite high in vitro potency and selectivity for COX-2, model fitting of the total data set 
yielded apparently conflicting results, as suggested by the IC50 estimates obtained here. [32]. 
These findings were further corroborated by the wide distributions for potency estimates 
observed in the bootstrap analysis. Clearly, this was not a statistical issue, i.e., imprecision 
in parameter estimation or identifiability. Rather it provides evidence for two underlying 
groups or phenotypes amongst the trial patients with differing sensitivities to COX-2 effects. 
Such heterogeneity in drug potency is not implausible given the potential differences in 
disease state, which are not controlled for by the inclusion/exclusion criteria used in typical 
experimental protocol [12, 13]. We acknowledge however, that such issues have not been 
previously evaluated using exposure-response modelling and further investigation will be 
required to confirm these findings. Nevertheless, wide inter-individual variation in pain 
response has been attributed to differences in the underlying disease status and molecular 
mechanisms, including as well variable gene expression [33]. Interestingly, we were not able 
to identify the two populations using purely statistical criteria, as implemented in a mixture 
model. In addition, we could not demonstrate whether these two populations of responders 
and non-responders correlated with placebo response or any influential covariates [34]. The 
effect of demographic factors such as age, sex, ethnicity was not statistically significant. 
However, besides inflammation-induced gene expression there are multiple factors 
(covariates) such as gender, and which are determinants of response [35].
Lastly, we point out that our approach has also circumvented the unidentifiability of inter-
individual variability in model parameters, which in turn prevented a more robust covariate 
analysis. Inter-individual variability was identifiable only on the placebo-related parameter. 
However, as shown in figure 8.2, it may be appreciated that there is considerable variability 
in the data, which might be explained by parameters such as Pcsm.  
Whereas the evidence of two distinct distributions in the NPDEs strongly suggests that two 
populations or phenotypes exist, our findings suggest that other biological or clinical factors 
need to identified and captured during a clinical trial for the development of mechanistic 






models. However, from a drug development perspective, we should also highlight that the 
doses used in the trial were sub-optimal, as indicated by our previous findings in which the 
doses required for PGE2 inhibition > 80% across the overall population should be at least 
150 mg [19]. These doses were derived taking into account pharmacokinetic variability in 
CyP3A4 as well as biological variability in COX-2 activity in an ex-vivo assay. In the current 
study, the difference in the proportion of responders relative to placebo treatment was 
approximately 15%. 
Limitations
We acknowledge that a mechanism-based approach would have been preferable to 
accurately characterise the correlation between drug exposure and clinical response. 
Unfortunately, pharmacokinetic data and biomarker response have not been collected in this 
trial. Undoubtedly, availability of individual plasma concentrations and biomarker response 
(e.g., PGE2 and TXB2 levels) would have allowed for a more comprehensive evaluation of the 
pharmacokinetic-pharmacodynamic relationships. Despite these limitations our approach 
shows that modelling of exposure-response is by far more informative than hypothesis 
testing based on a pair-wise comparison between active and placebo treatment arms.
from a methodological point of view, we reiterate that the use of a Weibull function imposes 
limitations on the trajectory of individual pain responses. In fact, the inclusion of all data in 
the analysis, including late follow-up visits reveal clear fluctuations in ACRn after completion 
of the treatment, which may be explained by the fact that patients are not taking the study 
medication. The use of all the data available also imposes assumptions about adherence to 
treatment, which may not have been 100%, in particular during the follow up period.
finally, we emphasise that even though the use of clinical phenotypes (i.e., responder vs. 
non-responder) as classifiers for differentiating subjects in a population may seem arbitrary 
at first sight, a similar approach has been previously used by Dervieux and Kooloos et al. as 
basis for the characterisation of patterns of interaction between genetic and non-genetic 
attributes and methotrexate efficacy in rheumatoid arthritis [36, 37]. These factors are 
incorporated into a model in which response and toxicity to methotrexate can be predicted. 
Most important, it was the clinical evidence of toxicity or non-response in some patients that 
triggered their research strategy. We hope that similar efforts may be undertaken to further 
explain response to selective COX-2 inhibitors and other non-steroidal anti-inflammatory 
drugs.
In summary, we have shown that modelling concepts can be used to characterise the 
exposure-response relationship of a selective COX-2 inhibitor. Our efforts also unravel an 





Table 8-3: final parameter estimates for the pharmacokinetic model used to simulate GW406381 plasma 
concentrations in patients with rheumatoid arthritis, including the results of a non-parametric bootstrap (n=2000).
Pharmacokinetic model 















Where V2 and V3 =central and peripheral volumes of distribution respectively, Cl=clearance from the central 





























Figure 8.6: Distribution of core set measures stratified by dose at baseline.






Figure 8.7: (left 4 panels) Goodness-of-fit plots for the final exposure-response model. Left upper 2 panels show the 
observed vs. predicted offset (CSM (bas) +ACRN) for the population and for individual patients.  Weighted residuals 
vs. individual predictions and time indicate random distribution of the discrepancies between observed and 
predicted scores (left lower panels). (Right 3 panels) Time course of the observed, individual and population 











































Figure 8.8: Example of the individual and predicted offset (CSM (bas) +ACRN) vs. time stratified by dose level. 
The dashed line represents individual model predictions, whereas the solid line depicts the mean population 























20 40 60 80
 
Figure 8.9: Distribution of estimated IC50 values obtained by bootstrapping (left panel) and the corresponding 
relative standard error (right panel) for the whole population. N=2000.














































Time Course of ACRN Observed & Simulated Data
Figure 8.10: Mirror plots showing the time course of the offset, with the original data in the left panel and simulated 
on the 3 vertical panels on the right. The offset was used to constrain initial positive values at baseline, given that, 
by definition, ACRn is 0 at t=0. See equation 2 for details.
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Figure 8.11: NPDEs for non-responders (left panels) and responders (right panels). The blue shaded areas are the 
prediction intervals of the upper and lower confidence (5 and 95%) intervals of the simulated errors; the pink 
shaded area is the prediction interval of the median. The solid lines represent the medians and the 5 and 95% CIs 
of the prediction errors respectively (lower panels). The blue shaded areas in the histograms and the QQ plots show 
the upper and lower confidence (5 and 95%) intervals of the simulated errors.
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Objective: Pain relief in clinical trials in rheumatoid arthritis and other chronic inflammatory 
pain conditions is assessed primarily by clinical measures without taking into account the 
underlying pharmacodynamic response. In this investigation we illustrate how a mechanism-
based approach can be used to characterise the relationship between drug exposure, 
prostaglandin inhibition and symptoms relief following treatment with a COX-2 inhibitor. 
Such an approach may provide better insight into the causes of variability in treatment 
response in phase 3 trials.
Methods: Using nonlinear hierarchical models previously developed in which drug exposure, 
prostaglandin (PGE2) inhibition and pain response, as assessed by the ACRn scores were 
characterised, we simulate pain response profiles across a wide dose range for GW406381. 
A typical protocol was considered in which treatment is allocated according to parallel, 
placebo-controlled design. A spline was plotted through the simulated data to assess the 
correlations between ACRn and percentage PGE2 in both responders and non-responders, 
as defined by ACRn changes from baseline. This was done for both the median as well as 
the total data.
Results: The proportion of responders increased nonlinearly across the range of doses 
tested. Our simulations show that target inhibition (>80%) may be expected at doses higher 
than 250 mg, whilst a median ACRn drop of >50% occurs at a dose >100 mg GW406381. A 
putative relationship between PGE2 inhibition and ACRn could be identified, which can be 
used to partly explain variability in response.
Conclusions Our analysis shows that the availability of exposure and biomarker data can 
provide a stronger basis for the dose rationale, enabling identification of patient subgroups 
in a trial population, for whom dose adjustments may be required. Whilst biomarkers 
of pharmacological activity may not always be available, mapping of clinical response to 
pharmacodynamics yields evidence of target engagement during the course of treatment. 
Unravelling such correlations can have important implications for further understanding of 
long term safety and efficacy.







In an earlier study in patients with stable rheumatoid arthritis, we have described the 
exposure-response relationships of GW406381, an investigational COX-2 inhibitor [38]. By 
contrast, the dose rationale for the treatment of chronic inflammatory conditions has been 
traditionally driven by empirical evidence of symptom relief. In fact, doses in Phase 2 and 3 
trials are selected without taking the underlying pharmacological activity of the compound 
into consideration. Such a practice is endorsed by clinical and regulatory guidelines and 
often accompanied by a reluctance to collect information on drug exposure in patients [1], 
[2, 3].
Undoubtedly, this paradigm needs to be revisited if the long term safety and efficacy are 
contemplated. The very nonlinear nature of exposure-response relationships is at the 
heart of the problem. Doses that are efficacious and apparently safe following a relatively 
short course of therapy may turn out to be unsafe when considered over a longer period 
of time. The rationale for dose selection is best demonstrated when evidence is generated 
of the appropriate level of target engagement together with the corresponding levels 
of pharmacological activity at the proposed therapeutic doses. A recent example of this 
concept has been shown by Rohatagi et al., who have evaluated the predictive value of 
pharmacokinetic-pharmacodynamic modelling using data from Caucasian subjects to 
predict pharmacodynamics (COX-1 and COX-2 activity) for a new investigational drug in 
subpopulations of interest (including Japanese subjects), and correlate pharmacodynamic 
parameters to safety outcomes. There was good correlation between COX-1 inhibition and 
the incidence of 7-day gastroduodenal mucosal injury [39]. Based on their findings, the 
authors have been able to identify a dose level that yields adequate inhibition of COX-2 
activity with a low risk of gastrointestinal mucosal injury.  
Hence, it should be clear in areas such as chronic pain research that the use of the maximum 
tolerated dose concept does not necessarily mean adequate target engagement or 
pharmacology[40]. Moreover, it leads to inaccurate assessment of the benefit-risk balance. 
Here we attempt to establish a putative relationship between pharmacology, as assessed by 
prostaglandin inhibition (PGE2) and response, as defined by the ACRn scores and thereby 
get better insight into the causes of variability in treatment response in phase 3 trials 
in rheumatoid arthritis. The ACRn is considered a robust continuous index of treatment 
response especially when compared to the traditional end point the ACR20 [9]. The ACRN 
is able to capture both improvement as well as worsening of disease and has been shown 
to provide a more accurate description of the placebo response as compared to the ACR20 
[10].  Whilst its utility as an index of clinical response is beyond doubt, the correlation 
between ACRn and the underlying pharmacological activity following administration of a 
non-steroidal anti-inflammatory drug has never been established. 
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Previously we have also modelled the inhibition of PGE2 by GW406381 as biomarker of 
pharmacological activity in healthy subjects. The concentration-effect relationship obtained 
in healthy subjects was then used to explore the impact of different sources of variability 
and to assess their implication for the dose rationale in later efficacy trials. [19]. Our 
working assumption has been that the optimal benefit-risk balance is likely to be achieved 
when COX-2 inhibition is maintained above 80% but below 95% [41, 42]. Using clinical trial 
(CT) simulations, we have combined the different models describing pharmacokinetics, 
pharmacodynamics and response to assess trial outcome as well as the putative correlation 
between response (ACRn) and pharmacological activity (PGE2 inhibition). We envisage that 
such an approach will make it possible to predict long-term outcome and most importantly 




Our exercise comprised a pharmacokinetic model describing drug concentrations in plasma, 
a pharmacodynamic-model describing prostaglandin (PGE2) inhibition and a disease model 
describing the placebo and drug effects on the clinical response in patients.
An overview of the simulation procedures is depicted in figure 9.1.
Simulation of systemic drug concentrations
Drug concentrations were simulated to subsequently characterise the biomarker-response 
relationship. Mean steady state concentrations were simulated at the time points at 
which the clinical response was recorded. To this purpose, a population pharmacokinetic 
model based on healthy subject data was used [19]. The pharmacokinetics of GW406381 
in adult male subjects was best described by a two-compartment model with first order 
absorption and elimination. Given the absence of covariate effects on the pharmacokinetics 
of GW406381, it in healthy subjects, it was assumed that rheumatoid arthritis has little or 
no effect on drug disposition. A summary of the pharmacokinetic model parameters are 
presented in Table 9.1. Only mean population concentrations were simulated for each dose 
level.
Simulation of drug effect on biomarker
The relationship between drug concentrations and biomarker were described by the 
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Where Imax represents the maximum inhibitory response to GW406381 plasma concentrations 
(c), I0 is the baseline production of PGE2 and γ is the Hill factor.
Simulation of the pain response
The placebo model
A Weibull function was deemed one of the best choices to describe the non-linear decrease 
in the scores from baseline, which reaches a plateau prior to completion of the treatment. 
This model can take into account both placebo responders as well as those with a flat (zero) 
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where Pdt is the clinical endpoint at time t, Basl=baseline value of the clinical endpoint, Pcsm 
is the estimate of the CSM with placebo treatment, td= time to reach the maximum placebo 
effect, α=shape parameter [23]. Pmax or the magnitude of the placebo effect is calculated as 
the difference between Basl and Pcsm.
In order to accurately describe the time course of ACRn, modifications to the basic equation 
is required to constrain ACRn to be 0 at baseline, as per clinical definition. Therefore, the 
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Where ACRn t0=ACRn at time=0, Bas_Sc= core set measures at baseline (time=0). This 
modification accounts for the need for a finite non-zero parameter representing baseline 
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The effects of GW406381 on the ACRn were best described using a standard Imax model, as 
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where Imax represents the maximum inhibitory effect, IC50 is the drug potency and Conc the 
systemic drug concentrations. The net effect on the time course of the ACRN at time t, was 
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Dichotomisation into Responders and Non-responders
To explore treatment and patient characteristics underlying clinical response across the 
different dose groups, subjects were split into responders (R) and non-responders (NR). A 
trial subject was categorised as a responder if he /she had decrease in ACRn > 25% relative 
to baseline at the last study visit (i.e., completion of treatment). 
A summary of the placebo and drug model parameters used for simulations are presented 
in Table 9.1.
Trial Execution Components
A virtual study protocol identical to the original trial was used for the purposes of this analysis. 
Treatment duration was 42 days with visits at baseline, on days 7, 14, 28 and 42 days after 
the start of treatment and follow-up approximately 7 days after completion of treatment. 
for the sake of clarity, data missingness, dropout rate and treatment compliance were also 
assumed to be comparable to the original trial.  Pharmacokinetic and pharmacodynamic 
sampling times were collected at the same time of the assessment of the clinical response.
Study Population: Patients were assumed to have the same demographic characteristics 
of those enrolled in the original clinical trial. However, this information was considered for 
completeness only, given that demographic covariates showed no influential effects on the 
pharmacokinetics, pharmacodynamics or clinical response to GW406381.
 Study design: A parallel placebo controlled study design was used in which treatment was 
assigned to eight different groups, who received placebo and 10, 35, 50, 100, 150, 250 and 
400 mg q.d. doses of GW406381.  five hundred patients were enrolled into each treatment 
arm.
Sampling scheme for ACRn and Core Set Measures: Individual predicted (IPRED) values of the 
ACRN were simulated at each scheduled time point. Due to the use of an additive random 
error structure in the model, response values that were less than -100 were excluded from 
further analysis. The disease core set measure (CSM) values were calculated from the 
simulated individual ACRn values according to the following expression.
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Where CSMEOS, CSMBAS represented, respectively, the CSM score at the end of the study 
(EOS) and at the baseline (BAS)  in the original scale. 
Given that interindividual variability has not been identified on baseline, individual 
patient data from the original trial was used to ensure comparable distribution during the 
simulations. 
Assessment of pharmacokinetic-pharmacodynamic correlations
To explore the link between clinical response and biomarkers of pharmacological effect, 
correlations between the predicted median prostaglandin inhibition and ACRn were 
evaluated. This was done by fitting a spline which described the relationship between these 
two variables. The spline belongs to the family GAM (generalised additive models) which 
lack any explicit functional form and are useful when no a priori assumption is made about 
the parametric form of the function to be fitted to the data. Instead, smoothing functions, 
which are polynomial functions, are fitted to the predictor variable(s) in the model. This 
approach is  appropriate for  prediction/interpolation as well as for exploratory analysis of 
the response[43, 44]. 
 
Figure 9.1: Overview of the simulation procedures.
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Table 9.1: final parameter estimates used for the simulations of pharmacokinetics, pharmacodynamics and clinical 
response.
Pharmacokinetic Model
Parameter Final Model estimates CV%
V2 (L) 252.38 35.06
V3(L) 959.78 60.54
CL (L/h) 30.21 43.97
Ka (h
-1) 15.24 78.7
Q (h-1) 37.28 35.82
Lag time (h) 0.47 6.05
F1 35 1.00 FIXED
F1 70 0.49 44.2
IIV V3 93% 73.05
IIV CL 56% 76.4
IIV Ka 198% 48.84
IIV F1 95% 50.58
Residual error 0.11 58.99
Pharmacodynamic (Biomarker) Model 
I0 (pg/ml) 63196.80 9.74
Imax (pg/ml) 479.00 FIXED
IC50 (ng/ml) 43.25 12.22
Hill factor 1.59 10.37
IIV I0 44% 28.63
Parameter Final Model estimates CV%
IIV Imax 272% 107.38
Residual error 0.002 10.91
Disease Model
Parameter Final Model estimates CV%
Bas_Sc (%) 36.5 1.5





IIV  Bas_Sc(CV%) 38.3 5.80
Residual Error(%) (additive) 17.46 32
where V2 and V3 =central and peripheral volumes of distribution respectively, Cl=clearance from the central 
compartment, Q=intercompartmental clearance, F1=relative bioavailability, 
Imax =represents the maximum inhibitory response to GW406381 plasma concentrations (C), I0 =i baseline production 
of PGE2 and γ = Hill factor, IC50=concentration at which half-maximal PD ( prostaglandin inhibition/decrease in 
ACRn) occurs
Basl=baseline value of the clinical endpoint, Pcsm is the estimate of the CSM with placebo treatment, Kon*, this is the 
reciprocal of td= time to reach the maximum placebo effect, α=shape parameter







Simulations were performed using non linear mixed effects population modelling 
methodology as implemented in the NONMEM  v7.2 (Icon Development Solutions, Eliott 
City, Maryland, USA).. Data manipulation, statistical and graphical summaries were made in 
R 2.13[28, 45].
RESULTS
Our simulations show a wide variation in the time course of the core set measures, irrespective 
of the initial baseline conditions. An overview of the individual profiles for all 4000 patients is 
summarised by dose level in figure 9.2. The ACRn scores, which represent the improvement 
from baseline, are depicted in figure 9.3 together with predicted prostaglandin levels (PGE2) 
for placebo and three dose levels of the active treatment, namely, 50, 150 and 400 mg 
GW406381. It should be highlighted that the model reproduces the variability observed 
previously in clinical trial data. 
Given that missingness and drop-out in the data set affected up to 16 % of the patients, 
with treatment terminating at different points during the course of 42 days, one can see an 
increase over time in ACRn and PGE2 concentrations for some individuals. This fluctuation 
indicates worsening of symptom severity with respect to the preceding visits.
To establish a correlation between biomarker and clinical response, an initial evaluation was 
performed by plotting the predicted median time course of ACRn and the corresponding 
PGE2 concentrations for each dose group. As shown in figure 9.4 ,at doses up to 50mg, 
there is little PGE2 inhibition (<10%). This is accompanied by ACRn scores which do not 
appear to differ significantly from placebo. However, at doses > 150mg, progressively 
greater decreases are observed in ACRn, which seems to plateau at 400mg, reaching levels 
of approximately 90%. In parallel, PGE2 inhibition was predicted to reach over 20%, at a dose 
of 50 mg, increasing to > 60% at 150 mg and > 80% at the highest dose level (i.e., 400 mg).
Based on these predictions, putative nonlinear correlation was identified between the 
median ACRn and the level of PGE2 inhibition, expressed as % change from baseline. 
Subsequently, patients were dichotomised into responders and non-responders according 
to the predefined criterion (i.e., decrease in ACRn > 25% relative to baseline at the last study 
visit). As shown in figure 9.5, PGE2 inhibition levels observed in responders is much higher 
than in non-responders. The proportion of responders increased nonlinearly with the dose, 
showing a plateau at the highest dose of 400 mg.
The median prostaglandin inhibition for non-responders was 4% and that for responders was 



















































































































































































In figure 9.6 in the appendix, percentage prostaglandin in inhibition is plotted against the 
corresponding ACRN scores  depicted for 4 doses, namely, placebo, 100, 250 and 400 mg 
along with a spline indicating the line of best fit. This figure confirms the findings of figure 
9.5, in that there are a non-linear sigmoid relationship between prostaglandin inhibition 
and ACRn scores, at all doses. Considerable variability is appreciable in both variables, and 
particularly in case of ACRn, for many individuals, maximum pain relief is attained at low 
doses. However with prostaglandin inhibition, a clearer dose dependency is visible with the 
top two panels showing lower inhibition rates compared to the lower panels. In comparison 
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Figure 9.3: Predicted time course of simulated ACRn and the corresponding prostaglandin concentrations after 
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Figure 9.4: Predicted median time course of the simulated ACRn and corresponding PGE2 concentrations after 
administration of placebo, 50, 150 and 400 mg GW406381.














































































Figure 9.5: fitting of the median PG inhibition (predictor variable) and ACRn (response variable) for responders 
(upper panel, A) and non-responders (upper panel, B) respectively using a nonlinear spline function. A clear 
correlation is observed between the relative proportion of responders and the dose of GW406381 (lower panel 
C). Symbols refer to individual doses namely, red dot-placebo, orange filled square-10mg, green filled diamond-
35mg,green filled triangle-50mg,blue open star-100mg,blue crossed square-150mg,purple crossed circle-
250mg,pink open square-400 mg. Note with the scales being harmonised for responders and non-responders, the 
non-linear correlation between the ACRn and the PGE2 is not appreciable.
DISCUSSION
There are numerous factors contributing to high failure rate in the development of drugs 
in chronic pain conditions.  A detailed analysis of the problem reveals that these factors 
may be categorised into three main classes: disease, drug and trial design-related factors. 
The main goal of the analysis described in here was to explore how in silico methodologies 
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can contribute to further understanding of drug and design-related factors. In fact, the 
importance of trial design-related factors has been highlighted by Katz et al. who have 
investigated the role of placebo effect and other confounders of treatment response[46]. 
Clearly, irrespective of the advancements in the understanding of disease and the possibility 
to identify biomarkers for chronic pain, our ability to demonstrate efficacy and differentiate 
novel treatments requires methodological research aimed at minimising this unacceptable 
false negative rate, whilst being able to select doses that yield the anticipated level of target 
engagement and consequently the expected pharmacological activity.
Our results show that the clinical response to a COX-2 inhibitor, as assessed by the ACRn, can 
be correlated to the underlying pharmacological activity. The availability of such a correlation 
represents a stronger basis for the dose rationale in efficacy trials, which have been primarily 
been determined by evidence of treatment response based on overt symptoms, rather than 
on the underlying concentration-effect relationships. The correlation is also evident after 
dichotomisation of the patients into responders and non-responders. However, it is clear 
that the results from the responders group may have strong prognostic value, since that 
improvement greater than 25% relative to baseline may be truly reflective of drug effect, 
as opposed to placebo response, which is significant in this indication [47, 48]. In addition, 
our simulations reveal that the number of responders in the dose range used in the original 
clinical trial would result in a response proportion of less than 70% at doses of 50mg, which 
corresponds to the observed data[38]. 
In an earlier work, we have predicted the therapeutic dose range was likely to lie above 150 
mg administered either a once daily or twice daily dosing regimen. [19]. Our simulations 
suggest that pharmacological activity corresponding to clinically relevant changes in ACRn 
are observed between 150 and 400 mg, administered as a q.d. regimen. Although compliance 
and dropout level in this exercise has been considered a fixed factor based on historical 
data, we believe that the observed levels of data missingness do not affect the conclusions 
about the required dose to ensure optimal clinical response in this patient population.
Another important point to consider in this investigation is how prior knowledge about 
the compound’s pharmacological properties can be formally incorporated into statistical 
inferences taking into account uncertainty and use the results to improve decisions deriving 
from the observed treatment effect in a clinical trial.  In a field where most clinical trials have 
a conservative design, this methodology offers an unique opportunity not only to assess the 
scientific rationale of the study, but also to explore innovative designs, including a formal 
evaluation of design features such as (a) sample size (number of patients), (b) randomisation 
ratio across treatment arms, (c) frequency of assessments (number of visits), (d) dropout 
mechanisms, (e) clinical endpoint and (f) statistical methods for the analysis[49].
Despite the potential advantages highlighted above, one should acknowledge that while 
the ACRn has been shown to be a robust index of response to treatment, it is not pathway 






specific [17, 50]. Therefore, this scale can be used to evaluate response to COX inhibitors as 
well as for DMARDs in rheumatoid arthritis [11]. This forms an important limitation to the 
implementation of a comprehensive mechanism-based approach, in that changes in the ACRn 
provides no evidence about the targets and pathways involved in the symptomatic response 
[35].  We raise this point to call attention to the challenges one faces in the implementation 
of physiologically meaningful parameters. In contrast, there are clinical scales, such as those 
used in neurodegenerative diseases (e.g. multiple sclerosis, Alzheimer’s or Parkinson’s 
disease), for which a correlation can be established (either directly or inversely) with markers 
of pharmacology. In Parkinson’s disease for example, the UPDRS (unified Parkinson’s disease 
rating scale) as well as the Hoehn and yahr scale have been shown to have a high degree of 
correlation with striatal and overall dopamine transporter (DAT) binding. [51-53]. This has 
been confirmed by PET scanning of dopamine transporters in affected patients[53].
In chronic pain conditions however, we are essentially interested in knowing how 
perturbations of the different pathways influence or determine clinical surrogate end 
points , which are defined as  characteristics or variables that measures how a patient feels 
functions or survives[54].
A caveat here is that our findings relate only to drugs acting via the COX pathway, thus the 
NSAIDs and specifically the COX2 inhibitors. for DMARDs other pathways may be recruited 
and hence this correlation may not applicable, though the concept is still valid.
In conclusion, the use of a model-based approach such as presented here offers the 
opportunity for protocol design optimisation and improved dose selection in efficacy trials. 
Most importantly, it provides a quantitative framework for establishing the connection 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 9.6: The non-linear correlation between PGE2 inhibition and the ACRn scores, presented for the entire 
dataset. The spline indicates the best fit.  
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ANALGESIC DRUG DEVELOPMENT AS IT STANDS TODAY
Chronic pain is a significant health problem that greatly impacts the quality of life of 
individual patients and imparts high costs to society. Despite intense research effort and 
progress in our understanding of the mechanistic and molecular basis of pain, chronic pain 
remains a significant clinical problem that has few effective therapies [1]. In fact, existing 
analgesics are relatively ineffective, have a high side-effect burden and do not reduce pain 
in all treated individuals. While a statistically significant reduction in pain in pivotal trials 
can result in an investigational analgesic obtaining regulatory approval, these treatments 
are palliative in nature making pain symptoms more manageable, with global pain scores 
reducing by 30% at best in responders [2-4]. However,  even in successful phase 3 analgesic 
trials, at the end the majority of subjects are still eligible to enter the same trial [5]. 
Experts across different disciplines acknowledge the unmet needs in analgesia and 
recommend strategies for enhancing analgesic drug development. Nevertheless, both 
treatment and research into chronic pain are greatly compromised by the fact that there 
is no objective diagnostic test that can complement the subjective assessment of chronic 
pain conditions.  Currently, there are no concrete diagnostic measures that enable early 
diagnosis, prevention or prophylaxis of a syndrome that endures for long periods of time. 
While there has been exploration of different treatment options, including novel putative 
mechanisms of action for analgesia, there has been wide-spread reluctance on the part 
of the pharmaceutical industry to take novel products further into development without 
demonstrating the efficacy of analgesics based on behavioural measures, which reflects the 
current status at which this pathological condition or syndrome is clinically detectable. As 
a consequence, efforts in drug development have been geared to the design of the clinical 
trials (e.g., fDA’s Analgesic Clinical Trials Innovation, Opportunities, and Networks - ACTION 
Initiative)[6], under the assumption that better trial designs will yield more successful results. 
This hypothesis is questionable in view of  the frequent failures of clinical efficacy trials of 
opioid drug products, considering the well-established effectiveness of these products from 
literally thousands of years of clinical experience. In this thesis, we have brought a different 
perspective to the evaluation of chronic pain by emphasising the role of pharmacology and 
target engagement as the basis for translational research and clinical evaluation of novel 
molecules in humans. Throughout the various chapters we have highlighted some important 
conceptual and experimental flaws in the way that pain signalling and pharmacological 
activity are characterised and translated across species and disease conditions. The common 
denominator of the work presented here is the requirement for accurate characterisation 
of exposure-response relationships, without which the dose rationale for the progression 
of a molecule cannot justified, whether drugs are aimed at symptomatic relief, disease 
modification or prophylaxis. In addition to a comprehensive review of the mechanisms 
underlying pain signalling and symptoms, the work developed here focuses on three 
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different aspects of research underpinning the use of pharmacokinetic-pharmacodynamic 
relationships. first, we have explored the requirements for the characterisation of behavioural 
measures of pain during the early screening of candidate molecules, shedding light onto the 
shortcomings of experimental protocols commonly used in preclinical research. Then we 
introduced the prerequisites for the parameterisation of pain behaviour to ensure accurate 
translation of the pharmacological properties across species as well as for bridging across 
different phases of development. Lastly, an attempt was made to model clinical response in 
chronic inflammatory pain and to establish correlations between symptom improvement and 
the underlying pharmacological effects using biomarkers. In addition our work showed how 
clinical trial simulations can be used as a design tool, enabling the evaluation of a variety of 
scenarios that disentangle the contribution of pharmacology from the confounding effects 
of placebo and disease dynamics.
CHRONIC PAIN AS A NOCICEPTIVE SIGNALLING DISORDER 
An overview of the ongoing research efforts in neuropathic and chronic inflammatory pain 
was presented in Chapter 1. We have shown that in addition to practical challenges, there 
are still several methodological issues that hinder the development of novel medications for 
the treatment of chronic pain. The most common problem is clearly the lack of construct 
validity of the experimental protocols used to assess drug effects. Pain experiments focus 
on transient behavioural models of pain, which do not necessarily reflect what is occurring 
in chronic pain patients. A new paradigm is proposed for the identification of relevant 
targets and candidate molecules in which pain is coupled to the cause of sensorial signalling 
dysfunction rather than to the symptoms. We have also shown that early diagnosis, timing 
of the intervention and reversibility of the underlying processes cannot be disentangled 
from each other and ultimately determine the success or failure of a treatment. It is 
therefore essential to understand the changes in the nervous system that result in the pain 
experience and consider the need for interventions before symptoms evolve. Consequently, 
one needs appropriate measures of patient response that are crucial in establishing patterns 
of response. On the other hand, such experimental protocols will remain of limited value 
unless relevant pathophysiological changes can be detected at the prodromic phase, i.e., 
before the metamorphosis from acute injury to chronic pain. This discussion is further 
extended to the limitations and flaws in the current paradigm for the screening and selection 
of compounds in drug development and used as a foundation for the subsequent chapters 
in this thesis. Here we have also highlighted the fact that the measures of pain perception 
currently used in experimental modelsedo not bring to light all involved pathways, which 
creates an important translational gap across species. 







MODEL-BASED ANALYSIS OF PAIN BEhAVIOuR IN PRE-CLINICAL 
INVESTIGATIONS
As discussed in Chapter 2, the translational value  of pre-clinical models of pain has 
been the subject of heated debate [7]. The generally held view is that these models lack 
construct or predictive validity and are only able to replicate symptoms [8, 9].  Moreover 
coarse behavioural endpoints such as the threshold to paw withdrawal (allodynia) or paw 
withdrawal latency (hyperalgesia) are employed as surrogates for evaluating analgesic 
activity. Despite these limitations, we have highlighted how further understanding of the 
pharmacology and target engagement can be relevant for the progression of a molecule 
into humans. 
Using recent examples from  published literature, we have emphasised the requirements 
for the assessment of concentration-effect relationships in pre-clinical species, including 
important changes in experimental procedures in standard screening protocols. Among 
other factors, we have indicated the importance of pharmacokinetic sampling and expressing 
drug properties such as potency in terms of exposure (EC50), rather than dose (ED50). Poor 
experimental design can lead to inaccuracies in parameter estimation and consequently to 
biased selection and ranking of candidate molecules during screening. In this context, we 
have introduced how mathematical and statistical models can be used as a tool to describe 
biological system and drug properties in a quantitative manner. Hierarchical or population 
models were proposed as the basis for identifying the different sources of variability as well 
as to assess treatment effects and disease progression.  In addition, here we bring in the 
concept of biomarkers as an intermediate step between drug action and behaviour, which 
can be integrated in a systematic manner by pharmacokinetic-pharmacodynamic modelling, 
enabling the characterisation of exposure-response relationships and consequently 
providing mechanistic underpinning, be it for the purpose of interspecies translation or 
determination of the therapeutic dose levels in patients.
 
ExPERIMENTAL PAIN MODELS: UNTRANSLATABLE YET INFORMATIVE
An important assumption underlying the work presented in this thesis was that some of 
the limitations of the current practice of pre-clinical research may be overcome by model-
based analyses, in that it facilitates the evaluation and discrimination between drug and 
system-specific properties. furthermore, it can be envisaged that estimates of potency that 
are based on concentrations rather than doses will be more informative, allowing for more 
accurate comparisons between compounds of the same class and possibly enhancing the 
predictive value of such estimates.  Another premise of our work was that standardised 
experimental protocols are not designed to ensure the informative value of the data 
collected or optimally discriminate between molecules or dose levels. Given the empirical 
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nature of pain experiments, standardisation procedures simply attempt to increase the 
reproducibility of measurements. Hence, efforts were made to evaluate the impact that such 
improvements could represent to the development of novel molecules for the treatment of 
chronic pain.
As indicated previously in the scope of this thesis, the lack of suitable markers of pharmacology 
is compounded by poor data integration at the time candidate molecules are selected. We 
have shown that whilst the assessment of concentration-response relationships across 
the different phases of development is a sine qua non condition to understand treatment 
effects and variability, accurate estimation of PKPD parameters is not guaranteed. PKPD 
relationships must have predictive validity or value for the target population, both in 
qualitative and quantitative terms. Such considerations are not formally embedded in the 
requirements for evidence generation, and consequently lead to experimental protocols, 
which are often not informative or eventually even biased[8].  
Two experimental models of pain behaviour were selected to illustrate the aforementioned 
concepts. first, the threshold to paw withdrawal to a normally non-noxious stimulus was 
measured as a marker of the anti-allodynic effect in the complete freund’s adjuvant (CfA) 
model, a well-known experimental animal model of inflammatory pain. In the second case, 
the change in flinching frequency observed after injection of formalin was selected as a 
marker of drug effect. The pain response in this model is based on spontaneous behaviour, 
rather than on the threshold for a painful stimulus. In addition, the pain reaction produced 
by formalin results from a conditioned motor response, reflecting higher cognitive function 
than simple withdrawal responses [10]. It has also been demonstrated that drugs with 
different mechanisms of action can be differentiated in terms of the type and magnitude 
of the effects on the flinching behaviour. We have hypothesised that for this reason the 
formalin-induced model is likely to show some construct validity as compared to other 
experimental models based on short duration stimuli [11]. from a methodological 
perspective, we have demonstrated that the choice of parameterisation is as critical as 
the precision of model parameters. Undoubtedly, the limited availability of data during 
the screening of compounds leads to two important statistical issues, namely parameter 
identifiability and poor precision.  
In Chapters 4 and 5 we showed therefore how efficacy can be reliably assessed for gabapentin 
and pregabalin. To prevent model and parameter identifiability issues, an approach was 
proposed based on the use of a binary response as parametric filter for drug screening. Our 
analysis showed that it is possible to dissect system from drug-specific features, allowing 
the assessment of potency as parameter of interest for two paradigm compounds. The 
aim was to decrease the uncertainty on EC50 estimates as well as on the corresponding 
inter individual variability. ED-optimality was therefore applied in combination with a 
logistic regression model describing the relationship between drug exposure and response 







to evoked pain in rats, enabling us to take parameter uncertainty into account [12]. The 
design variables selected for optimisation included the dose levels and sampling times 
required for the characterisation of the analgesic effects. Moreover, information regarding 
system-specific model parameters and relative in vitro potency data were also incorporated 
as priors during optimisation. Our analysis also shed light onto the implications of the 
empirical choice of dose levels, which are often too high to allow accurate estimation of 
drug potency in vivo. Moreover, despite the wide range of doses used in the experiments, 
simulated concentration profiles of gabapentin were not significantly different from each 
other. Relative bioavailability was found to decrease nonlinearly from 100 % at 10 mg/kg to 
9 % at 300 mg/kg.  In contrast to results from typical experiments in which ED50 is calculated, 
irrespective of the underlying exposure levels, protocol optimisation procedures clearly 
showed the importance of optimised sampling and dose schemes. EC50 values for gabapentin 
and pregabalin were 1400 and 897 ng/ml, confirming that the relative difference potencies 
observed in vitro are also seen in vivo. Overall, these findings demonstrate that protocol 
optimisation does represent an improvement in terms of parameter precision and bias. We 
anticipate that these procedures will provide the basis for further validation of experimental 
models of pain in terms of sensitivity and specificity, i.e., enabling the characterisation of 
the false positive and false negative rates during the screening process.
The advantages of model parameterisations based on drug- and system-specific properties 
was further explored in Chapter 6, where we investigated the feasibility of developing  a 
semi-mechanistic model to describe the effects of a wide dose range of gabapentin (i.e., 
0 – 100 mg/kg) on formalin-induced pain, which is characterised by two peaks of flinching 
behaviour. The first peak of hypersensitisation was described by a mono-exponential declining 
function, whereas the second, prolonged phase of nociception was best parameterised by 
an indirect response model with a time variant synthesis rate. Drug effect was parameterised 
as an Imax function. Here, however, the drug effect represented a covariate on pain response. 
The approach contrasts to traditional parameterisation of drug effects in indirect response 
models where it is applied to the synthesis or the elimination rate of the disease [13]. yet, 
our choice of parameterisation has a mechanistic basis, given that gabapentin is known 
to have no disease-modifying effects. Interestingly, the mean IC50 values of 7510 ng/ml 
were found to be in the same log order of magnitude as those reported by Lockwood et al. 
and Whiteside for gabapentin in clinical studies [14, 15]. On the other hand, despite high 
exposure levels, gabapentin did not completely suppress the behavioural effects induced 
by formalin. This apparent discrepancy appears to reflect the somewhat limited efficacy in 
neuropathic pain patients.
Whilst concrete improvements in the estimation of drug- and system-specific parameters 
were demonstrated by the use of a model-based approach, our endeavour thus far to 
characterise behavioural endpoints as a measure of drug effects has highlighted the 
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implications of the lack of biomarkers as an intermediate step for the translation of the 
pharmacological properties across different phases of development.  Undeniably, there is 
a pressing need to obtain early signals of efficacy by means of biomarkers, which could 
be used not only as “scaling factors” to translate drug effects from pre-clinical species to 
humans, but also as a tool for extrapolating drug effects across populations during drug 
development, i.e., from health to disease conditions. The points-to-consider for the use of 
biomarkers as the basis for the dose rationale were presented in the subsequent section of 
the thesis.
Biomarker-guided dose selection and prediction of clinical response 
As indicated in the introduction, to address the escalating attrition rate in drug development, 
focus must be given to two key approaches in parallel [16]. The first is better target selection, 
taking into account the pathways as well as the timing of diagnosis and intervention. The 
second is the routine pursuit of early proof-of-concept studies, preferably already in Phase 
I or in human tissue, in which biomarkers or surrogate endpoints could be employed as 
markers of efficacy and safety. Despite the evidence  from other therapeutic areas supporting 
such an approach [17, 18], chronic pain protocols have remained primarily based on clinical 
scales without any reference to the underlying pharmacology or target engagement [19, 
20]. Clearly, the integration of biomarkers of pharmacology into drug development also 
offers the possibility to eliminate part of the bias that arises from empirical evidence using 
nonspecific behavioural measures. 
In Chapter 7, we made therefore an attempt to show that opportunities exist for truly 
characterising the clinical pharmacological profile of novel molecules in humans when 
biomarkers are used as predictors of efficacy, enabling mechanistic insight into the 
exposure-response relationships and consequently better rationale for the therapeutic dose 
range. Moreover, the assessment of pharmacokinetic-pharmacodynamic relationships using 
biomarkers can provide a stronger basis for personalised medicine. 
Here data from GW406381, a cyclo-oxygenase (COX) inhibitor was used to illustrate the 
concept of biomarker-guided dose selection and emphasise the importance of gaining 
insight into the clinical pharmacology of the compound as the basis for the dose rationale. 
The choice of the COX-2 system as a paradigm was dictated by the various reports arising 
from the withdrawal of different drugs from the market, for which the clinical pharmacology 
profile was clearly known to determine efficacy and safety. Data from a phase I, randomised 
double-blind single dose followed by a 10-day repeated dose study in healthy male subjects 
were available for the analysis. Doses of 35 or 70 mg GW406381 were administered orally 
under fasting conditions. Plasma concentrations of GW406381 and PGE2 (prostaglandin E2) 
as well as thromboxane B2 (TXB2) were measured at regular intervals throughout the study. 







The analysis was performed in two stages. first, a compartmental pharmacokinetic model 
with first order absorption was used to describe the time course of drug concentrations 
in the plasma. Then an Imax model was fitted to the prostaglandin data to describe the 
exposure-response relationships.
from a methodological standpoint, by integrating pharmacokinetic data from a Phase 
I trial with PGE2, as determined by an ex vivo assay, we have illustrated how biomarkers 
can be used to guide dose selection in subsequent phases of drug development. It is 
noteworthy to mention that our analysis was successful despite the high variability in PGE2 
data. Mean potency estimates (IC50) were 43.25 ng/ml, with IC80 and IC95 values reaching 
103.43 and 275.58 ng/ml respectively. In addition, the high variability in pharmacokinetics 
and pharmacodynamics observed in healthy subjects exposed an important limitation of 
using in vitro potency as a benchmark to compare compounds in early clinical development, 
which does not reflect differences in selectivity or metabolic activity in vivo. In fact, fries et 
al. showed that despite the higher potency of rofecoxib relative to celecoxib in vitro, their 
in vivo selectivity is likely to be the same [21]. Likewise, the in vitro potency of GW406381 
was estimated to be approximately 30 times as high as rofecoxib. However, the optimal 
recommended dose range proposed from our simulations lies between 150-250 mg, while 
that for rofecoxib is 25-50mg. This is mostly explained by the inter-individual differences in 
pharmacokinetics. Given the proposed therapeutic range (i.e., <80% and < 95% inhibition), 
it was found that a b.i.d. regimen allowed peak concentrations to remain above the 
IC95 for a shorter time and at much higher dosages, without significant effect on trough 
concentrations, which were comparable to those achieved with a q.d. regimen. 
With the help of simulation scenarios we have also demonstrated how biomarkers can be used 
to explore dose adjustment in special populations. The simulated clinical scenarios included 
factors known to have potential effect on the pharmacokinetics and pharmacodynamics of 
GW406381, namely hepatic impairment, metabolic induction and systemic inflammation. 
Our results showed that moderate to severe hepatic impairment or metabolic induction do 
lead to significant changes in exposure and consequently in dose adjustments  to ensure 
target exposures are achieved and maintained during the course of therapy. Conversely, 
increases in baseline levels of PGE2 appeared to require no changes in dosing regimen.
In brief, this analysis allowed for the evaluation of the dose rationale taking into account 
the benefit-risk balance, which depends not only on the total dose level, but also on the 
dosing regimen [22]. Such a balance is likely to be achieved when PGE2 is maintained above 
80% but below 95%. Under these conditions, chronic treatment would effectively block the 
inducible fraction of the available COX-2 pool, whilst allowing for the residual or basal activity 
of PGE2 and other COX-2 related prostacyclins, which have an essential role in normal tissue 
homeostasis and repair. 
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In the last part of this thesis, we have expanded the concept of biomarker-guided dose 
selection to Phase 2 clinical trials to gain further insight into the relationship between 
biomarkers and overt pain symptoms. By applying the mechanistic classification proposed 
by Danhof et al. [23], it was possible to unravel a putative exposure-biomarker response 
relationship for GW406381. To this purpose, ACRn scores from a large clinical trial in 
rheumatoid arthritis patients were used. Even though the utility of the ACRn as an index of 
clinical improvement is beyond doubt, its correlation with the underlying pharmacological 
activity following administration of a COX-2 inhibitor has not been established. In Chapters 
8 we have progressed with the use of biomarkers from health to disease and attempted to 
ascertain whether biomarkers could be correlated with ACRn. In spite of the limited number 
dose levels that were tested in the trial (0, 10, 35 and 50 mg, administered orally as a once 
daily dosing regimen), our objective was to show how longitudinal modelling can provide 
the basis for inferences about the pharmacological effects underlying clinical response. An 
integrative approach was therefore proposed in which information was derived about the 
whole time course of treatment response. This contrasts with current practice, in which 
efficacy is determined by comparing the differences in clinical response at completion of 
treatment only. The time course of the pain response was best characterised by a Weibull 
function with an Imax model describing the drug effects. We could identify a responder 
phenotype in the population, which included all individuals who displayed at least a 25% 
decrease in ACRn from baseline at the end of the study. Interestingly, the percentage of 
responders was not dose proportional, which reflects the impact of high pharmacokinetic 
and pharmacodynamic variability. Whilst direct evidence of efficacy could not be obtained 
from higher dose levels, these findings are in agreement with the predicted levels of 
target engagement, as determined by the PGE2 inhibition. Based on the premise that 
pharmacological activity translates into clinical analgesia when PGE2 inhibition reaches a 
threshold of  at least 80%, it appears that the doses selected for the clinical study were sub-
therapeutic. According to the analysis of the biomarker response, the therapeutic doses for 
GW406381 were likely to be between 100 and 250mg/day.
Our endeavour to evaluate the predictive value of a model-based approach for the dose 
selection of analgesic drugs would not be complete without further characterisation of the 
correlation between biomarker and clinical response [24]. In Chapter 9 we explore therefore 
the putative relationship between prostaglandin inhibition (PGE2) and the ACRn scores in 
rheumatoid arthritis patients.  In addition to demonstrating the suitability of PGE2 as a proxy 
for target engagement (i.e., COX-2 inhibition), inferences about the correlation between 
biomarker and clinical response provide better insight into the causes of variability in a large 
population.  Using the pharmacokinetic and pharmacokinetic-pharmacodynamic models 
previously developed in chapters 7 and 8 simulations were performed of the time course 
of the clinical response (ACRn) and PGE2 concentrations. The hypothetical experimental 







protocol was based on a typical clinical trial in rheumatoid arthritis, with treatment duration 
of 6 weeks and five hundred patients per dose level. A range of doses from 10 to 400 mg 
GW406381 was considered in our exercise to ensure accurate characterisation of the potential 
sources of variability. Patients were classified as responders or non-responders based on 
the simulated response at completion of treatment. Our results showed a wide variation 
in the time course of the core set measures, irrespective of the initial baseline conditions, 
with predicted PGE2 inhibition over 80% at doses greater than 250mg. furthermore, the 
proportion of responders increased in a non-linear fashion across the simulated dose levels, 
with a decrease of 50% in the median ACRn at doses >100mg/day.  The availability of such 
a correlation represents a stronger basis for the dose rationale in efficacy trials, which 
have been primarily been determined by evidence of treatment response based on overt 
symptoms, rather than on the underlying concentration-effect relationships.
In conclusion, we have shown that modelling and simulation can facilitate the translation 
of experimental findings across different phases of drug discovery and development, 
improving the dose selection and the design of experimental protocols.  To this end, we 
have demonstrated that the availability of longitudinal data is paramount. However, 
experimental protocols must be based on sampling schemes that allow for the accurate 
characterisation of pharmacokinetics, biomarkers and efficacy. Moreover, the choice of 
appropriate model parameterisations, which enable discrimination between drug and 
system-specific parameters, offers the possibility to systematically explore drug effects 
taking into account the historical evidence for system-specific properties. In fact, we have 
shown that statistical priors can be used to reduce uncertainty during parameter estimation 
and protocol optimisation and as such enable further understanding of the underlying 
variability in experimental data. furthermore, using paradigm compounds with known 
analgesic activity, we have underlined how essential concentration-effect relationships are 
for the dose rationale in humans. It provides the basis for evaluating the effect of influential 
covariates on drug exposure and response. 
Albeit a preliminary exercise, in which modelling and simulations are used as inferential 
tools, the approach presented throughout this thesis represents a shift from the empiricism 
which has dominated selection of candidate molecules, the rationale for the therapeutic 
doses and the design of Phase 2b and 3 trials for chronic pain conditions. The critical point 
here is that drug response cannot be expected without sufficient target engagement. On the 
other hand, further increases in exposure do not yield additional efficacy when maximum 
pharmacology has been reached. Undeniably, the use of pharmacokinetic-pharmacodynamic 





Drug development has traditi onally been considered a linear process beginning with target 
selecti on and ending with regulatory approval [1, 25]. This creates a sequenti al approach 
to decision making, in which there should be learning at each step, i.e., knowledge from a 
previous step informs the subsequent one (see figure 10.1). Currently, however, as shown 
throughout this thesis each step appears to occur in isolati on and there is litt le or no 
integrati on and accrual of informati on from preceding steps.
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F igure 10.1: Translati onal steps in drug discovery and development. The standard linear model of drug development 
is depicted, for illustrati ve purposes only. Translati onal acti vity is bidirecti onal. Translati onal assessment needs to 
start early and requires constant updati ng according to progress in both directi ons ‘including reverse translati on’. 
Adapted with permission from [25].
from a clinical and biological perspecti ve, an approach is required that allows us to  depart 
from the current fragmented strategy, which focuses on individual signal transducti on 
pathways,  to studying pain as a system based-approach [26]. Moreover, eff orts must be 
made to detect the underlying signalling disorder that precedes the overt pain experience. 
Prophylacti c or pre-empti ve treatments are needed to ensure normal ti ssue homeostasis 
is maintained aft er onset of injury and subsequent acute infl ammatory response. In this 
context, drug development programmes will have to consider co-development of diagnosti c 
markers.







Clearly, the issue in the evaluation of neuropathic pain conditions is whether existing or new 
experimental models may ever provide us the basis for translating drug effects from animals 
to humans without evidence of common biological substrates. yet, a model-based approach 
is essential to optimise the design and interpretation of preclinical experiments, making it 
more informative. The availability of models will also contribute to mechanistic inferences, 
enabling systematic integration of data and information from a vast range of experimental 
protocols, including in vitro human cell and tissue cultures. In fact, Woolf and collaborators 
have proposed a new approach to analgesic drug development, in which human genetics 
is employed to validate potential analgesic targets. Some examples include the role of 
polymorphisms in voltage-gated sodium channel Nav1.7 and GTP cyclohydrolase-1, which 
have been linked to decreased pain perception. Likewise, other approaches are being 
considered which entail early exploration of the pharmacology of the compound (proof 
of principle) in humans (see figure 10.2). Irrespective of differences in choice of tools or 
research protocol, all proposals are unanimous on the role of mechanistic biomarkers to 
guide development [1], [26]. 
Figure 10.2: A proposed new analgesic development pathway. The preclinical and clinical distinction must be 
abolished. The choice of a target must be driven by data from patients using unbiased screening techniques. 
Screening and validation must focus on the native human target expressed in human cells relevant to the target’s 
action in pain; preclinical toxicity studies must be done in human cells; Phase I must include pharmacokinetic 
data showing engagement or target occupancy. Phase 2b must be designed to differentiate true efficacy by 
detailed phenotyping, use of appropriate biomarkers and outcome measures. Phase 3 should be a confirmatory 
step to identify responders and assess the clinical impact of patient heterogeneity. iPs= induced pluripotent 
cell, PET=positron emission tomography, POP=proof of principle, fMRI= functional magnetic resonance imaging. 
Adapted with permission from [1].
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Currently there is no validated biomarker for chronic pain. In fact, the identification and 
use of biomarkers for CNS disease are more challenging than other diseases [27] due to the 
inaccessibility of the brain. A number of reviews have summarized the current state of the 
art of imaging pain in the brain [28]; [29, 30] but none have evaluated the potential of using 
imaging to discover and define biomarkers of pain and their potential application in drug 
development. 
        
Figure 10.3: Imaging biomarkers or disease state and drug effects. functional biomarkers may include specific fMRI 
signals for pain based on evoked or resting state connectivity patterns. Morphometric biomarkers include changes 
in volume or thickness of brain gray matter or alterations in white matter integrity. Chemical biomarkers include 
specific chemical changes in brain regions related to disease state or drug effect (adapted with permission from 
[37]).
Developments in functional imaging will unquestionably facilitate the identification of 
biomarkers of pain and help us to better understand the role of various brain areas in the 
expression of pain, especially in processes that are associated with neuroplasticity, which is 
a critical step for the development of chronic pain [31].  In conjunction with physiological 
(sensory) challenges it may be possible to anticipate signalling disorders before symptoms 
emerge. Collectively, a refined understanding of abnormal activity or connectivity of synaptic 
elements may allow us to more effectively target interventions in patients who are likely 
to later experience chronic pain [32]. In the context of drug development, these advances 
may also improve  translational go/no go decision making between the laboratory and 
early clinical trials. However, a reductionist approach needs to be avoided in that further 
understanding of the pain syndrome cannot be achieved by functional imaging alone. When 
integrated with clinical subjective assessments [33], genetic [34], metabolomics [35], or 
proteomics [36], such evidence could provide orthogonal views that together may improve 
the predictive value of pain biomarker strategies. The challenge to be overcome as for any 







chronic disease that requires prolonged dosing is that one will need to differentiate the 
early direct effects of the drug from chronic effects on brain systems that are associated 
with longer-term effective treatment.
Irrespective of the advancements in the field of imaging and proteomics as an important step 
to generate evidence of target engagement and possibly of markers of disease progression, 
pharmacokinetic-pharmacodynamic models can play an essential role as translational tool, 
providing guidance for the introduction of novel research protocols aimed at reducing 
uncertainty about the potential clinical relevance of candidate molecules and enabling 
selection of the putative therapeutic dose range and transition from the pre-clinical phase 
to humans. Through the use of systems pharmacology, pathways associated with signalling 
processes can be better mapped and system-specific parameters disentangled from drug-
specific properties. Under the assumption of common substrates in experimental and 
disease conditions, modelling can be used to predict target engagement and consequently 
the downstream pharmacological effects. It is also conceivable that scaling factors could be 
identified to describe potential differences, such as receptor density, between experimental 
protocols and disease conditions in humans. Similar concepts have been recently applied for 
antipsychotics, for which in vitro receptor occupancy in rats has been scaled all the way to 
clinical efficacy [38, 39]. As already proposed in this last section of this thesis, quantitative 
techniques could then be used further explore the role of phenotypic differences and other 
influential factors (covariates) on pharmacokinetics and response, thereby supporting dose 
selection and other label claims (figure 10.4).
       
Figure 10.4: An integrated model-based approach across drug discovery and development, from systems biology 
all the way to exposure-response modelling. Adapted with permission from [40].
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A slightly different scenario can be envisaged with regard to the challenges one faces in the 
evaluation treatment effects in chronic inflammatory pain, for which a few biomarkers exist 
and imaging technology is already being used. The challenge will be to reach consensus about 
the importance of revisiting current guidelines, which dismiss the role of pharmacological 
activity as the basis for dose selection and exclude the concept of learning and confirming 
as the paradigm for drug development. Undoubtedly, the use of simulation scenarios will 
play an increasingly important role in the evaluation of the impact of heterogeneity in target 
population as well as of variability in pharmacokinetics, pharmacodynamics and response 
to intervention. In this context the integration of statistical models that describe trial design 
factors, such as drop-out and censoring, with mechanism-based models describing the 
underlying progression of the disease will be of great value [41]. finally, we envisage that 
further advancements in the prediction of pain response can be obtained by expanding the 
concepts to multiple endpoints as well as by incorporating fully mechanistic models to the 
pharmacometric framework proposed in this thesis.
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PKPD RELATIES EN KEUzE VAN DE DOSIS BIJ DE ONTWIKKELING VAN  
ANALgETICA – STREVEND NAAR hET VOORSPELLEN VAN 
RECEPTORBEzETTING
Chronische pijn wordt beschouwd als een aanzienlijk probleem in de geneeskunde. Een 
belangrijk klinisch en maatschappelijk gevolg van deze aandoening is de vermindering 
van de kwaliteit van het leven voor de betrokkenen en de daarbij behorende hoge kosten 
voor de gezondheidszorg. Ondanks doorlopend onderzoek en vordering in de kennis van 
de moleculair-mechanistische basis van pijn, blijft het een complex probleem waarvoor 
tot op heden geen effectieve behandeling bestaat. De bestaande geneesmiddelen worden 
voornamelijk gebruikt voor de behandeling van pijnsymptomen. Ze zijn en als zodanig relatief 
ineffectief, aangezien analgesie vaak gepaard gaat met veel bijwerkingen. Bovendien blijken 
deze medicijnen beperkt werkzaam te zijn in patiënten die reeds met andere medicatie 
behandeld werden, en dit vormt een groot probleem voor de ontwikkeling van nieuwe 
analgetica. 
Om tot de markt toegelaten te kunnen worden, moet namelijk in klinische studies 
aangetoond worden dat een nieuw pijnstillend geneesmiddel statistisch significant beter is 
dan bestaande middelen. Doorgaans leidt de werking van de gangbare pijnstillers slechts tot 
een vermindering van de verschijnselen van pijn, waardoor de aandoening beter verdragen 
wordt. Hierbij kan er maximaal een reductie van 30% in de pijnscore van patiënten bereikt 
worden. Bij het merendeel van patiënten die deelneemt in de zogeheten fase 3 klinische 
studies, is de verlichting van pijn symptomen gering. Aan het einde van de studie voldoen 
zij vaak nog aan dezelfde criteria en eisen als voorafgaand aan de deelname in de studie. 
Deskundigen van verschillende disciplines zijn het met elkaar eens over de grote behoefte 
aan effectievere farmaca en trachten daarom strategieën te ontwikkelen voor het verbeteren 
van het ontwikkelingsproces voor een nieuwe geneesmiddel. Onder anderen worden zowel 
pijnbestrijding als het onderzoek naar chronische pijn momenteel gehinderd door het 
ontbreken van objectieve diagnostische testen op basis waarvan de subjectieve waarneming 
van pijn kan worden vastgesteld en eventueel aangevuld met pathofysiologische criteria. 
Daarnaast zijn er  tot op heden zijn geen diagnostische methodes beschikbaar die tot een 
tijdige diagnose en daarmee tot preventie van chronische pijn kunnen leiden.  Als gevolg 
daarvan worden alle inspanningen gericht op het verbeteren van het ontwerpen en uitvoeren 
van klinische studies, waarbij wordt aangenomen dat verbeteringen van de studieopzet 
en protocol voldoende kunnen zijn voor het identificeren van  de benodigde dosis voor 
adequate pijnbestrijding. Deze laatste veronderstelling wordt echter in vraag gesteld door 
het frequente mislukken van klinische studies voor opiaten, waarvan de effectiviteit door de 
jaren heen is bewezen door ervaring in de praktijk.
In dit proefschrift hebben we geprobeerd een nieuwe benadering te ontwikkelen 
voor de evaluatie van de werking van analgetica waarbij de nadruk ligt op de mate van 
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receptorbezetting als basis voor translationeel onderzoek en de klinische evaluatie van 
nieuwe geneesmiddelen. In de verschillende hoofdstukken in dit proefschrift hebben we 
opmerkelijke conceptuele en experimentele vergissingen en fouten in de manier waarop 
pijnsignalen en farmacologische activiteit worden vastgesteld belicht. Tenslotte hebben we 
geprobeerd de vertaalslag te vinden tussen species en ziektes . 
De rode draad van dit proefschrift is dat nauwkeurige karakterisering van de concentratie–
effect-relatie een absolute eis is voor het bepalen van de therapeutische dosis van ieder 
geneesmiddel, ongeacht zijn werkingsmechanisme. Naast de inhoudelijke uiteenzetting 
van de onderliggende mechanismen van pijnsignalen en symptomen, worden er drie 
aandachtsgebieden bestudeerd. Deze benadrukken het belang van farmacokinetiek-
farmacodynamiek (PKPD) relaties. Allereerst hebben we de eisen voor het karakteriseren 
van gedragsmetingen van pijn onderzocht bij het vroeg screenen van geneesmidel-
kandidaten. Daarna hebben we de tekortkomingen van de huidige experimentele 
protocollen belicht. Vervolgens worden de vereisten voor de parameterisering van pijn 
gedrag toegelicht. Dat maakt de nauwkeurige vertaling van farmacologische eigenschappen 
tussen species mogelijk, evenals de overbrugging tussen de verschillende fasen van het 
ontwikkelingsproces. Ten slotte hebben we de klinische respons in chronische inflammatoire 
pijn gemodelleerd en de correlatie onderzocht tussen de verlichting in de verschijnselen 
en de onderliggende farmacologische effecten. We hebben aangetoond hoe clinical trial 
simulaties gebruikt kunnen worden voor de evaluatie van uiteenlopende scenario’s om 
onder andere de bijdrage van het farmacologisch effect te kunnen onderscheiden van zowel 
het placebo effect als de onderliggende ziekteprocessen.
Samengevat zijn de vraagstellingen van dit proefschrift als volgt:
1. Is het mogelijk om door middel van modellering en simulatie een verband te leggen tussen 
bevindingen in verschillende fasen  van de ontwikkeling van een nieuw geneesmiddel 
waardoor de voorspellende waarde van specifieke  experimenten wordt verbeterd?
2. Is het mogelijk om bestaande data te gebruiken voor het berekenen van parameterverdeling 
(priors) en deze vervolgens toepassen bij het vaststellen van de werkzaamheid van een 
nieuw geneesmiddel?
3.Welke experimentele en methodologische eisen zijn van belang voor het optimaliseren 
van de evaluatie van nieuwe stoffen?
4. Wat kan het karakteriseren van de concentratie-effect relatie betekenen voor de keuze 
van de therapeutische dosis ?
5. Kunnen clinical trial simulaties toegepast worden voor het optimaliseren van de 
therapeutische dosis, en op basis daarvan de farmacologische effecten te kunnen 
onderscheiden van andere verstorende effecten in de bestudeerde populatie of 
doelgroep?







Om de bovengenoemde doelstellingen helder te behandelen is dit proefschrift in drie 
secties ingedeeld.
In sectie I, de algemene inleiding, wordt de onderliggende pathofysiologische basis van 
chronische inflammatoire pijn en zenuwpijn toegelicht. Daarnaast zijn de meest voorkomende 
methodes voor het ontwikkelen van een analgetisch geneesmiddel beschreven.
In de hierop volgende sectie bestuderen we de technische eisen voor de parameterisering 
van een PKPD model en aan de hand hiervan definiëren we eisen voor het optimiseren 
van de opzet van een preklinisch screeningsexperiment, met de nadruk op het gebruik 
van binaire metingen tijdens het screenen en het ordenen van kandidaat-moleculen voor 
zenuwpijn.
Ten slotte hebben we zowel biomarkers als de klinische respons in chronische inflammatoire 
pijn gemodelleerd. Met behulp van een klinische pijn-respons model zijn er correlaties 
tussen symptomatische pijnverlichting en de onderliggende farmacologische effecten 
vastgesteld aan de hand van mechanistische biomarkers. Hierbij hebben we de toegevoegde 
waarde van clinical trial simulaties aangetoond. In de hierop volgende alinea’s worden de 
verschillende hoofdstukken die dit proefschrift omvat één voor één belicht.
Chronische pijn als een stoornis in het signaleren van de pijnwaarneming
Hoofdstuk 1 bestaat voornamelijk uit een overzicht van de vorderingen in het onderzoek naar 
zenuwpijn en chronische pijn. We hebben aangetoond dat er naast praktische hindernissen 
meerdere methodologische aspecten zijn, die de ontwikkeling van nieuwe farmaca voor 
pijnbestrijding verhinderen. Het meest voorkomende probleem is het ontbreken van 
de zogenaamde constructvaliditeit of begripsvaliditeit van preklinische proeven die 
tegenwoordig worden gebruikt voor het bepalen van de pijnstillende activiteit van een nieuw 
geneesmiddel. Pijn-experimenten zijn ontworpen om kortdurende uitingen van pijngedrag 
te meten, die niet noodzakelijkerwijs de ziekte bij chronische pijn patiënten weerspiegelen. 
In dit hoofdstuk hebben we een nieuwe benadering voorgesteld waarbij de identificatie 
van relevante doelwitten  is gekoppeld aan potentiële stoffen, en de verschijnselen van 
pijn zijn gekoppeld aan de onderliggende oorzaak van de stoornis. We hebben aangetoond 
dat een tijdige diagnose, de timing van de ingreep en de omkeerbaarheid van relevante 
pathofysiologische processen niet kunnen worden verwaarloosd. Uiteindelijk bepalen deze 
zaken het succes of het falen van de therapie. Het is daarom essentieel om de onderliggende 
veranderingen in het centraal zenuwstelsel die betrokken zijn bij het waarnemen van pijn 
te begrijpen.  Idealiter zou men  moeten ingrijpen voordat de pijn symptomen tot uiting 
komen. Zonder deze mogelijkheid blijven experimentele protocollen van beperkte waarde 
aangezien de onderliggende veranderingen niet tijdig gedetecteerd kunnen worden in 
de prodromische fase, oftewel vòòr de overgang van  acuut letsel naar chronische pijn. 
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Tevens benadrukken we ook dat de metingen van de waarneming van pijn, zoals deze bij 
proefdieren wordt uitgevoerd, niet alle betrokken pathways in kaart brengen. Hierdoor 
ontstaat een belangrijke translationele (interspecies) kloof. Dit heeft verdere gevolgen voor 
de ontwikkeling van nieuwe farmaca, met name voor het screenen en selecteren van nieuwe 
moleculen. Bovenstaande punten vormen de grondslag van dit proefschrift.
Modelmatige analyse van pijn gedrag in preklinische onderzoek
Zoals bediscussieerd in hoofdstuk 2, is er een verhit debat geweest over de translationele 
waarde van preklinische modellen. De algemene opinie is dat deze modellen geen 
construct of begrijpvaliditeit hebben, en dat deze enkel de verschijnselen van pijn 
kunnen nabootsen. Sterker nog, grove eindpunten zoals het terugtrekken van de poot /
de voetdrukdrempelwaarde en  de tijd tot het terugtrekken van de poot, zijn toegepast 
als surrogaten voor de evaluatie van de verwachte analgetische activiteit in de kliniek. 
Ondanks de bovengenoemde beperkingen hebben we benadrukt hoe een beter begrip van 
het concept van receptorbezetting relevant kan zijn om preklinische gegevens te kunnen 
vertalen naar de mens en daarmee de therapeutische dosering van een nieuw molecuul 
beter te voorspellen. Met behulp van recente voorbeelden uit de literatuur hebben we 
de eisen voor de beoordeling van concentratie-effect relaties in preklinische diersoorten 
belicht. We hebben het belang van het nemen van bloedmonsters voor farmacokinetische 
analyse aangeduid, en het samenvatten van de farmacokinetisch-farmacodynamische 
eigenschappen van het molecuul door middel van parameters die de blootstelling weergeven 
(EC50 in plaats van ED50). 
Daarnaast laten we zien dat de zogenoemde standaard experimentele opzet die gebruikt 
wordt tijdens screening, tot onnauwkeurige parameterberekeningen kan leiden, 
waardoor onjuiste keuzes worden gemaakt  met betrekking tot de potentie en ordening 
van kandidaat-moleculen. In dit verband hebben we aangetoond hoe wiskundige en 
statistische modellen toegepast kunnen worden om zowel het biologische systeem als de 
geneesmiddeleigenschappen op een kwantitatieve manier te beschrijven. Hiërarchische of 
populatie modellen zijn voorgesteld als basis voor het identificeren van de verschillende 
bronnen van variabiliteit, evenals voor het beoordelen van de effecten van de behandeling 
en de progressie van de ziekte. Hiernaast stellen we het concept van biomarkers voor als 
een intermediaire stap tussen geneesmiddeleffect en de uiteindelijke verschijnselen, die op 
een systematische manier geïntegreerd kan worden. 
Het vastellen van concentratie-effect relaties op basis van PKPD modellering biedt de 
mogelijkheid om deze relaties mechanistisch te onderbouwen en de verschillen tussen 
interspecies mee te nemen bij het bepalen van de therapeutische dosis.







Experimentele pijn modellen. Onvertaalbaar maar toch informatief
Een belangrijke veronderstelling voor het werk in dit proefschrift is dat sommige beperkingen 
van de manier waarop hedendaags preklinisch onderzoek wordt verricht, ondervangen 
kunnen worden met behulp van een modelmatige aanpak. Daarmee wordt het mogelijk 
om onderscheid te maken tussen geneesmiddel-specifieke en systeem-specifieke 
eigenschappen. Bovendien kan verwacht worden dat parameterwaarden die gebaseerd zijn 
op concentraties meer informatief kunnen zijn dan die waarbij de dosis wordt gebruikt. 
Hierdoor is de vergelijking tussen diverse stoffen nauwkeuriger en zijn daardoor betere 
voorspellingen mogelijk. 
Een andere aanname van ons werk was dat gestandaardiseerde experimentele protocollen 
niet noodzakelijkerwijs ontworpen zijn om optimaal data te genereren of onderscheid te 
maken tussen moleculen en tussen dosisniveaus. Aangezien pijnexperimenten per definitie 
empirisch zijn, zullen standaardprocedures simpelweg proberen de reproduceerbaarheid 
van de metingen te verhogen. Daarom zijn er pogingen gedaan om het resultaat van 
verbeteringen in de ontwikkeling van nieuwe farmaca voor de behandeling van chronische 
pijn te evalueren. Zoals eerder in dit proefschrift is vermeld, wordt het gevolg van ontbrekende 
markers van farmacologie verergerd door gebrekkige data-integratie en geschikte analyse 
methodes gedurende de selectie van kandidaat-moleculen. We hebben aangetoond dat, 
terwijl het bestuderen van concentratie-effect relaties gedurende de ontwikkelingfase van 
farmaca een condicio sine qua non is voor het vaststellen van het effect van behandeling en 
de variabiliteit daarvan, zulke nauwkeurige berekeningen niet altijd vanzelfsprekend zijn. 
PKPD relaties moeten voorspellende waarde hebben voor de doelgroep, in kwalitatieve 
en kwantitatieve termen. Echter tot op heden zijn bovengenoemde overwegingen geen 
formele voorwaarden voor het genereren van experimentele data, waardoor experimentele 
protocollen vaak niet informatief genoeg zijn of sterker nog, zelfs onjuist.
Om de probleemstelling en bovengenoemde concepten nader te illustreren, hebben we 
twee experimentele modellen van pijngedrag geselecteerd. Eerst werd de drempelwaarde 
voor het terugtrekken van de poot gemeten na een normaal niet-pijnlijke prikkel in het 
zogeheten complete freund adjuvant (CfA) model in de rat. In het tweede geval werd 
de verandering in de frequentie van terugdeinzen (flinching) na injectie van een pijn 
opwekkende stof, namelijk formaline, gekozen als een marker voor het pijnstillende effect. 
In tegenstelling tot het CfA model, is de pijnrespons bij deze laatste methode een spontaan 
gedrag. Daarvoor wordt geen pijnprikkel gebruikt. De pijnlijke reactie die veroorzaakt werd 
door formaline is het resultaat van een geconditioneerde respons, die de betrokkenheid 
van hogere cognitieve functies weerspiegelt. Geneesmiddelen met uiteenlopende 
werkingsmechanismen kunnen onderscheiden worden aan de hand van het type en de 
omvang van de effecten op het gedrag. Daarom veronderstellen we dat het formaline-
geïnduceerde pijnmodel meer constructvaliditeit toont ten opzichte van andere modellen 
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die gebaseerd zijn op kortdurende stimulaties. Vanuit een methodologisch oogpunt 
hebben we tevens aangetoond dat de juiste parametrisering evenals de nauwkeurigheid 
van de geschatte waarden (modelparameters) van cruciaal belang zijn. Ongetwijfeld zijn 
de beperkte beschikbare data gedurende de screeningsfasen van farmaca de oorzaak van 
twee belangrijke statistische kwesties voor de toepassing van een modelmatige benadering, 
oftewel de identificeerbaarheid en precisie van de parameters.
In hoofstuk 4 en 5 hebben we aangetoond hoe de werkzaamheid van twee analgetische 
stoffen (gabapentine en pregabaline) kan worden vastgesteld en eventuele verschillen 
tussen hen geïdentificeerd. Om de toepassing van onze benadering in toekomstig onderzoek 
te vereenvoudigen werd werkzaamheid gedefinieerd in termen van een binaire (ja of 
nee) respons. Op basis van een logistisch regressiemodel hebben we systeem-specifieke 
eigenschappen weten te onderscheiden van stof-specifieke eigenschappen. Hierdoor kon 
de werkzaamheid geschat worden en de twee geneesmiddelen met elkaar vergeleken 
worden. Het was ons doel om de schatting van de EC50 en de interindividuele variabiliteit (IIV) 
nauwkeuriger te maken. Daarvoor gebruikten we de zogeheten ED optimaliteit techniek om 
de relatie tussen bloedconcentraties en de pijnrespons te beschrijven, rekening gehoudend 
met de onzekerheid rondom de geschatte parameterwaarden. Om practische en theoretische 
redenen wilden we zowel de dosis als de bloedmonster-afname-tijdpunten optimaliseren. 
Informatie betreffende de systeem-specifieke eigenschappen werd geïntroduceerde als 
priors (bestaande informatie) voor de optimalisatie procedures. Onze analyse heeft ook 
de consequenties van de empirische dosisselectie in kaart gebracht, die vaak te hoog zijn 
waardoor de berekening van de EC50 aanzienlijk minder precies wordt. Ondanks het grote 
bereik van de doseringen  die gebruikt werd in de oorspronkelijke protocollen, verschilden 
de gesimuleerde concentratieprofielen niet significant van elkaar. De relatieve biologische 
beschikbaarheid daalde van 100% bij de 10 mg/kg dosis tot 9% bij 300mg/kg. In tegenstelling 
tot experimenten waarbij ED50 wordt berekend ongeacht de plasmaspiegels, toonden 
protocol-optimalisatie procedures de waarde van de juiste bloedafname tijd en dosisschema. 
EC50 waarden voor gabapentine en pregabaline waren respectievelijk 1400 en 897 mg/ml. 
Wij stellen hierdoor vast dat de verschillen in werkingssterkte in in vitro experimenten 
ook aantoonbaar zijn in de in vivo studies. Al met al toonden deze bevindingen aan dat 
protocol-optimalisatie een verbetering betekent voor de precisie en een vermindering in 
de systematische fout. Wij verwachten dat deze procedures een basis zullen verschaffen 
voor de validatie van experimentele diermodellen, waardoor niet alleen de gevoeligheid en 
specificiteit van de protocollen verhoogd kunnen worden, maar ook vals-positieve en vals-
negatieve resultaten beter gekarakteriseerd  kunnen worden.
In hoofdstuk 6 hebben we getracht een semi-mechanistisch model te ontwikkelen om de 
effecten van gabapentine op formaline-geïnduceerde pijn in een rat diermodel te kunnen 







beschrijven. De pijn-inducerende effecten van formaline in dit diermodel zijn aangeduid 
als een verhoogde frequentie van terugdeinzen waarin er twee pieken van maximale 
pijnintensiteit voorkomen. In ons semi-mechanistische model werd de eerste piek 
beschreven met behulp van een mono-exponentiëel afnemende functie terwijl de tweede, 
meer aanhoudende piek werd beschreven met een indirect respons model met een in de 
tijd variërende parameter die de synthese van pijn gerelateerde mediatoren weerspiegelt. 
De effecten van het geneesmiddel werden geparametriseerd door een Imax functie, die als 
een covariabele de pijn-respons beïnvloedt. 
Onze parametrisering van geneesmiddeleffecten wijkt af van effecten die tradioneel 
beschreven worden in het desbetreffende model, waarin effecten worden toegepast op 
de synthesesnelheid of eliminatiesnelheid van de ziekte. Ondanks dit verschil heeft onze 
weergave van de pijnrespons en geneesmiddeleffecten een mechanistische basis omdat 
gabapentine geen ziekteremmende effecten heeft, en het slechts de pijn enigszins kan 
verminderen. Interessant is dat de gemiddelde IC50 waarden die we hebben gerapporteerd 
(7510 ng/ml) van dezelfde orde van grootte zijn als die gepubliceerd door Lockwood 
en Whiteside et al. voor gabapentine in klinische studies. Anderzijds, ondanks hoge 
bloedspiegels werden de pijnsymptomen (frequentie van terugdeinzen) niet volledig 
onderdrukt door gabapentine. Deze discrepantie geeft duidelijk aan, dat  de werkzaamheid 
van gabapentine beperkt is in deze aandoening.
Terwijl we concrete verbeteringen hebben kunnen aantonen door het invoeren van 
een modelmatige benadering, hebben we ook in kaart gebracht dat biomarkers van 
kritische belang zijn om een vertaalslag te kunnen maken tijdens de ontwikkeling van een 
geneesmiddel. Het is onbetwist dat er een behoefte is aan het verkrijgen van aanwijzingen 
van de werkzaamheid in de vroege stadia van het ontwikkelingstraject. Dit kan door het 
inschakelen van biomarkers die als schaalfactoren kunnen dienen bijvoorbeeld bij de 
interspecies-translatie, en tevens ook als hulpmiddelen voor de extrapolatie van effecten in 
verschillende populaties zoals gezonde vrijwilligers en patiënten. 
In de volgende secties worden de overwegingen voor het gebruik van biomarkers als basis 
voor het bepalen van dosisschema’s gepresenteerd.
BIOMARkER-gESTuuRDE DOSISSELECTIE EN hET VOORSPELLEN VAN 
KLINISCHE RESPONSE
Om het percentage geneesmiddelen dat faalt tijdens de ontwikkeling terug te dringen 
moet men focus geven op twee strategieën. Ten eerste een verbeterde selectie van targets, 
rekening houdend met de betrokken pathways evenals de timing van de diagnose en 
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ingreep. Ten tweede dienen routinematig zogeheten proof-of-concept onderzoeken plaats 
te vinden, bij voorkeur gedurende de fase 1 trials of in experimenten (bijvoorbeeld in 
humaan weefsel) waarbij het farmacologische effect (farmacodynamiek) op de doelgroep 
kan worden nagebootst. Op deze manier kunnen biomarkers gebruikt worden als maatstaf 
voor werkzaamheid en/of veiligheid. Ondanks de aanwijzingen uit andere therapeutische 
gebieden die deze benadering ondersteunen, wordt dit concept verwaarloosd in 
onderzoeksprotocollen  voor chronische pijn.  In het algemeen wordt onderzoek naar 
pijnstillende farmaca voornamelijk gebaseerd op klinische schalen, zonder de onderliggende 
farmacologie of  receptorbezetting in ogenschouw te nemen.
De integratie van biomarkers die het farmacologische effect voorspellen al in de vroege stadia 
van het ontwikkelingstraject geeft de mogelijkheid de therapeutische dosis nauwkeuriger 
te selecteren dan wanneer gebruik wordt gemaakt van empirisch bewijs afkomstig van 
aspecifieke metingen van gedrag. 
In hoofdstuk 7 hebben wij laten zien dat, wanneer biomarkers gebruikt worden voor 
het voorspellen van de werkzaamheid, het klinisch-farmacologisch profiel van nieuwe 
moleculen gekarakteriseerd kan worden, waardoor een mechanistisch inzicht wordt 
gegeven in de relatie tussen blootstelling en effect, wat op zijn beurt leidt tot een betere 
onderbouwing voor het therapeutische doseringsbereik. Bovendien kan het kwantificeren 
van de farmacokinetisch-farmacodynamische relatie waarbij gebruik wordt gemaakt van 
biomarkers een meer solide basis geven voor behandeling van individuele patiënten.
Het concept van biomarker-gestuurde dosisselectie werd geïllustreerd door middel van 
data van GW406381, een cyclo-oxygenase (COX) remmer, waarbij de nadruk werd gelegd 
op het verwerven van inzicht in de klinische farmacologie van het middel om de optimale 
dosering al voor phase 2 vast te kunnen stellen. De keuze voor deze klasse geneesmiddelen 
als paradigma werd ingegeven door het van de markt halen van diverse middelen waarbij 
voldoende informatie betreffende het farmacologisch profiel voorhanden was om de 
veiligheid en werkzaamheid te kunnen bepalen. 
Ons onderzoek is gebaseerd op data van een gerandomiseerde, dubbel blinde fase 1 studie 
in gezonde mannelijke vrijwilligers waarbij een enkele dosis werd gevolgd door meermalige 
doses gedurende 10 dagen. De nuchtere proefpersonen kregen een orale dosis van 35 
of 70 mg GW406381 toegediend, waarbij plasma concentraties van het geneesmiddel, 
alsmede de waarden van de biomarkers prostaglandin E2 (PGE2) en thromboxane B2 (TXB2) 
op vaste tijdstippen werden bepaald. De analyse werd verricht in twee stappen: eerst werd 
de farmacokinetiek van GW406381 beschreven met behulp van een één-compartiment-
model met eerste-orde absorptie. Vervolgens werd aan de hand van de prostaglandine 
concentraties een Imax model ontwikkeld om de blootstelling-respons relatie te beschrijven. 
Door integratie van de farmacokinetische data uit de fase 1 studie met de PGE2-data, 
zoals bepaald in een ex vivo analyse, werd getoond hoe biomarkers kunnen leiden tot 







verbeterde dosis selectie in de opeenvolgende fasen van geneesmiddelontwikkeling. Het 
is noemenswaardig dat onze analyse succesvol was ondanks het hoge variabiliteit in de 
PGE2 data. De gemiddeld werkingssterkte (IC50) bedroeg 43 ng/ml met  een IC80 en IC95 van 
respectievelijk 103 en 276 ng/ml. 
Hiernaast toonde de hoge variabiliteit in zowel farmacokinetiek als farmacodynamiek in de 
gezonde vrijwilligers  een belangrijke beperking van het gebruik van de in vitro potentie 
als criterium om geneesmiddelen te vergelijken in vroege fases van ontwikkeling, omdat 
die de verschillen in selectiviteit of metabole activiteit in vivo niet reflecteren. fries et al. 
lieten zien dat, ondanks de aanzienlijke hogere in vitro potentie van rofecoxib ten opzichte 
van celecoxib, de in vivo potentie weinig verschilt. Ook de in vitro potentie van GW406381 
werd 30 maal hoger geschat dan die van rofecoxib. Echter, de aanbevolen optimale dosis 
gebaseerd op onze simulaties ligt tussen 150-250 mg terwijl die van rofecoxib 25-50 mg 
bedraagt. Dit wordt grotendeels verklaard door interindividuele (metabolische) verschillen 
in de farmacokinetiek. Verder hebben wij aangetoond dat, met de voorgestelde dosis 
leidend tot 80-95% inhibitie, tweemaal daags doseren gunstiger was dan eenmaal daags; 
piekconcentraties bleven korter boven de IC95 bij  hogere doses, zonder dat een significant 
effect had op de dalconcentraties. 
Aan de hand van uiteenlopende simulatiescenario’s lieten we zien hoe, door gebruik te maken 
van biomarkers, dosis aanpassingen bij speciale populaties konden worden gedaan. Dit betrof 
patiënten met leverfunctiestoornissen, metabole inductie en gegeneraliseerde inflammatie. 
Hieruit kwam naar voren dat metabole inductie evenals leverfunctiestoornissen leiden tot 
significante verschillen in de totale blootstelling waardoor dosis aanpassen cruciaal zijn om 
een vergelijkbare blootstelling te verkrijgen en te behouden gedurende de behandeling. 
Omgekeerd behoeft een verhoogde uitgangsconcentratie PGE2 geen dosisaanpassingen. 
Samengevat maakte dit werk de evaluatie van doseringen mogelijk, rekening houdend 
met de balans tussen de baten en de risico’s van de behandeling, die naast de totale dosis 
ook afhangen van het doseerschema. Zoals aangetoond wordt deze balans bereikt bij een 
inhibitie van PGE2 tussen 80 en 90%. Onder deze omstandigheden wordt bij chronische 
therapie de induceerbare fractie van de beschikbare COX2 geblokkeerd, terwijl voldoende 
residuele activiteit van PGE2 en andere COX2-gerelateerde enzymen behouden blijft voor 
homeostase en weefselherstel. 
In de laatste gedeelte van dit proefschrift hebben we het concept van biomarker-gestuurde 
dosisselectie verruimd naar fase 2 klinisch onderzoek om de relatie tussen biomarkers en 
de symptomen van pijn te onderzoeken. Door de mechanistische classificatie toe te passen, 
die  beschreven werd door Danhof et al., was het mogelijk om de veronderstelde relatie 
tussen blootstelling en biomarker van GW406381 te beschrijven. Hiertoe werden ACRn 
scores gebruikt, die verzameld waren in een grote klinische studie naar de effecten van 
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COX2 remmers bij rheumatoide artritis. Hoewel de rol van ACRn als een maat van klinische 
verbetering vaststaat, is de relatie met de onderliggende farmacologische activiteit na 
toediening van COX2 remmers niet eerder bepaald.  In hoofdstuk 8 werd de rol van 
biomarkers verder onderzocht door deze bij gezonde personen en patiënten te correleren 
aan ACRn. 
Ondanks het beperkte aantal doses welke tijdens de studie onderzocht waren (0, 10, 35 en 50 
mg eenmaal daags oraal), lieten wij zien hoe simulaties en longitudinale farmacokinetisch-
farmacodynamische modellen inzicht verschaffen in de farmacologische effecten welke ten 
grondslag liggen aan de klinische respons.
Een integrale benadering werd ontwikkeld waarbij informatie over het gehele tijdsverloop 
van het behandelingseffect werd gebruikt, terwijl het in de huidige praktijk gebruikelijk is 
de werkzaamheid tussen groepen te bepalen op basis van de respons na afloop van de 
behandeling. Het tijdsverloop van de pijnrespons werd het best beschreven door een 
Weibull functie met een Imax model voor het geneesmiddel effect. Twee fenotypes konden 
worden geïdentificeerd in de populatie, waarbij patiënten met een minimale daling van 
25% in ACRn scores ten opzichte van basislijn werden beschouwd als responders. Opvallend 
genoeg was het percentage responders niet evenredig met de dosis, wat de hoge variabiliteit 
in farmacokinetiek en farmacodynamiek reflecteert.  Hoewel informatie over hogere doses 
ontbrak, zijn deze bevindingen in lijn met het voorspelde percentage receptorbezetting, 
zoals bepaald door PGE2 inhibitie.
Gebaseerd op de aanname dat klinische analgesie optreedt bij een prostaglandine-inhibitie 
van minimaal 80%, kan voorgesteld worden dat de geselecteerde doses gebruikt in deze 
klinische studie niet optimaal en meestal sub-therapeutisch waren. Volgens onze analyse 
van de biomarker respons ligt de therapeutische dosis van GW406381 waarschijnlijk tussen 
100 en 250 mg per dag.
Om de voorspellende waarde van een modelmatige benadering voor de dosisselectie van 
analgetische geneesmiddelen te evalueren werd verder ingegaan op de relatie tussen 
biomarker en klinische respons. In hoofdstuk 9 werd de veronderstelde relatie tussen 
inhibitie van PGE2 en ACRn onderzocht in patiënten met reumatoïde artritis. Er werd niet 
alleen aangetoond dat PGE2 kon worden gebruikt als surrogaat voor receptorbezetting (d.w.z. 
COX2 inhibitie), ook gaf de relatie tussen biomarker en klinische respons inzichten in de 
verschillende oorzaken van de variabiliteit in een heterogene populatie. Met behulp van de 
in hoofdstuk 7 en 8 ontwikkelde farmacokinetische en farmacokinetisch-farmacodynamische 
modellen kon het tijdsverloop van de klinische respons (ACRn) en PGE2 worden  gesimuleerd. 
Dit hypothetische experimentele protocol was gebaseerd op een typerende klinische studie 
bij reumatoïde artritis waarbij 500 patiënten per dosisgroep gedurende 6 weken behandeld 
werden. Om de verschillende bronnen van variabiliteit te kunnen karakteriseren varieerden 
de doses GW406381 van 10 tot 400 mg per dag. Patiënten werden geclassificeerd als 







responders of non-responders op basis van de gesimuleerde uitkomst na afloop van de 
behandeling. Onze resultaten lieten een grote variatie in het tijdsverloop van de pijnscores 
zien, ongeacht de uitgangswaarde, waarbij de voorgespelde PGE2 inhibitie boven 80% lag bij 
doses hoger dan 250 mg. Verder nam het aantal responders niet-lineair toe bij toemende 
gesimuleerde doses, waarbij een 50% reductie van ACRn werd bewerkstelligd bij een dosis 
van meer dan 100 mg/dag. De aangetoonde concentratie-effect relatie geeft een robuustere 
basis voor het bepalen van het doseerschema, welk traditioneel worden bepaald door het 
effect van de behandeling op basis van zichtbare symptomen. 
Concluderend hebben we aangetoond dat modelleren en simuleren de vertaling van 
experimentele bevindingen gedurende de diverse fasen van ontdekking en ontwikkeling 
van geneesmiddelen kan vergemakkelijken, waardoor de dosisselectie alsmede de 
ontwikkeling van experimentele protocollen verbeterd kunnen worden. Hiervoor is de 
beschikbaarheid van longitudinale data van cruciaal belang. De experimentele protocollen 
moeten worden gebaseerd op schema’s welke het karakteriseren van farmacokinetiek, 
biomarkers en werkzaamheid mogelijk maken. Hiernaast kunnen, wanneer in het model 
onderscheid wordt gemaakt tussen geneesmiddel- en systeem-specifieke eigenschappen, 
de geneesmiddel-specifieke eigenschappen systematisch onderzocht worden, rekening 
houdend met bestaande kennis over het systeem. 
We hebben aangetoond dat statistische veronderstellingen gebruikt kunnen worden 
om de onzekerheid in de schatting van de parameters te verminderen, om zodoende de 
variabiliteit in de experimentele data te onderzoeken. Door een geneesmiddel te gebruiken 
met aangetoonde analgetische activiteit konden wij het belang van de concentratie-effect 
relatie voor doseeradviezen onderstrepen. Dit vormt de basis voor de evaluatie van het 
effect van covariabelen op de blootstelling en de invloed daarvan op de respons op het 
geneesmiddel.
De in dit proefschrift gepresenteerde benadering, waarin modellering en simulatie worden 
gebruikt als gereedschap om conclusies te trekken, vertegenwoordigt een verschuiving van 
het empirisme dat de selectie van kandidaat moleculen, de onderbouwing van dosisselectie 
en het ontwerp van fase 2b en 3 klinische studies voor chronische pijn heeft gedomineerd. 
Het lijdt geen twijfel dat de klinische respons niet mogelijk is zonder voldoende receptor 
bezetting. Anderzijds heeft een toename van blootstelling geen toename van de respons tot 
gevolg wanneer de maximale of benodigde receptor bezetting bereikt is. Tenslotte laten onze 
resultaten ook zien dat door gebruik te maken van farmacokinetisch-farmacodynamische 
modellen kan niet alleen receptorbezetting maar ook biomarkers systematisch worden 




Doorgaans wordt de ontwikkeling van een geneesmiddel beschouwd als een lineair proces 
dat begint met het identificeren van een target en eindigt met markt toelating. Dit creëert 
een sequentiële aanpak bij de besluitvorming waardoor de gelegenheid ontstaat om te 
kunnen leren bij iedere stap in de ontwikkelings keten. In de werkelijkheid echter vindt 
iedere stap  geïsoleerd plaats en is er bij elke stap nauwelijks integratie of toename van 
informatie van de voorafgaande stappen vanuit een klinisch of biologisch perspectief.  Er 
is daarom een aanpak vereist die afwijkt van de huidige gefragmenteerde strategie gericht 
op geïsoleerde targets of werkingsmechanismes. Er moet rekening worden gehouden 
met de onderliggende systemen en ziekteprocessen die neurale overgevoeligheid voor 
pijn (hypersensitisatie) opwekken. Verder moet geprobeerd worden om de onderliggende 
stoornissen in signalen te detecteren die voorafgaan aan de zichtbare belevenis van pijn.
Profylactische behandelingen zijn noodzakelijk om te zorgen dat de homeostase in het 
weefsel is hersteld na het optreden van letsel en de daarop volgende acute inflammatoire 
respons. In deze context moet overwogen worden om parallel aan geneesmiddelontwikkeling 
ook diagnostiche biomarkers te ontwikkelen. Een belangrijk vraagstuk dat telkens opduikt 
is of bestaande diermodellen ons ooit de benodigde informatie kunnen leveren om een 
vertaalslag tussen dieren en mensen te kunnen maken. Een aanpak gebaseerd op modellen 
is essentieel om de opzet van experimenten te optimaliseren en de kwaliteit van informatie 
te verbeteren. Wiskundige modellen kunnen gegevens afkomstig van een breed scala 
aan experimentele protocollen, waaronder in-vitro experimenten, op systematische wijze 
integreren.
Woolf en collega’s hebben een nieuwe aanpak voor geneesmiddelontwikkeling voorgesteld, 
waarbij genetica wordt toegepast om potentieel analgetische targets te valideren. 
Voorbeelden zijn de genetische polymorfismen van het voltage-gated kanaal Nav1.7 en het 
enzyme  GTP cyclohydrolase-1 die betrokken zijn bij verminderde gewaarwording van pijn. 
Op dezelfde manier kunnen andere aanpakken worden overwogen, waarbij een vroege 
extrapolatie van de farmacologie naar mensen wordt toegepast, ongeacht verschillen in de 
keuze van onderzoeksmethoden of protocollen. 
Alle voorstellen voor aanpak zijn in overeenstemming met de rol van mechanistische 
biomarkers in geneesmiddelontwikkeling. Anderzijds zijn er nog steeds geen gevalideerde 
biomarkers voor chronische pijn. De identificatie en het gebruik van biomarkers voor CNS 
aandoeningen is moeilijker dan voor andere ziekten. Een aantal overzichtsartikelen hebben 
de huidige kennis over kwantitatieve beeldvorming van de hersenen belicht maar geen 
daarvan heeft de mogelijkheden van deze technieken onderzocht voor het ontdekken 
en definiëren van biomarkers van pijn en hun toepassing bij het ontwikkelingstraject van 
geneesmiddelen. Nieuwe ontwikkelingen in functionele imaging zullen ongetwijfeld het 
identificeren van biomarkers van pijn mogelijk maken en zullen daarbij helpen de rol van 







verschillende hersengebieden beter te begrijpen. Dit is vooral nuttig voor processen waarbij 
neuroplasticiteit optreedt, wat een voorloper is van de ontwikkeling van chronische pijn. 
Tezamen met fysiologische verschijnselen zou het mogelijk kunnen zijn te anticiperen op 
signaalstoornissen voordat deze zichtbaar worden. 
Alles bij elkaar zal een verhoogd en verfijnd begrip van abnormale activiteit, met name 
van de  synaptische connectiviteit resulteren in de ontwikkeling van effectieve en meer 
doelgerichte behandelingen. Deze vorderingen zullen het beslissingsproces tussen de 
experimenten in het laboratorium en de eerste klinische studies zowel versnellen als 
verbeteren. Echter, een diepgaand begrip van het pijnsyndroom is niet haalbaar op basis 
van functionele imaging alleen. Dit zal geïntegreerd moeten worden met uiteenlopende 
disciplines zoals metabolomics en proteonomics om beter inzicht te verschaffen in hoe 
de voorspellende waarde van biomarkers verhoogd kan worden. Het zal cruciaal zijn om 
de vroege directe effecten van het geneesmiddel te onderscheiden van latere chronische 
effecten geassocieerd met langdurige behandeling. Ongeacht de vooruitgang in de 
disciplines van imaging en proteonomics, spelen PKPD modellen een belangrijke rol als 
hulpmiddelen om de klinische relevantie van een kandidaat geneesmiddel in te schatten en 
bij te dragen aan het bepalen van de therapeutische dosis. Daarnaast zullen PKPD modellen 
ons in staat stellen om een vertaalslag te maken tussen dieren en mensen. Door middel 
van systems pharmacology kunnen pathways geassocieerd met signaal processen beter 
in kaart gebracht worden. Door aan te nemen dat betrokken pathways in experimentele 
omstandigheden en ziekte hetzelfde zijn, kan modellering gebruikt worden om de receptor 
bezetting en tevens de daardoor veroorzaakte farmacologische effecten te voorspellen. Het 
is aannemelijk dat schalingsfactoren geïdentificeerd kunnen worden om de invloed van 
potentiële verschillen zoals receptordichtheid tussen proefdieren en patiënten te verklaren. 
Een soortgelijk concept is recentelijk succesvol toegepast voor antipsychotica waarvoor in 
vitro receptorbezetting bij ratten werd vertaald naar klinische werkzaamheid. 
Hiernaast kunnen kwantitatieve technieken ingevoerd worden om de rol van fenotypische 
verschillen en andere invloedrijke factoren (covariabelen) op de farmacokinetiek en respons 
in kaart te brengen. Door deze factoren mee te nemen in de rationale voor dosisselectie 
en aanbevolen indicaties zal de variabiliteit in klinische respons verminderd worden. Wat 
betreft de uitdagingen bij het geneesmiddelonderzoek voor chronische inflammatoire pijn, 
is er een verschil met neuropathische pijn. In inflammatoire pijn zijn reeds enkele biomarkers 
bekend en worden imaging technieken al gebruikt. Er is behoefte aan overeenstemming 
tussen alle betrokkenen over het aanpassen van de regulatorische richtlijnen die momenteel 
geen onderzoek van de onderliggende farmacologie vereisen en het paradigma van ‘leren 
en bevestigen’ niet toepassen. Ongetwijfeld zal simulatie een belangrijke rol gaan spelen bij 
de evaluatie van heterogeniteit in de doelgroep evenals bij het evalueren van de variabiliteit 
in de respons op de behandeling. In deze context zal de integratie van stastistische modellen 
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die factoren zoals drop-out, censurering en andere studieopzet aspecten beschrijven 
samen met mechanisme-gebaseerde modellen van ziekteprogressie, uitermate belangrijk 
zijn. Tenslotte voorzien we dat er vooruitgang behaald kan worden in het voorspellen 
van de respons op pijn door het bestuderen van meerdere eindpunten alsmede door 
het incorporeren van volledig mechanistische modellen in het farmacometrische kader 








After achieving her dream and creating a world record by crossing the 154 kilometer wide 
florida Straits , endurance swimmer Diana Niyad remarked, ‘it looks like a solitary sport but 
it is a team effort. The completion of this thesis would not have been a reality without the 
seminal contributions of many.
Oscar, we have had our share of disagreements and even heated debates, but looking back 
we can both be proud of having done good science. This meant challenging established 
beliefs and being confronted and disregarded by certain reviewers repeatedly, but that is 
how a scientist’s insight evolves. finally but for your trust in an ‘unknown variable’, or a 
voice at the end of a telephone line, it would not have begun! Ti ringrazio di tutto.
Dealing with pain research represented an opportunity to optimise some rudimentary 
aspects of current protocols. Optimal design theory is considered daunting even by hardened 
mathematicians and I had the good fortune of being mentored by one of the gurus in the 
field, Joakim Nyberg, from the University of Uppsala. It was also a pleasure to work with 
Inaki Troconiz on the formalin project, which in the beginning seemed undoable. I express 
my gratitude for his guidance through the concepts of indirect response modeling and for 
making himself always available for telecons even at short notice.
It is said that if you want to teach someone to build a boat, teach him a love for the sea. 
from our insightful discussions, Vincenzo di Iorio, I have learnt immensely about how to 
parameterise a problem. you were able to infect me with your passion for R and programming 
in general. I may not have become a complete nerd as yet, but I will get there someday. you 
will agree with me that it is indeed possible for an old dog to learn new tricks. Grazie mille.
Maurice Wang, with your unassuming nature and astute mind, you were an asset in the 
PKPD group and like many others, I benefitted from our interactions. Tarj Sahota, you have a 
special ability to explain difficult concepts in a lucid manner, I could always get leads to the 
problems that I was confronted with. I am also grateful to my internal review committee, 
comprising of Massimo, francesco, and Li for taking the time out to review the various 
sections of my thesis.
Venkatesh and Martin, it was quite a coincidence that three Indians, all from the Indian 
pharmaceutical industry (of which two from the same company), started at almost the same 
time in TI Pharma. I enjoyed our camaraderie over the years and thanks for all the helpful 
hints when I moved to Groningen.
All in all, the nearly five years I spent in the Division of Pharmacology were as instructive 
as they were fun. It was a vibrant atmosphere with academic interactions and journal clubs 
interspersed with social events, department picnics, bowling evenings and more. In short 
‘gezelligheid’ exemplified. Thanks to all those who made it possible.
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for being my sheet anchor and for just being there, dear Aanchal, no words would suffice. At 
times when the going got really tough, it was your support that got me through those times. 
It was not easy to set up a life and a home in a foreign country, with Avnay still small, and me 
being preoccupied with my research, but yet you made it work. Lastly, thanks to mom and 
dad for giving me your blessings to seek a challenging path when I was at the cross-roads 
of my career. The values you have instilled in me define who I am today. Manik, there is a 
part of you that will always be a happy-go-lucky school boy, but there is nobody else I would 
rather have as my kid brother. Nanu nani, for your unconditional love and support we were 
able to take this step in our lives. I count myself lucky to have a family such as you all.
To close this section  my favourite sher  Hazaron kwaishen aisi ki har khwaish pe dam nikale
Nikale armaan bahut se par phir bhi kam nikale.
De reis van een duizend mijl begint met een enkel stap (Chinese gezegde). In tegenstelling 
tot de Chinese filosoof, hoefde ik mijn duizend mijl niet in mijn eentje af te leggen, maar er 
waren veel mensen die een steentje hebben bijgedragen om de reis leuk en aangenaam te 
maken. 
Meindert, mede dankzij uw leiderschap konden problemen met data beschikbaarheid, 
verblijfvergunningen en afnemende interesse van de partners afgehandeld worden, 
waardoor ik dit onderzoek kon volbrengen. Ondanks dat u gelijktijdig meerdere functies 
moest uitvoeren, wist u altijd op de hoogte te blijven van de stand van zaken van iedere 
AIO in de groep. Ik zal de regenachtige avond in mei dit jaar niet gauw vergeten toen ik 
kleddernat op uw stoep belandde om de puntjes op de “i” van mijn proefschrift te zetten.  
Als project manager van de eerste TI Pharma PKPD platform, wist jij, Margot, op een 
efficiënte wijze project-gerelateerd problemen op te lossen. Daarnaast zorgde je ervoor dat 
er geen gebrek was aan hard- of software. Dankzij allerlei cursussen en workshops die je 
regelde, konden we snel aan de slag met ons onderzoeksprojecten.  Anderzijds heb ik de 
gelegenheid gehad om te leren hoe frusterende modelleren kan zijn. Vincent, Ibrahim en 
Rick, de tijd dat we hebben doorgebracht leidde tot het vormen van hechte banden; dat 
heeft me geholpen om mijn teleurstellingen tegen te gaan. Vincent, je behulpzame instelling 
stel ik zeer op prijs. 
Van een stagiair wordt verwacht dat hij of zij een steentje bijdraagt aan het onderzoek 
van een promovendus. Sean je overtrof mijn verwachtingen met gemak. Al gauw had je 
de fijne kneepjes van het vak begrepen en ik hoefde alleen maar een ondersteunende rol 
te spelen. Met jouw natuurlijke aanleg voor de beta-wetenschap en jouw bekwaamheid in 
programmeren had je überhaupt weinig begeleiding nodig. En als je ooit met vakantie in 
India bent, dan bezorg ik je een rit op een echte olifant!
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